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GENERAL ABSTRACT 
Disparate lines of evidence including in vitro cell culture, ex vivo brain slice culture, 
and virtually every in vivo model system have clearly implicated microglia activation and 
neuroinflammation in the pathophysiology of the dopaminergic neuronal cell death in 
Parkinson’s disease (PD). The signaling pathways that lead to this chronic activation are still 
being elucidated. We show herein, the role of the non-receptor Src family tyrosine kinase 
Fyn in mediating pro-inflammatory signaling in microglia cells in response to various 
inflammogens. Our results from cell and animal models as well as postmortem brain tissues 
conclusively demonstrate that Fyn is preferentially activated in microglia post-stimulation 
with either Lipopolysaccharide (LPS) or Tumor necrosis factor alpha (TNFα). Activated Fyn 
then tyrosine-phosphorylates the known pro-inflammatory kinase PKCδ, mediating PKCδ-
dependent activation of the NF-κB pathway, leading to pro-inflammatory cytokine and nitrite 
production. Both Fyn-/- and PKCδ-/- mice were remarkably resistant to LPS-mediated 
neuroinflammation, as well as neuroinflammation and dopaminergic neuronal loss induced 
by the Parkinsonian toxicant 6-hydroxydopamine (6-OHDA).  
Activation of the NLRP3 inflammasome, mediated by fibrillar amyloid-β, the major 
component of Alzheimer’s disease-associated senile plaques, has recently been shown to 
contribute to disease progression. Thus, we sought to validate whether the aggregated form 
of the PD-associated protein α-synuclein could activate the NLRP3 inflammasome within 
microglia. Our results conclusively demonstrate that α-synuclein can elicit the NF-κB-
dependent induction of the inflammasome components pro-IL-1β and NLRP3, as well as the 
Caspase-1- and ASC-dependent processing of pro-IL-1β to mature IL-1β. Remarkably, Fyn 
kinase was shown to contribute to both processes, via PKCδ-dependent NF-κB pathway 
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activation to prime the NLRP3 inflammasome as well as to the uptake of α-synuclein into the 
cell, which leads to the assembly and activation of the inflammasome complex. Lastly, we 
demonstrate activation of the NLRP3 inflammasome in various α-synuclein-overexpressing 
PD model systems, as well as in post-mortem PD patient tissues. Fyn also contributes to 
microglial ASC speck formation in the adenoviral α-synuclein overexpression system. 
Overall, we identify Fyn kinase as a key upstream regulator of the microglia-mediated 
chronic neuroinflammatory cascade that is central to the pathophysiological process of nigral 
dopaminergic degeneration in PD.  
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CHAPTER 1. GENERAL INTRODUCTION 
Thesis Layout & Organization 
The alternative format was chosen for this thesis and consists of manuscripts that 
have been published, or are being prepared for submission. The dissertation contains a 
general introduction, three research papers and a conclusions/future directions section that 
briefly discusses the overall findings from all chapters, and charts out where the research 
story will be taken next. The references for each manuscript chapter are listed at the end of 
that specific section. References pertaining to the background and literature review as well as 
those used in general conclusion section are listed at the end of the dissertation. The 
introduction section under Chapter 1 provides a background and overview of Parkinson’s 
disease (PD). The Background and Literature Review-I section covers current evidence 
implicating a pathogenic role for reactive microgliosis in mediating progressive 
dopaminergic neuron loss in Parkinson’s disease. It also introduces the non-receptor tyrosine 
kinase Fyn and serine threonine kinase protein kinase C delta (PKCδ) and discusses their 
roles in pro-inflammatory signaling in immune cells, thus providing an overview of the 
research objectives pertaining to Chapter 2.  The Background and Literature Review-II 
pertains to Chapters 3 and 4 and provides an introduction to inflammasomes and their roles 
in neurodegenerative and neuroimmune diseases. The manuscript from Chapter 2 was 
recently published in the Journal of Neuroscience. It studies the roles of the Fyn-PKCδ axis 
in mediating pro-inflammatory responses in microglia in in-vitro and in-vivo models of PD.  
Chapter 3 explores how aggregated  α-synuclein, the major component of PD-associated 
Lewy bodies and a gene linked to the development of familial PD, can prime and activate the 
NLRP3 inflammasome in a Fyn dependent manner. Chapter 4 studies how Fyn contributes to 
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microgliosis and inflammasome activation in α-synuclein mediated in-vivo PD models as 
well as in post-mortem PD brain tissues. Chapters 3 and 4 are in the process of being 
submitted for publication. 
All of the research described by the author in this thesis was performed during the 
course of his doctoral studies at Iowa State University under the guidance of Dr. Anumantha 
G. Kanthasamy.  
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Introduction 
First described as the shaking palsy by James Parkinson in 1817, Parkinson’s Disease 
is a progressive neurodegenerative disorder characterized by the onset of motor deficits- 
resting tremors, bradykinesia (or slowness of movement), akinesia (or absence of 
movement), rigidity and postural instability.  Recently, various non-motor symptoms have 
also been linked to PD 
development.  These include 
olfactory deficits, constipation, 
and sleep disorders. In many 
cases, these symptoms can 
precede motor deficits by 
several years. PD is the second 
most-prevalent neurodegener-
ative disorder in the world, 
with over a million currently 
affected in the United States 
alone (von Bohlen und 
Halbach et al., 2004). 
Idiopathic PD has a median onset of 60 years, and the occurrence frequency increases with 
age. The best-characterized feature of PD is the selective death of melanized dopaminergic 
neurons in the substantia nigra (SN) pars compacta (pc) of the brain, which project to the 
caudate putamen. This results in the depletion of dopamine in this region in PD patients. By 
the time the symptoms are manifested, more than 60% of the dopaminergic neurons have 
 
SNpc 
Ventral tegmental 
     area (VTA) 
 
Figure 1. Murine coronal ventral-midbrain section stained for the 
dopaminergic neuronal marker tyrosine hydroxylase (TH) via 3,3'-
diaminobenzidine (DAB) immunohistochemistry 
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already been lost, along with 80% of the striatal dopamine content (Dauer and Przedborski, 
2003).  The death of neurons in other regions, such as the ventral tegmental area (VTA), has 
also been documented. The mouse SNpc and VTA are demonstrated in Figure 1. 
In PD genetics nomenclature, 18 chromosomal regions, which have been assigned a  
‘PARK’ status, have been found to be associated with PD. However, only 6 of these regions 
code for genes that are conclusively responsible for monogenic PD (whereby a mutation in 
the gene is sufficient to cause PD). Among these 6 genes, mutations in SNCA, the gene that 
codes for the α-synuclein protein (PARK1 and 4), and LRRK2 (PARK8) are responsible for 
autosomal-dominant PD (AD–PD) forms, whereas mutations in Parkin (PARK2), PINK1 
(PARK6), DJ-1 (PARK7), and ATP13A2 (PARK9) result in a form of autosomal recessive 
PD (AR-PD) (Klein and Westenberger, 2012). 
The major neuropathological hallmark of sporadic PD is the presence of aggregated 
α-synuclein containing intracytoplasmic Lewy Bodies. The factors that are associated with 
PD associated neurodegeneration include mitochondrial dysfunction, proteasomal 
impairment and excessive reactive oxidative species (ROS) production(Jenner and Olanow, 
2006; Levy et al., 2009; Olanow, 2007; Przedborski, 2005). The emerging consensus 
suggests that PD is a complex, heterogeneous disease with multiple genetic as well as 
environmental causative factors. The fact that multiple interacting factors appear to 
contribute to PD progression makes therapeutic intervention an immense challenge. Most of 
the drugs and therapies that are prescribed for PD patients today, including L-DOPA 
administration and deep brain stimulation, only alleviate PD symptoms and have no effect in 
slowing the progression of the disease.  
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Reactive microgliosis is another prominent feature of PD; loss of dopaminergic 
neurons within the SN is accompanied by a concomitant increase in the number of microglial 
cells found in this region, as well as by an increase in the activation of these cells (Bartels 
and Leenders, 2007; Mosley et al., 2006; Whitton, 2007). Chronic activation of microglia has 
been shown to contribute to 
dopaminergic neuronal death. 
Activated microglia produce ROS 
and nitrite, as well as pro-
inflammatory mediators that can 
directly effect neuron death, and/or 
bring about further glial activation, 
perpetuating the inflammatory 
response. Figure 2 shows Iba-1 
positive microglial cell within the 
SNpc, apposed against a TH positive dopaminergic neuron. 
 The current consensus on the progression of PD is that is arises from the complex 
interactions between the environmental and genetic processes, which in tandem cause the 
progressive loss of dopaminergic neurons over time. A ‘multiple hit’ hypothesis for disease 
onset has been postulated, wherein multiple causative factors can accumulate over decades, 
resulting in what is described as idiopathic PD (Carvey et al., 2006). 
Several genes associated with Parkinson’s Disease have multifactorial roles, 
specifically with regards to neuroinflammation, that may contribute to PD pathology; fibrilar 
α-synuclein can cause apoptosis (Cookson, 2009), and in its aggregated form, can also 
Figure 2 
Figure 2 
Figure 2. Confocal Z-stack maximal projection image of 
dopaminergic neuron and microglial cell in the SNpc of a 6-OHDA 
injected mouse. 
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potently activate microglial cells, leading to the production of proinflammatory cytokines and 
chemokines (Kim et al., 2013a; Lee et al., 2010; Su et al., 2008).  LRRK2, PINK1 and DJ-1 
have also been implicated to play a role in the process of autophagy, required for proper 
degradation and turnover of various proteins and/or organelles within the cell. LRRK2 has 
been shown to promote microglial pro-inflammatory responses (Moehle et al., 2012). PINK1 
deficiency enhances microglial pro-inflammatory signaling in brain slices, including the 
activation of the NF-κB pathway (Kim et al., 2013b), and the loss of DJ-1 promotes pro-
inflammatory signaling in microglia and astrocytes due to hyperactivation of STAT1 (Kim et 
al., 2013c).  
Hence, neuroinflammation may be a promising target to control the progression of 
PD, as well as other neurodegenerative disorders; exacerbated neuroinflammation has been 
demonstrated in every model of PD, and non-steroidal anti-inflammatory drug intake has 
been linked to a lower risk of acquiring PD (Bower et al., 2006; Chen et al., 2003). 
Therefore, identification of novel signaling pathways that play a role in the hyperactivation 
of microglia may serve as an attractive drug target to prevent the progression of PD. 
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Background and Literature Review – I 
Neuroinflammation and an introduction to Fyn and PKCδ signaling  
Inflammatory responses need to be tightly regulated; on the one hand, they must effectively 
deal with invading pathogens, killing and clearing them as well as dead or dying cell debris, 
which if left uncleared, would prevent healing and serve as sites for infection. At the same 
time, the responses themselves produce potentially toxic factors that can elicit significant 
pathology (Glass et al., 2010). Neuroinflammation is an example of the latter process gone 
awry within the central nervous system (CNS). An exaggerated neuroinflammatory 
component has been consistently associated with most neurodegenerative disorders, such as 
Alzheimer’s disease, Amyotrophic lateral sclerosis, Huntington’s disease and PD (Block et 
al., 2007; Minghetti, 2005). The hallmark of neuroinflammation is the persistent 
hyperactivation of the microglia and astrocytes at the site of neurodegeneration.  In many of 
these diseases, this hyperactivation is mediated by sterile inflammogens in the form of 
aggregated or misfolded proteins or peptides, as indicated in Table 1. Previously, the major 
role of reactive gliosis accompanying neurodegeneration was believed to be phagocytic 
clearance of dead and dying neurons, and thought to be a generally supportive process to 
maintain homeostasis within the central nervous system (CNS). One major reason for this 
line of thought is because microglia have been demonstrated to play a role in establishment 
of synapses within the developing brain, and contribute to neuronal health by the production 
of various trophic factors (Aarum et al., 2003; Walton et al., 2006). Microglia also serve as 
the major neuroimmune response to infection within the central nervous system. In many 
cases post acute brain injury or infection, neuroinflammatory responses are transient, and 
subside upon clearance of the offending substance. However, in neurodegenerative disorders  
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such as PD, the neuroinflammatory responses are chronic and progressive, and are 
demonstrated in most animal models of the disease, such as the MPTP, 6 –OHDA and LPS 
models (Panicker et al., 2015) as well as in post mortem PD patient tissues (Imamura et al., 
2003). 
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Microglial cells and their role in the CNS 
Microglia are the resident macrophagic cells of the CNS. Rio Hortega was the first to 
observe their phagocytic properties and suggest that they could function similarly to 
macrophages. This was later corroborated by Hickey and Kimura (Hickey and Kimura, 
1988), when they demonstrated that perivascular microglia are antigen presenting cells that 
express high levels of MHC class II molecules. Contrary to popular opinion, microglial cells 
do not arise from the bone-marrow hematopoietic stem cells. Utilizing studies carried out 
with parabiotic mice (which are surgically connected and have a common blood circulatory 
system) suggested that postnatal microglial cells are maintained in the CNS independently of 
circulating monocytes. They were found to arise from primitive myeloid progenitors, which 
arise from the yolk sac (Ginhoux et al., 2013). Microglia comprise 10-15% of the total cells 
in the brain, and their density varies with different areas of the brain – the hippocampus and 
ventral midbrain, including the SN, show highest concentrations of microglia. Microglial 
activation is our body’s first response to neuronal injury in both acute and chronic 
neurodegenerative states. In a normal adult brain, microglia typically exist in their normal or 
‘resting’ state, which is consistently identifiable by a ramified morphology. They secrete 
anti-inflammatory and neurotrophic factors which promote neuronal survival and plasticity 
(Carson, 2002). Recent studies have demonstrated that microglia are highly dynamic and 
mobile; constantly scanning and surveying their external microenvironment for signs of any 
kind of neuronal injury (Nimmerjahn et al., 2005). Upon encountering a potential pathogen 
or neuroinflammatory agent, these cells undergo a rapid transformation to an amoeboid form, 
or ‘activated’ state, with concurrent upregulation of various cell surface proteins as well as 
cytokine and chemokine receptors. Transcriptional activation of response genes typically 
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occurs rapidly in microglia. Activated microglia can produce a plethora of secreted factors 
that can alter the environment at the site of neuronal injury or cell death. ‘Natural’ activation 
of microglia, which is transient and highly regulated, typically facilitates a microenvironment 
that is conducive to neuron survival and restoration of homeostasis (Glezer et al., 2007; 
Napoli and Neumann, 2010; Simard and Rivest, 2007). To achieve that goal, microglia 
produce anti-inflammatory factors such as BDNF, GDNF, IL-10 and TGFβ1, which can 
actually prevent neuronal apoptosis and effect neuronal differentiation of existing pools of 
neuronal progenitor cells. Microglia have also been shown to protect neurons from 
excitotoxicity by upregulating GLT-1, a glutamate uptake protein under conditions where 
astrocytic glutamate uptake is impaired (Persson et al., 2005; Shaked et al., 2005). 
Additionally, microglia are solely responsible for the phagocytic clearance of dead cells from 
the site of injury. They can also participate in the regeneration of synapses by facilitating 
synapse removal at the site of injury. The stripping of synapses and clearance of local cell 
debris provides an environment that engenders neurogenesis and the migration of 
neuroprogenitor cells in the brain. Microglia can also inhibit local neurogenesis by providing 
a local pro-inflammatory environment (Butovsky et al., 2006). Their activation and secretion 
of trophic factors at the site of injury for infection was thought to facilitate a return to 
homeostasis (Kreutzberg, 1996). 
 
Microglial activation in neurodegenerative disorders 
Unregulated, elevated and sustained levels of microglial activation leads to microglial 
hyperactivation, which is the predominant state of microglia at the site of neuron loss in case 
of neurodegenerative disorders. Hyperactivation of microglia is distinct from the transient 
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microglial activation, both morphologically as well as in regards to the secretory factors 
produced. Several lines of evidence, from cell culture, co-culture, animal models, post 
mortem tissue analyses and genetic linkage analysis conclusively demonstrates that sustained 
neuroinflammation negatively affects neuron health, and in fact contributes to neuron death. 
Activated microglia change their morphology from ramified or branched to amoeboid. 
Activated microglia release ROS, nitrite and various other pro-inflammatory mediators and 
cytokines that can be toxic over time (Aschner et al., 1999; Glass et al., 2010). 
 
Clinical evidence of neuroinflammation playing a critical role in the progression of PD 
Substantiation for the critical role of neuroinflammation and microglial 
hyperactivation in PD comes from several sources; Post mortem analysis of PD brains clearly 
indicates amoeboid microglia around the regions of melanized dopaminergic neuron loss. PD 
Patients also display upregulated levels of pro-inflammatory cytokines in their cerebrospinal 
fluid (Banati et al., 1998; McGeer et al., 1988; Vawter et al., 1996; Whitton, 2007). Increased 
levels of many of these cytokines, such as TNFα, IL-1β and IFNγ has also directly 
demonstrated within the PD brain itself (Hirsch et al., 2005; Hunot et al., 1997; McGeer et 
al., 1988; Mogi et al., 2000). Apart from nigral inflammation, excessive inflammation in the 
striatum and basal ganglia has also been demonstrated via PET imaging. New evidence also 
suggests that innate immune responses may not be the sole signaling mechanisms that go 
awry in PD; Animal PD models, and more importantly, post-mortem PD tissue analysis also 
revealed the entry of CD8+ and CD4 + cells into the SN. Infiltrating T cells can serve as 
neuroprotective as well as neurotoxic agents, depending on the pre-existing stimuli within the 
brain. Post mortem analysis of the heroin addicts who accidentally injected MPTP and 
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developed rapid onset Parkinsonism also demonstrated massive microgliosis (Langston et al., 
1999). Adenoviral overexpression of IL-1β in the SN of mice was discovered to cause 
progressive dopaminergic neurodegeneration and a concurrent loss of motor function (Ferrari 
et al., 2006). Several genetic linkage studies in PD patient and age-matched control groups 
have identified single nucleotide polymorphisms (SNPs) that are linked to PD development. 
Some of the SNPs are found within the promoter regions of pro-inflammatory genes 
(Hakansson et al., 2005; Kruger et al., 2000; Nishimura et al., 2001; Nishimura et al., 2000).  
Lastly, as mentioned in the introduction section, regular NSAID use is associated with a 
reduced risk for developing PD. 
 
Evidence for neuroinflammation in animal models of PD 
Neuroinflammation has consistently been demonstrated as being a fundamental 
hallmark of every PD mouse model: 
1. The MPTP model  
An acute regimen of the Parkinsonian toxicant MPTP (4 injections at 18 mg/kg, 
spaced out every 2 hours) has widely been used to evoke a neuroinflammatory response, 
evidenced by an induction of pro-inflammatory proteins with the SN and the Striatum, and 
concurrent change in microglial morphology from ramified to amoeboid. (Hirsch and Hunot, 
2009; Sriram et al., 2006; Wu et al., 2002; Wu et al., 2003). Preventing microglial 
hyperactivation by preventing microglial ROS generation via NAPDH complex inhibition, as 
well as inhibiting microglial NOS2 and NF-κB function can be greatly neuroprotective in 
this model (Du et al., 2001; Ghosh et al., 2002; Ghosh et al., 2007). 
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2. The 6-OHDA model  
Before the development of the MPTP model, the 6-OHDA model was widely utilized 
to elicit neurodegeneration within the SN. Despite its usage, which began in the 1960s, 
evidence of neuroinflammation in this model was only recently demonstrated with 
unequivocal clarity (Stott and Barker, 2014; Virgone-Carlotta et al., 2013). 
3. AAV-Synuclein overexpression model  
Recently developed models of PD include the AAV-SYN model, which entails 
delivery of an adeno-associated virus overexpressing human α-synuclein into the SN or the 
striatum. 
Green 
fluorescent 
protein 
overexpressi
ng adeno-
associated 
virus(AAV-GFP) is used as the control for these experiments. Several studies have 
demonstrated a clear role of microgliosis, including increased pro-inflammatory cytokine 
production,  and IgG deposition within the SN (Chung et al., 2009; Theodore et al., 2008). 
AAV mediated GFP overexpression in the SNpc dopaminergic neurons is demonstrated in 
Figure 3. 
4. The Mitopark model  
The recently developed Mitopark model entails the selective knockdown of the 
mitochondrial transcription factor TFAM in dopaminergic neurons. This results in a 
 
SNpc Red: TH Green:GFP 
Figure 3. AAV-mediated GFP overexpression in the SNpc dopaminergic neurons. The AAV-
GFP construct was stereotactically injected into the mouse SNpc and targeted overexpression 
validated by double IHC for GFP and TH. 
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progressive, age dependent loss of dopaminergic neurons that begins from 12 weeks 
onwards. Recent evidence of neuroinflammation in the MitoPark mice were recently 
demonstrated by our group (Langley et al., unpublished). 
5. Lipopolysaccharide (LPS) based models of PD  
Possibly the strongest evidence for the role of inflammation in PD, comes from 
various animal models that utilize LPS as a Parkinsonian neurotoxin. LPS is a component of 
the cell wall of gram negative bacteria. It is a potent inflammogen, acting as a pathogen 
associated molecular pattern (PAMP) that evokes an innate inflammatory response from 
immune cells. Intranigral injection of LPS is sufficient to elicit both a neuroinflammatory 
response, as well as dopaminergic neuron death in the absence of any other neurotoxic agent. 
Intraperitoneal administration of LPS is also able to elicit a  rapid, yet sustained 
neuroinflammatory response (Castano et al., 1998, 2002; Herrera et al., 2000; Hsieh et al., 
2002; Qin et al., 2007). The LPS model is distinct from all the aforementioned models, since 
the other models elicit a microglial response by first bringing about dopaminergic neuron 
loss or stress, whereas LPS selectively brings about microglial activation and subsequent 
neuron death. LPS can also act in concert with MPTP and other mitochondrial toxicants 
including rotenone, paraquat and manganese to amplify dopaminergic cell death (Gao et al., 
2003a, b; Zhang et al., 2010), indicating that PD associated environmental hazards can 
contribute to PD associated neuroinflammation and neuron loss. 
 
Signaling mechanisms that regulate microglial hyperactivation in Parkinson’s disease 
Although the LPS model clearly demonstrates that microgliosis can initiate and contribute to 
dopaminergic neuronal loss, the clinical significance of using LPS is limited, since PD does 
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not involve CNS bacterial infection. However, in the past few years, it has become evident 
that misfolded proteins within 
the CNS can elicit a sterile 
inflammatory response in 
microglial cells. Exploring the 
cell signaling mechanisms that 
regulate microgliosis is an 
active area of investigation. α-
synuclein, the 14 kDa protein 
which was found to be 
associated with AD PD as well as a major component of PD associated Lewy bodies was 
found to activate microglia in its aggregated, nitrated and oxidized form (Reynolds et al., 
2008; Zhang et al., 2005), α-synuclein is taken up by microglia, which is followed by the 
production of ROS and various pro-inflammatory cytokines, and this neuroinflammatory 
response has been shown to be complicit in the cell death that occurs in these models. Even 
though it has been conclusively demonstrated that pathogenic forms of α-synuclein can lead 
to MAP kinase activation and nuclear p65-NF-κB translocation, the signaling pathway 
through which these classical inflammatory signaling pathways were activated in microglia 
post synuclein stimulation is poorly characterized.  The aggregated α-synuclein mediated 
pro-inflammatory cytokine induction was only recently shown to be Myd-88 dependent 
(Daniele et al., 2015). The receptor that mediates α-synuclein uptake and is responsible pro-
inflammatory signaling has not been conclusively identified, although circumstantial 
evidence in various studies has identified TLR2 (Kim et al., 2013a), TLR4 (Fellner et al., 
Figure 4. Sterile inflammation and neurodegeneration: A mutually 
amplifying, self-sustaining process. 
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2013) CD36 (Su et al., 2008), And the gamma chain subunit of Fc receptors (Cao et al., 
2012). 
Apart from modified forms of α-synuclein, the neuromelanin found in melanized 
dopaminergic neuronal cells can be taken up my microglia and activate them (Wilms et al., 
2003; Zecca et al., 2008). Neuron secreted Matrix Metalloprotease 3 (MMP-3) MMP-3, 
which activates microglia via protease-activated receptors (Kim et al., 2007). Lastly, PD 
associated environmental toxicants such as the pesticides rotenone and paraquat (Bonneh-
Barkay et al., 2005; Gao et al., 2002) were shown to elicit neuronal death through microglial 
ROS generation.  
The current consensus of the role that neuroinflammation plays in PD is summarized 
in Figure 4, (adapted from Block et al., 2007), which demonstrates that neuronal damage, 
wrought by environmental toxicants or mutations, effect the release of misfolded proteins 
from dead or dying dopaminergic neurons. These misfolded proteins can activate resident 
brain microglia, bringing about the release of ROS, nitrite and pro-inflammatory cytokines, 
which can further exacerbate neuronal health. In summary, sterile neuroinflammation plays a 
significant role in the development of PD, but the signaling mechanisms that underlie this 
process are poorly understood and characterized. Discovering novel signaling nodes could 
identify potential targets for developing therapies for PD. 
 
Fyn kinase 
 Fyn is a member of the Src family kinase (SFK) family, which comprises of proto-
oncogenes that play key roles in cell morphology, motility, proliferation, and survival. v-Src 
(a viral protein) is encoded by the chicken oncogene of the Rous sarcoma virus, and Src (the 
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cellular homologue) is encoded by a physiological gene, the first of the proto-oncogenes. 
From the N- to C-terminus, as demonstrated in Scheme 2, Src kinases contain an N-terminal 
14-carbon 
myristoyl 
group, a unique 
segment, an 
SH3 domain, an 
SH2 domain, a 
protein–tyrosine kinase domain, and a C-terminal regulatory tail (Roskoski, 2004). Src 
activity is regulated by a well-studied post-translational mechanism - tyrosine 
phosphorylation. The phosphorylation of different domains is responsible for the control of 
the kinase activity of this family of enzymes, bringing about a change in their conformation 
to activated or inhibited states (Boggon and Eck, 2004). The key sites that were identified to 
undergo these events were - Y529, which is 6 residues upstream of the C-terminus and Y417 
in the kinase domain. Phospho-Y-529 binds intramolecularly with the Src SH2 domain, 
keeping the kinase in a closed and inactive conformation. Y417, which occurs in the 
activation loop, is sequestered and is not a substrate for phosphorylation by another kinase. 
When phospho-Y-529 dissociates or is displaced from the SH2 domain, Y417 can be 
phosphorylated, usually by another Src kinase molecule. The phosphorylation of Y417 
residue is a key to several signaling events, activating Src kinases and enabling them to 
achieve high levels of kinase activity.  
The switch between phosphorylation dependent activation and inactivation of Src 
kinases is controlled by several cellular signaling molecules.  Csk (C-terminal src kinase) and 
Figure 5. Domain structure of Fyn kinase. 
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Chk (Csk homologous kinase) are two tyrosine kinases that are known to phosphorylate 
Y529 – the inhibitory tyrosine of SFK (Chong et al., 2005; Cole et al., 2003). Csk forms an 
inhibitory complex with Src through non-covalent interactions regardless of the 
phosphorylation state of Src (Chong et al., 2005).  
Signal transduction involving SFKs are initiated by ligand mediated as well as ligand-
independent pathways. Non-ligand mediated activation of SFKs involve several ROS species 
such as H2O2 and nitric oxide (Meurer et al., 2005; Yan and Berton, 1996), diamide 
(Nakamura et al., 1993), oxidized low-density lipoproteins (Maschberger et al., 2000), 
alkylating agents such as iodoacetamide (Devary et al., 1992), heavy metal ions such as 
mercury and arsenic (Soto-Pena and Vega, 2008) and X-rays (Kharbanda et al., 1994). 
Ligand mediated pathways such as coupling of T-cell receptors, Fc receptors and cytokine 
receptors have been shown to activate SFKs (Gilfillan and Rivera, 2009; Salmond et al., 
2009; Smith-Garvin et al., 2009). Fyn’s putative role in Alzheimer’s disease associated 
neurodegeneration has been a subject of intense scientific investigation for the past decade. 
Fyn kinase mediates the accumulation and redistribution of amyloid-β in the lipid rafts. This 
mechanism explained the accumulation of amyloid-β and tau and the key mechanism to 
amyloid-β derived diffusible ligand mediated neuronal death (Williamson et al., 2008). Fyn 
has also been shown to phosphorylate α-synuclein at tyrosine residue 125 (Nakamura et al., 
2001). However, the physiological or pathological implications of this phosphorylation and 
PD are yet to be investigated. It was recently demonstrated that amyloid-β oligomers bound 
to post-synaptic prion protein in neurons, activating Fyn and Fyn-mediated tyrosine 
phosphorylation of the NR2B subunit of the NMDA receptor, leading to cell death (Um et 
al., 2012). Fyn was also shown to directly phosphorylate Tau at tyrosine residue 18, 
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promoting its disassociation from microtubules and the formation of Tau fibrils (Lee et al., 
2004). Recently, we published a study that identified Fyn as the Src kinase that 
phosphorylates PKCδ at Y311 upon oxidative stress administration in dopaminergic neuronal 
cells, leaving it susceptible to caspase-3 mediated proteolytic cleavage (Saminathan et al., 
2011).  
 
Role of Fyn in immune signaling  
Early studies demonstrated that thymic Fyn plays a crucial role in mounting signaling 
responses in T cells in response to stimulation with antibodies raised against the TCR co-
receptor CD3 as well as mitogens (Appleby et al., 1992; Cooke et al., 1991). In mast cells, 
Fyn was found to associate with the FcεRI receptor, and mediate degranulation and pro-
inflammatory cytokine production (Furumoto et al., 2005). Subsequent research in this area 
showed that Fyn activation downstream of FcεRI activation fed into the JNK pathway, and 
NF-κB pathway activation, leading to the production of the pro-inflammatory cytokines IL-6 
and TNF-α, as well as the secretion of arachidonic acid. Interestingly, in a gene expression 
array used in the same study to identify transcripts whose levels were lower in stimulated 
Fyn-/- mast cells, the pro-IL-1β transcript was identified (Gomez et al., 2005). IL-1β is a 
cytokine associated with activation of inflammasomes, which will be the subject of the 
subsequent literature review. The hypersensitivity of Lyn deficient mast cells to stimulation 
was attributable to increased levels of Fyn mRNA and Fyn signaling (Hernandez-Hansen et 
al., 2005). With respect to mast cell degranulation, Fyn was shown to mediate Gab2 and Akt 
phosphorylation, feeding into PKCδ mediated degranulation (Parravicini et al., 2002). The 
anti-inflammatory activities of delphinidin, an anthocyanidin found in red wine and berries, 
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were attributed to its inhibition of Fyn kinase directly (Hwang et al., 2009). GPRC5B-
associated Fyn contributed to NF-κB activation in inflammatory signaling in adipocytes, 
leading to increased obesity and inflammation in murine adipose tissue (Kim et al., 2012). 
More recently, Fyn was also shown to mediate NF-κB pathway activation downstream of 
NKG2D and CD137 activation in natural killer cells, utilizing a signaling mechanism 
dependent on ADAP (Rajasekaran et al., 2013). The role of Fyn in neuroinflammation has 
been an active area of investigation, and studies have shown that CD36 associated Fyn and 
Lyn contribute to amyloid-β induced ROS generation and (Moore et al., 2002).  Fyn was also 
shown to regulate microglial migration via phosphorylation of p130Cas (Stuart et al., 2007). 
However, these studies were largely performed using peritoneal macrophages as substitutes 
for microglial cells. Microglia and macrophages have different origins and disparate gene 
expression profiles (Hickman et al., 2013).  Recent work also demonstrated that CD36 
contributes to pro-inflammatory cytokines in BV2 microglia post activation by neurotoxic 
prion protein fragment, and associates with Fyn to mediate its pro-inflammatory actions. 
However, the authors of this study did not directly show interaction of Fyn and CD36, 
(activation of Fyn was prevented using neutralizing antibody to CD36, providing 
circumstantial evidence for interaction) Moreover, the authors did not chemically or 
genetically inhibit/ reduce Fyn levels to show what role it might play in the process. Also, 
activation of Fyn was by a blot for activated Src family kinases, which does not distinguish 
between Fyn and other Src family kinases (Kouadir et al., 2012). 
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Protein kinase C delta (PKCδ) 
PKCδ was 
discovered by 
Geschwendt in 1986 and 
cloned from the rat 
brain cDNA library 
(Gschwendt et al., 1986). Classified under the AGC kinase family, twelve distinct PKC 
isoforms have been identified and grouped into three well-characterized sub-families. Based 
on their modes of activation, PKCs are classified as classical or conventional PKCs (α , βI, 
βII and γ ; cPKCs), novel PKCs (δ, θ, ε, η ; nPKC), and atypical PKCs (ζ and λ  (mouse)/ 
τ(human); aPKCs (Corbalan-Garcia and Gomez-Fernandez, 2006).  
All PKCs are composed of an N-terminal regulatory domain and C-terminal catalytic 
domain that is connected at the variable region - V3. cPKCs contain four conserved regions 
(C1-C4) and five variable regions (V1-V5). The structure of PKCδ is depicted in Scheme 1. 
The cPKCs are dependant on intracellular calcium concentrations and are activated by 
diacylglycerol (DAG), while nPKCs are activated by DAG and are calcium independent. The 
aPKCs don’t require either calcium or phospholipids for their activity (Kanthasamy et al., 
2003). PKCδ does not possess the C2-region that binds Ca2+ and therefore is calcium-
independent for its activity (Pappa et al., 1998). PKCδ has been implicated in cell 
differentiation, secretion and apoptosis. We have shown PKCδ is expressed in the rat and 
mouse substantia nigra and striatum (Yang et al., 2004; Zhang et al., 2007). PKCδ is 
activated by DAG binding to the regulatory domain and by translocation to the cell 
membrane and other sub-cellular organelles. Several apoptotic stimuli activate PKCδ in 
Figure 6. Domain structure of PKCδ 
22 
 
different cell types by post-translational modifications such as phosphorylation at 
serine/threonine and tyrosine residues. Ser-643, Thr-505, and Ser-662 are known to be 
phosphorylated, and influence PKCδ kinase activity (Kanthasamy et al., 2003).  
Proteolytic cleavage of PKCδ by caspase-3 in non-neuronal cell types in response to 
several apoptotic stimuli has been identified (Emoto et al., 1995; Ghayur et al., 1996; 
Koriyama et al., 1999; Leverrier et al., 2002; Sitailo et al., 2006). Studies from our group 
demonstrated that PKCδ is proteolytically cleaved by caspase-3 in response to numerous 
apoptotic stimuli in neuronal models to yield a 41 kD catalytically active and a 38 kD 
regulatory fragment. This results in increased activity of the kinase. We have also shown that 
prevention of the proteolytic activation of PKCδ rescues the dopaminergic neurons from 
apoptosis (Kitazawa et al., 2003; Kitazawa et al., 2005; Kitazawa et al., 2002; 
Latchoumycandane et al., 2005; Sun et al., 2005). The pro-apoptotic role of PKCδ in 
experimental PD models is well-established finding and understanding the mechanisms of 
activation of this kinase presents with a novel molecular candidate in the intervention of PD 
progression. Tyrosine phosphorylation of PKCδ and caspase-3 dependant cleavage during 
apoptotic stimuli are the key determinants of its pro-apoptotic function. Moreover, 
preincubation of the neuronal cells with both, a broad specific kinase inhibitor, and a Src 
kinase inhibitor, prevented Y311 phosphorylation and cleavage of PKCδ, thereby rescuing 
the cells from apoptosis (Kaul et al., 2005).  
 
Role of PKCδ in immune signaling 
PKCδ has been found to contribute to pro-inflammatory signaling in several cell 
types; In monocytes, LPS treatment caused the cytosol to membrane translocation of PKCδ . 
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Pharmacological inhibition of PKCδ by Rottlerin, a chemical inhibitor, attenuated the 
production of TNFα and IL-1β via diminishing the DNA binding activity of the transcription 
factor AP-1 (Kontny et al., 2000). Staphylococcus aureus peptidoglycan mediated nitrite 
production in macrophages was diminished by inhibition of PKCδ (Bhatt et al., 2011). A 
mechanistic investigation into how PKCδ might mediate its pro-inflammatory activities 
showed that it interacted with the TLR adaptor protein TIRAP via its TIR domain (Kubo-
Murai et al., 2007).  PKCδ-/- macrophages showed diminished cytokine and nitrite levels 
when stimulated with LPS/IFNγ, with or without co-infection with Leishmania major (Guler 
et al., 2011). It was also shown to mediate the LPS mediated induction of the sepsis effector 
soluble fms-like tyrosine kinase-1 receptor in macrophages (Lee et al., 2008). Genetic 
knockdown of PKCδ via sh-RNA resulted in reduced oxidized LDL (OxLDL) uptake and the 
intracellular accumulation of cholesterol in THP-1 monocyte derived macrophages as well as 
primary macrophages, leading to CD36 upregulation and foam cell formation (Lin et al., 
2012). In vascular smooth muscle cells, PKCδ interacted with the p65 subunit of the NF-κB 
subunit, and mediated S536 phosphorylation (Ren et al., 2014). In dendritic cells, it was 
found to contribute to antigen presentation and activation (Majewski et al., 2007). PKCδ 
mediates Cd11b expression and MMP release in eosinophils (Langlois et al., 2009).  It also 
mediates the activation of the NAPDH oxidase and the ROS production in response to COS-
7 cell stimulation (Cheng et al., 2007). In a model of sepsis, a PKCδ inhibitor peptide treated 
mice had reduced levels of several pro-inflammatory chemokines in lung and blood samples.  
There was also a concurrently diminished infiltration of inflammatory cells into the lungs, 
and alleviated pulmonary edema (Kilpatrick et al., 2011). PKCδ inhibited the anti-apoptotic 
signaling mediated by TNFα in neutrophils (Kilpatrick et al., 2002). In human bronchial 
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epithelial cells, PKCδ was shown to participate in NF-κB activation and IL-8 release 
(Cummings et al., 2004). PKCδ deficient mice that were exposed to asbestos showed 
diminished accumulation of several pro-inflammatory cytokines in their lung fluid, as well as 
a reduced infiltration of immune cells within the lung (Shukla et al., 2007). Specifically with 
regards to neuroinflammation, chemical inhibition of PKCδ prevented NF-κB activation and 
nitrite generation in microglia (Kim et al., 2005). PKCδ has been shown to mediate 
neuroinflammatory responses to LPS and IFNγ in microglial cells (Shen et al., 2005). 
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Background and Literature Review – II 
Inflammasomes and their role in neurodegenerative diseases 
A major role of the innate immune system is to recognize tissue damage that occurs 
as the result of an injury, requiring clearance of cell debris and dead cells. Invading 
pathogens need to be eliminated and cleared. The innate immune system does this by the 
means of receptors that recognize both, modified self-molecules, as well as foreign molecules 
(Kato et al., 2011; Kawai and Akira, 2011). Inflammasomes are a crucial arm of the innate 
immune system. First described by Tschopp in the early 2000s, inflammasomes are large, 
cytosolic multimeric assembly platforms that effect the activation of pro-inflammatory 
caspases such as Caspase-1.  These complexes comprise of an inflammasome sensor 
receptor, the adaptor protein ASC, and Caspase-1, which upon receiving the appropriate 
stimulus cleaves itself into the active p20 form, which in turn cleaves inflammatory pro-
cytokines into their mature secretable form. The 2 major cytokines that are released upon 
inflammasome activation are IL-1β and IL-18 (Martinon et al., 2002). Concurrently, 
inflammasomes also bring about a rapid, pro-inflammatory form of cell death called 
pyroptosis (Miao et al., 2011). 
Inflammasome biology is an extremely active area of research; as pattern recognition 
receptors such as cytosolic inflammasome receptors are identified, the cellular signaling 
processes that occur downstream of their activation are being elucidated. Although 
inflammasomes play a crucial role in mounting innate immune responses to potential 
pathogens, recent discoveries have shed light on how their signaling goes awry in a whole 
host of diseases such as atherosclerosis, type 2 diabetes, and Alzheimer’s disease. Recent 
compelling evidence has suggested that inhibiting inflammasomes could protect against 
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many of the aforementioned diseases, which have an immune hyperactivation component.  
 
Structure of major inflammasome components 
The components of the major 
studied inflammasomes are shown in 
Figure 7, (adapted from Lamkanfi and 
Dixit, 2014). 
1. Cytosolic receptors  
Inflammasome receptors 
belong to the class of pattern 
recognition receptors that reside in the 
cytoplasm, and include the nucleotide 
binding domain and Leucine-rich 
repeat containing receptors (NLRs) 
(Takeuchi and Akira, 2010) and the 
AIM-2 like receptors (ALRs). NLRs, such as NLRP3, NLRP1b and NLRC4 contain a 
NACHT domain and variable number of Leucine-rich repeat domains (LRR). NLRP3 and 
AIM2 contain pyrin domains, through which they interact with the pyrin domains of ASC. 
The NACHT domains possess ATPase activity, and may contribute to the oligomerization of 
inflammasome complexes, and the LRRs may facilitate ligand interaction. NLRP1b and 
NLRP3 have Caspase activation and recruitment domains (CARD), through which they can 
directly activate Caspase-1. However, the presence of ASC can stabilize and increase the 
efficiency of these inflammasomes (Mariathasan et al., 2004; Proell et al., 2013). The NLRP1 
Figure 7. The major studied inflammasomes. 
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inflammasome has a function to find domain (FIIND), and seems to require auto-proteolysis 
within this domain in order to become active (D'Osualdo et al., 2011; Finger et al., 2012).  
2. The adaptor molecule ASC  
ASC is an adaptor protein encoded by the PYCARD gene. It interacts with the 
cytosolic inflammasome receptors via its pyrin domain. This interaction facilitates the 
condensation of the cytosolic ASC into large specks, which mostly comprise of multimers of 
ASC dimers (Fernandes-Alnemri et al., 2007).  In ASC overexpressing cells, the pool of ASC 
coalesces into a single large speck following inflammasome activation and assembly. 
3. Caspase-1  
Caspase-1 is recruited to the inflammasome assembly via ASC, by the means of its 
CARD. Two monomers of Caspase-1 are brought close to each other, and this results in the 
self-cleavage and consequent activation of Caspase-1. Active Caspase-1 cleaves the pro-
cytokines pro-IL-1β and pro-IL-18 into their mature forms, following which they are 
secreted from the cell (Gu et al., 1997; Thornberry et al., 1992). 
Caspase-11 can also bring about the cleavage of pro-IL-1β through non-canonical 
inflammasome activation, and it is activated by a hitherto unknown receptor. 
The major studied inflammasomes are: 
1. The NLRC4 inflammasome  
Expressed mainly in cells that are hematopoietic in origin, NLRC4 can directly 
activate Caspase-1 through its CARD. Deletion of the LRR domain results in excessive 
Caspase-1 activation, indicating that the LRR may have an inhibitory function to prevent 
hyperactivation of the inflammasome (Poyet et al., 2001). The NLRC4 inflammasome has 
been found to play a role in host response to microbial infection. Infection of murine 
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macrophages with Shigella brings about dual activation of both the NLRC4 and NLRP3 
inflammasomes (Suzuki et al., 2007; Willingham et al., 2007), showing that multiple NLRs 
might respond to the same microorganism, but recognize disparate bacterial products. The 
NLRC4 mediated response to these pathogens is dependent on ASC, evidenced by the 
finding that ASC deficient macrophages produce significantly less IL-1β and IL-18. 
However, ASC is not required for NLRC4 dependent pyroptotic cell death. The major 
bacterial activator of the NLRC4 inflammasome was shown to be flagellin (Franchi et al., 
2006; Miao et al., 2006). However, responses to Shigella were found to be NLRC4 
dependent even though Shigella lacks flagellin, but these apparent discrepancies can be 
explained by the fact that certain rod protein components in microorganisms can serve as 
activators of the NLRC4 inflammasome (Miao et al., 2010). The posttranslational 
modifications that govern NLRC4 activation are largely unstudied. One notable exception is 
the study that showed how NLRC4 serine 533 phosphorylation mediated by PKCδ is 
strongly required for NLRC4 inflammasome activation (Qu et al., 2012). 
2. The NLRP1 inflammasome  
NLRP1 is expressed on adaptive immune cells as well as other cell types, including 
neurons. The first discovered activator of the NLRP1 inflammasome thus far is the major 
toxin from Bacillus anthracis, Lethal toxin (LT). This discovery stemmed from the 
observation that certain strains of mice with polymoprhisms for the NLRP1b gene were more 
susceptible to LT (Boyden and Dietrich, 2006). This lead to the discovery of the NLRP1b 
inflammasome, which is a membrane-associated inflammasome that mediates the LT 
induced production of IL-1β and IL-18. NLRP1 has a CARD domain through which it can 
recruit and activate Caspase-1 without ASC (Nour et al., 2009), although studies have shown 
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that ASC presence can increase the efficiency of the inflammasome (Faustin et al., 2007). 
The NLRP1 inflammasome is unique in its requirement for muramyl di-peptide for its 
assembly. Its assembly was also found to require K+ efflux from the cell and lysosomal 
cathepsin B release, and these requirements for activation are shared by the NLRP3 
inflammasome as well. 
3. The AIM2 inflammasome  
This is the only inflammasome described here that does not comprise of a NLR as its 
cytosolic receptor. AIM2 was initially identified in a tumor screen for melanoma (DeYoung 
et al., 1997). It was later identified as an inflammasome receptor (Hornung and Latz, 2010). 
AIM2 contains an N terminal pyrin domain, which is utilized for interactions with ASC, and 
a C terminal HIN200 domain. The latter binds to double stranded DNA. AIM2 
inflammasome activation occurs through DNA binding, and the ds-DNA- AIM2 complex 
then recruits ASC, and Caspase-1. The AIM2 inflammasome does not sense the origin of 
DNA as self or non-self, but instead detects the presence of cytosolic DNA to become 
activated. Owing to these properties, this inflammasome was thought to play a role in the 
response to microorganisms that invade the cells. In favor of this hypothesis, Aim1-/- 
macrophages display diminished IL-1β and IL-18 production in response to vaccinia and 
mouse cytomegalovirus (Fernandes-Alnemri et al., 2010; Rathinam et al., 2010). 
4. The NLRP2 inflammasome  
NLRP2 is a NLR that was found to inhibit the NF-κB pathway and subsequent TNFα 
production in macrophages, whilst simultaneously contributing to the production of IL-1β 
through ASC (Bruey et al., 2004; Conti et al., 2005). Intriguingly, the expression of NLRP2 
itself was found to be mediated by p65- NF-κB, in what might constitute a negative feedback 
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loop that limits NF-κB activation (Fontalba et al., 2007). Even though limited studies exist 
on this inflammasome, it may have clinical relevance; a functional and unique NLRP2 
inflammasome was discovered in astrocytes, which will be discussed in the subsequent 
section. 
5. The NLRP3 inflammasome  
The NLRP3 inflammasome is the best-characterized and most widely studied 
inflammasome. It is unique among other inflammasomes, in that the basal levels of NLRP3 
are low in 
‘resting’ cells 
such as 
macrophages or 
microglia.  
Activation of 
this 
inflammasome 
is a two-step 
mechanism, 
and is summarized in Figure 8.  It is hypothesized that this two-step activation mechanism 
provides a checkpoint to prevent uncontrolled release of IL-1β. The first step, priming, is 
required to increase the levels of pro-IL-1β and NLRP3. The TLR ligand LPS and the 
TNFR1 ligand TNFα are adept at mediating this induction via activation of the NF-κB 
pathway (Bauernfeind et al., 2009). The nature of the second step, which induces the 
Figure 8. Dual signal activation mechanism of the NLRP3 inflammasome. 
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assembly of the inflammasome, is strongly contested. However, the generally accepted 
consensus is that mitochondrial dysfunction and mito-ROS generation, along with lysosomal 
disruption, play a role in the process. K+ efflux is also important for optimal activation to 
occur. The NLRP3 inflammasome is activated by a huge variety of molecules, calling into 
question whether it really is a receptor at all, or if it reacts to changes in the cytosol as a 
result of mitochondrial or lysosomal disruption. In support of this notion, mitochondrial 
toxicants can bring about activation of NLRP3 inflammasome dependent responses in 
macrophages (Zhou et al., 2011). Many of the early discovered activators of the NLRP3 
inflammasome were non-self in origin. Crystalline and particulate substances in particular, 
can contribute to the sterile inflammation mediated by the NLRP3 inflammasome. Examples 
of such substances include asbestos and silica (Cassel et al., 2008; Dostert et al., 2008; 
Hornung et al., 2008). Of note, NLRP3 deficient mice are protected from asbestos and silica 
induced neutrophil infiltration, pro-inflammatory cytokine generation and cell death 
(Hornung et al., 2008). Metal alloy particles from prosthetic joints were also found to 
activate the NLRP3 inflammasome (Caicedo et al., 2009).  The NLRP3 inflammasome is 
also activated in response to several microorganism pathogens. Staphylococcus aureus 
hemolysin (Craven et al., 2009; Munoz-Planillo et al., 2009), listerialysin from Listeria 
monocytogenes (Meixenberger et al., 2010) and tetanolysin-O from Clostritidium tetani (Chu 
et al., 2009) have all been demonstrated to elicit NLRP3 inflammasome activation, as have 
ds-RNA molecules from the influenza virus (Ichinohe et al., 2009). The NLRP3 
inflammasome is thought to play a supportive role during DNA virus infection (Delaloye et 
al., 2009; Muruve et al., 2008). Fungal toxins and the malarial toxin Hemozoin also elicit the 
activity of the NLRP3 inflammasome, probably through the activation of the tyrosine kinase 
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SYK (Joly et al., 2009; Shio et al., 2009). The NLRP3 inflammasome can also be activated 
by many self-moieties, which are generally crystalline or aggregated, and are associated with 
cell death, danger, and inflammation. Extracellular ATP, which is probably mitochondrial in 
origin, is a danger associated molecular pattern (DAMP), which acts as a potent danger 
signal to activate the NLRP3 inflammasome (Iyer et al., 2009). This activation is dependent 
on the K+ efflux mediated by the P2X7 receptor. Uric acid, a byproduct of purine biogenesis 
forms crystalline urate crystals when deposited into the extracellular space. Chronic urate 
crystal deposition in the joints is a hallmark of the disease gout. This deposition is 
accompanied by the secretion of various pro-inflammatory cytokines, including IL-1β and 
IL-18 (Martinon, 2010).  When phagocytosed by macrophages, the crystals activate the 
NLRP3 inflammasome, which contributes to disease pathology. In strong evidence of the 
role that NLRP3 plays in the disease process, patients who suffered from acute gout showed 
symptomatic relief in clinical trials when treated with Anakinra, which is an interleukin-1 
receptor antagonist. Another well studied activator of the NLRP3 inflammasome that has 
great clinical relevance is crystalline cholesterol; It was observed that cholesterol crystal 
deposition contributed to macrophage infiltration, chronic inflammation and plaque 
development but did so to a lesser extent under conditions of NLRP3 inflammasome 
inactivation (Duewell et al., 2010). Hyaluronan is a component of the extra-cellular matrix 
and is also found in the bacterial cell walls. In its polymeric form, it can activate the NLRP3 
inflammasome (Yamasaki et al., 2009). During traumatic injuries, a plethora of 
inflammasome activators such as ATP, hyaluronan and uric acid can be released which can, 
in concert, bring about massive inflammation via NLRP3 inflammasome activation (Gasse et 
al., 2009; Idzko et al., 2007; Muller et al., 2011; Nakae et al., 2003; Riteau et al., 2010). 
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Cryopyrin-associated periodic syndromes (CAPS) are a set of autoimmune diseases that are 
used to describe three phenotypes depending on the severity of the disease; familial cold 
autoinflammatory syndrome (FCAS), the mildest phenotype, Muckle-Wells syndrome 
(MWS) with intermediate severe disease phenotype, and neonatal-onset multisystem 
inflammatory disease (NOMID), which is the severest form of the disease. CAPS is an 
autosomal dominant condition, caused by a gain of function mutation in the NLRP3 gene, 
leading to the uncontrolled production of IL-1β in immune cells. In the past few years, 
several drugs to treat this disease have been effectively utilized (Yu and Leslie, 2011). In 
2008, it was discovered for the first time that the aggregated form of the senile plaque 
associated protein amyloid-β could activate the NLRP3 inflammasome. This was the first 
time a misfolded protein was demonstrated to activate the NLRP3 inflammasome, and was 
the first link that inflammasomes may play a role in the pathogenesis of neurodegenerative 
disorders (Halle et al., 2008). This topic will be covered in more detail in the subsequent 
section. 
6. Non-canonical inflammasomes  
Activation of the non-canonical inflammasomes is primarily mediated by Caspase-11. 
This was protein was shown to mediate the activation of other Caspases, contributing to 
apoptosis (Kang et al., 2000). Caspase-11 was subsequently demonstrated to be essential for 
Caspase-1 activation and IL-1β production upon infection with Escherichia coli, Citrobacter 
rodentium or Vibrio cholerae, but was found to not affect the activation of Caspase-1 
downstream of typical NLRP3 activators such as ATP and urate crystals (Kayagaki et al., 
2011). Incidentally, this was also the study that demonstrated that Caspase1-/- mice inherently 
lacked Caspase-11 as well, necessitating the use of Caspase-11-/- macrophages as negative 
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controls for inflammasome activation in many studies, including ours. It was later discovered 
that the non-canonical activation of this inflammasome occurred independent of TLR4, 
leading to the current consensus that a cytosolic receptor mediates Caspase-11 activation to 
elicit non-canonical inflammasome activation (Kayagaki et al., 2013). 
7. The NLRP6 inflammasome  
Although included in this section, current evidence has not yet conclusively identified 
the protein NLRP6 as being part of an inflammasome complex; evidence needs to be 
provided showing that it associates with procaspase-1 directly and mediates the processing of 
pro-IL-18 and/or pro-IL-1β. NLRP6 was found to associate with ASC and effect NF-κB and 
Caspase-1 activation in a model system that utilized overexpression of the protein to validate 
the findings (Grenier et al., 2002). Recent studies have expounded a role for this 
inflammasome in colitis; NLRP6-/- mice are more susceptible to colitis in response to colitis 
inducing agents (Chen et al., 2011; Elinav et al., 2011; Normand et al., 2011). In fact, one 
study showed that NLRP6-/- mice have spontaneous colitis and inflammatory cell recruitment, 
as well as amplified inflammatory responses to dextran sodium sulfate (DSS), an inducer of 
colitis like symptoms, as well as expanded pathobiont gut microbiota. This points to a role of 
the NLRP6 inflammasome in serving as a checkpoint to prevent gut inflammation (Elinav et 
al., 2011). Related studies also showed that NLRP6 is expressed in myofibroblasts, and its 
absence triggered colitis and tumorigenesis, accompanied by dysregulated regeneration of the 
colonic mucosa However, IL-1β levels were not significantly altered. (Normand et al., 2011)  
NLRP6 deficiency enhanced MAP kinase and NF-κB pathways downstream of TLR 
activation, leading to increased levels of cytokine and chemokine production (Nigam and 
Narula, 1990). 
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Role of inflammasomes in neurodegenerative disorders 
1. The NLRC4 inflammasome  
As mentioned previously, NLRC4 mainly recognizes bacterial pathogen associated 
molecular patterns (PAMPs). This makes the NLRC4 inflammasome the primary CNS 
responder to bacterial infections of the brain that cause meningitis and encephalitis 
(Jamilloux et al., 2013; Wu et al., 2010). As in peripheral bacterial infections, the NLRC4 
inflammasome senses the presence of flagellin, as well as PrgJ (Miao et al., 2006; Miao et 
al., 2010).  Recent evidence suggests, however, that this sensing may be mediated indirectly; 
neuronal apoptosis inhibitory proteins (NAIPs) first detect the bacterial proteins, and may 
then subsequently interact with NLRC4 to mediate inflammasome activation (Kofoed and 
Vance, 2011; Zhao et al., 2011).  
2. The NLRP1 inflammasome  
Interaction studies carried out on the NLRP1 inflammasome showed that the anti-
apoptotic proteins BCL-2 and BCL-X could bind to and subsequently inhibit NLRP1 
activation (Bruey et al., 2007). The NLRP1 inflammasome was subsequently shown to be 
activated in neurons (de Rivero Vaccari et al., 2009; de Rivero Vaccari et al., 2008; 
Silverman et al., 2009). Recent studies have demonstrated that neuronal NLRP1 mediates 
pyroptosis in response to β-amyloid treatment (Tan et al., 2014).  It was also demonstrated 
that there was a massive upregulation of NLRP1 containing neurons in AD brains versus 
controls, and that the functional NLRP1 inflammasome in these cells could activate Caspase-
1 and Caspase-6, and the processing of IL-1β in neurons (Kaushal et al., 2015). Hence, 
activation of the NLRP1 inflammasomes in neurons may identify a novel cell death pathway 
that mediates neuronal loss in AD.  Circumstantial evidence for this hypothesis comes from 
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studies that have linked NLRP1 variants with AD development (Pontillo et al., 2012). 
NLRP1 might also contribute to the pathogenesis of stroke, evidenced by the finding that 
administering neutralizing antibodies against NLRP1b was found to be protective in a stroke 
model (Abulafia et al., 2009). Middle cerebral artery occlusion in rats induces NLRP1 
expression (Frederick Lo et al., 2008), and increased NLRP1b  in the cerebrospinal fluid  is 
associated with a poorer prognosis in patients with traumatic brain injuries (Adamczak et al., 
2012).  
3. The AIM2 inflammasome  
The AIM2 inflammasome has not been studied in the central nervous system. 
However, it is hypothesized that it might play a role in CNS infections (Walsh et al., 2014), 
since within the peripheral immune system, it binds to ds-DNA from Listeria 
monocytogenes, which can cause meningitis (Wu et al., 2010). 
4. The NLRP2 inflammasome  
Stimulation of astrocytes with ATP resulted in the activation of the NLRP2 
inflammasome, the activation of which was inhibited by the pannexin inhibitor probenecid 
and the P2X7 receptor antagonist Brilliant Blue G (Minkiewicz et al., 2013). The clinical 
significance of the activation of this inflammasome is not known. 
5. The NLRP3 inflammasome 
a. Role in brain infections- Activation of the NLRP3 inflammasome can have 
disparate consequences inside or outside the CNS; in a mouse model of Streptococcus 
pneumoniae induced pneumonia, the NLRP3 response had a beneficial effect and was 
required for clearance of the pathogen (McNeela et al., 2010). However, in a 
meningitis model that utilized the same pathogen, activation of the NLRP3 
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inflammasome and pro-inflammatory cytokine secretion had a detrimental effect 
(Hoegen et al., 2011; Mitchell et al., 2012). In response to the Japanese Encephalitis 
Virus (JEV) and West Nile Virus (WNV) infections, activation of the NLRP3 
inflammasome is protective (Kaushik et al., 2012; Kumar et al., 2013; Ramos et al., 
2012). 
b. Role in sterile brain inflammatory responses: Unlike its role in CNS 
infections, activation of the NLRP3 inflammasome in sterile inflammatory responses 
within the CNS has mostly been shown to be detrimental. In mouse models of 
experimental autoimmune encephalitis (EAE), activation of the NLRP3 
inflammasome was demonstrated to be critical to disease progression (Gris et al., 
2010; Inoue et al., 2012). Inhibiting the action of the NLRP3 inflammasome 
prevented T-cell infiltration into the CNS.  Treatment regimen with a small molecular 
inhibitor of the NLRP3 inflammasome, MCC950, was found to be protective in an 
EAE mouse model (Coll et al., 2015).  
Many neurodegenerative disorders are propagated by misfolded proteins which can activate 
the innate immune system (Glass et al., 2010).  As mentioned previously, fibrilar amyloid-β 
was the first misfolded/aggregated protein shown to activate the NLRP3 inflammasome.  In a 
subsequent study, it was shown that NLRP3 and Caspase-1 deficient mice were massively 
protected against the Alzheimer’s Disease (AD) pathology, when crossed to the APP/PS1 
transgenic mice. The same study also demonstrated increased Caspase-1 and IL-1β levels 
under APP/PS1 and AD conditions (Heneka et al., 2013). Misfolded prion protein fibrils 
were also shown to activate the NLRP3 inflammasome (Hafner-Bratkovic et al., 2012).  In 
the field of PD biology, the aggregated form of α-synuclein was shown to effect the 
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production of IL-1β in monocytes (Codolo et al., 2013). However, this study used monocytes 
as cell culture model system, which, unlike microglia and macrophages, have constitutively 
activated Caspase-1 (Netea et al., 2009), and hence any stimulus that primes the NLRP3 
inflammasome will also bring about inflammasome activation, without the need for an 
intervening signal-2. Thus, we question the relevance of using a model system that does not 
take into consideration all the factors that engender inflammasome activation. Moreover, 
there was no direct evidence, either by specific chemical inhibition, or by genetic knockdown 
of NLRP3 specifically being involved. There is some evidence to suggest that 
inflammasomes may play a role in-vivo. Overexpression of α-synuclein within the SN 
effected increased IL-1β levels in the striatum. However, inflammasomes were not directly 
implicated (Chung et al., 2009). Lastly, increased levels of the cytokine IL-1β have been 
found in PD brain and CSF levels (Mogi et al., 1996; Mogi et al., 2000). Recently, NLRP3-/- 
mice were demonstrated to be resistant to MPTP induced dopaminergic neuronal cell loss 
and serum IL-1β secretion, but this protection was attributed to the inherent inhibitive effect 
dopamine has on NLRP3 inflammasome activity (Yan et al., 2015). Hence, to conclude, 
activation of the NLRP3 inflammasome may play a role in the development of several 
neurodegenerative disorders that have a sterile inflammatory component to them. 
 
Inflammasomes: Beyond the role of IL-1β 
IL-1β is a versatile cytokine; it can elicit a proinflammatory response from immune 
cells such as microglia and macrophages (Basu et al., 2002; Jayaraman et al., 2013), as well 
as from astrocytes (John et al., 2004). It can also directly elicit cell death in neurons through 
p38 MAP kinase activation (Wang et al., 2005). However, the significance of NLRP3 
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inflammasome activation may extend beyond IL-1β processing and secretion. It was recently 
demonstrated that upon NLRP3 inflammasome activation, oligomeric forms of the NLRP3 
inflammasome were released from the cell, where they were able to activate Caspase-1 in 
non-activated cells extracellularly. Oligomeric ASC particles were found in the serum of 
patients with CAPS (Baroja-Mazo et al., 2014).  In a study that was simultaneously 
published, specks of ASC released by cells could take up and seed the nucleation of soluble 
ASC in unactivated cells, thereby contributing to inflammasome activation and the spreading 
of inflammation in a prionid manner (Franklin et al., 2014). 
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CHAPTER 2. FYN KINASE REGULATES MICROGLIAL NEUROINFLAMMATORY 
RESPONSES IN CELL CULTURE AND ANIMAL MODELS OF PARKINSON’S 
DISEASE1 
 
Modified from a paper published in the Journal of Neuroscience. 
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Harishchandra2, Richard Gordon2, Kavin Kanthasamy3, Vivek Lawana2, Souvarish Sarkar2, Jie 
Luo2, Vellareddy Anantharam2, Anumantha G. Kanthasamy2 and Arthi Kanthasamy2, 4 
 
Abstract 
Sustained neuroinflammation mediated by resident microglia is recognized as a key 
pathophysiological contributor to many neurodegenerative diseases, including Parkinson’s 
disease (PD), but the key molecular signaling events regulating persistent microglial 
activation have yet to be clearly defined. In the present study, we examined the role of Fyn, a 
non-receptor tyrosine kinase in microglial activation and neuroinflammatory mechanisms in 
cell culture and animal models of PD. The well-characterized inflammogens 
lipopolysaccharide (LPS) and tumor necrosis factor alpha (TNFα) rapidly activated Fyn 
kinase in microglia. Immunocytochemical studies revealed that activated Fyn preferentially 
localized to the microglial plasma membrane periphery and the nucleus. Furthermore, 
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activated Fyn phosphorylated PKCδ at tyrosine residue 311, contributing to an inflammogen-
induced increase in its kinase activity. Notably, the Fyn-PKCδ signaling axis further 
activated the LPS- and TNFα-induced MAP kinase phosphorylation and activation of the 
NFκB pathway, implying that Fyn is a major upstream regulator of the pro-inflammatory 
signaling. Functional studies in microglia isolated from wild type (Fyn+/+) and Fyn knockout 
(Fyn-/-) mice revealed that Fyn is required for the pro-inflammatory responses, including 
cytokine release as well as iNOS activation. Interestingly, a prolonged inflammatory insult 
induced Fyn transcript and protein expression, indicating that Fyn is upregulated during 
chronic inflammatory conditions. Importantly, in vivo studies using MPTP, LPS, or 6-OHDA 
models revealed a greater attenuation of neuroinflammatory responses in Fyn-/- and PKCδ -/- 
mice when compared to wild-type mice. Collectively, our data demonstrate that Fyn is a 
major upstream signaling mediator of microglial neuroinflammatory processes in PD.  
 
Introduction 
Parkinson’s disease (PD) is a highly prevalent neurodegenerative disorder and is 
mainly characterized by the loss of dopaminergic neurons in the substantia nigra (SN) of the 
ventral midbrain region. Extra nigral lesions and non-motor deficits have recently been 
recognized (Chaudhuri et al., 2006; Bohnen et al., 2014). Although the etiopathogenesis of 
PD is not known, both environmental insults and genetic defects have been implicated in its 
onset. Mutations in seven disparate genes have been linked to Parkinsonism, which clinically 
resembles PD with varying onset and disease progression. Additionally, 19 other genes have 
been postulated to have a disease-causing role (Puschmann, 2013). 
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The pathophysiology of PD is complex and multifactorial, with mitochondrial 
dysfunction, oxidative stress, apoptosis and proteasomal dysfunction, being identified among 
others as potential disease mechanisms underlying nigrostriatal dopaminergic neuronal 
degeneration (Przedborski, 2005; Jenner and Olanow, 2006; Olanow, 2007; Levy et al., 
2009). Recently, a wealth of data from cell culture, animal models and post-mortem analyses 
of human PD brains have established chronic, sustained microglia-mediated 
neuroinflammation as being a major event in the delayed and progressive loss of 
dopaminergic neurons within the SN (Imamura et al., 2003; Block et al., 2007; Glass et al., 
2010; Tansey and Goldberg, 2010). As the macrophagic cells of the central nervous system 
(CNS), microglia comprise a major component of the brain’s innate immune system. Under 
‘normal’ physiological conditions, they produce anti-inflammatory and neurotrophic factors 
to promote neuronal survival and plasticity (Carson, 2002). However, when they encounter a 
potential pathogen, a dead or dying neuron or neurotoxic stress, they switch to an ‘activated’ 
phenotype, producing pro-inflammatory cytokines and chemokines, reactive nigtrogen 
species, and reactive oxygen species. Activated microglia may also directly contribute to cell 
death by phagocytizing dopaminergic neurons (Barcia et al., 2012; Virgone-Carlotta et al., 
2013). Thus, the pathophysiology of PD is accompanied by a sustained pro-inflammatory 
microglial response that contributes to neuron death, thereby exacerbating disease 
progression. 
Fyn, a member of the Src family of kinases, is a non-receptor tyrosine kinase 
expressed in the brain. The kinase has been shown to play a role in amyloid-mediated 
apoptosis in cortical neurons (Lambert et al., 1998), astrocyte migration (Dey et al., 2008) 
and oligodendrocyte differentiation (Sperber et al., 2001). In the peripheral immune system, 
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Fyn plays a role in mast cell and B/T cell activation (Palacios and Weiss, 2004; Gomez et al., 
2005a). Fyn was shown to mediate pro-inflammatory mediator production in mast cells, 
macrophages, basophils as well as in natural killer cells (Rajasekaran et al., 2013). Fyn was 
shown to be activated following fibrillar β-amyloid peptide engagement of its receptor 
CD36, contributing to activation and migration of primary murine peritoneal macrophages 
(Moore et al., 2002; Stuart et al., 2007), and in BV2 microglial cells stimulated with the 
neurotoxic fragment of prion protein (Kouadir et al., 2012). Recently, we have identified a 
pro-apoptotic Fyn/PKCδ-mediated signaling pathway that contributes to oxidative stress-
induced cell death in dopaminergic neurons (Kaul et al., 2005; Saminathan et al., 2011). 
However, the role of Fyn in microglial activation and neuroinflammation has never been 
studied in PD. Therefore, we sought to characterize the role of the Fyn-PKCδ signaling 
pathway in microglial activation and neuroinflammation in cell culture and animal models of 
PD. The results from these comprehensive studies reveal that Fyn kinase plays a key role in 
microglial activation and sustained neuroinflammation in the nigral dopaminergic system.  
 
Materials and Methods 
Chemicals and reagents 
Dulbecco’s modified Eagle’s medium/F-12 (DMEM/F-12), ascorbic acid, RPMI, 
fetal bovine serum (FBS), L-glutamine, Hoechst nuclear stain, penicillin, streptomycin and 
other cell culture reagents were purchased from Invitrogen (Gaithersburg, MD). 
Recombinant TNFα was purchased from Peprotech (Rocky Hill, NJ), and LPS (E. coli 
0111:B4, Endotoxin content 6.6000000 EU/mg) and 6-OHDA were purchased from Sigma 
(St. Louis, MO). The mouse Fyn antibody was purchased from Thermo Scientific (Waltham, 
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MA). Antibodies for rabbit Fyn, PKCδ, p-Y311 PKCδ, IκBα, Lamin-B, NOS2 (iNOS) and 
mouse Tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibodies against rabbit p-Src family kinase Y416 (p-Y416 SFK), native p65, p-p38 MAP 
kinase, native p38 MAP kinase, p-p44/42 MAP kinase (p-ERK) and native p44/42 MAP 
kinase (ERK) were purchased from Cell Signaling (Beverly, MA). The gp91phox antibody was 
purchased from BD Biosciences (San Jose, CA). The mouse GFAP antibody was purchased 
from Millipore (Billerica, MA). The TH antibody was purchased from Chemicon (Temecula, 
CA). Mouse M2 FLAG and β-actin antibodies, as well as the rabbit β-actin antibody were 
purchased from Sigma. Rabbit and goat Iba-1 antibodies were purchased from Wako 
Chemicals (Richmond, VA) and Abcam (Cambridge, MA), respectively. The goat TNFα 
antibody was purchased from R&D Systems (Minneapolis, MN). 32P-ATP was purchased 
from Perkin Elmer (Boston, MA) and the histone substrate from Sigma. The Bradford protein 
assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). FLAG-tagged human 
WT Fyn and Y417A mutant Fyn constructs were obtained as described previously (Kaspar 
and Jaiswal, 2011).  
 
Animal studies  
The Fyn-/- and PKCδ-/- mice used in these studies were bred in our animal facility. 
Fyn-/- mice were originally obtained from Dr. Dorit Ron’s laboratory at the University of 
California, San Francisco and are available from Jackson Laboratory (stock number 002271). 
PKCδ-/- mice were obtained originally from Dr. Keiichi Nakayama's laboratory (Division of 
Cell Biology, Department of Molecular and Cellular Biology, Medical Institute of 
Bioregulation, Kyushu University, Fukuoka, Japan). Wild type (Fyn+/+ and PKCδ+/+), PKCδ-/- 
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and Fyn-/- mice were housed under standard conditions of constant temperature (22 ± 1°C), 
humidity (relative, 30%), and a 12-h light cycle with food and water provided ad libitum. 
Six- to eight-week-old male mice were used for all studies. The well-characterized acute 
MPTP mouse model of PD (Wu et al., 2003; Przedborski et al., 2004; Kim et al., 2007; Hu et 
al., 2008) was primarily used for neuroinflammation studies. The mice from the MPTP 
treatment group received 4 intraperitoneal (i.p.) injections of MPTP-HCl (18 mg/kg free-
base) dissolved in saline at 2-h intervals. Mice were sacrificed 3 h after the last injection. The 
nigral neuroinflammatory response was also studied using the systemic LPS injection model 
(Qin et al., 2007), which induces chronic neuroinflammation and progressive dopaminergic 
degeneration in mice. A single injection of LPS (5 mg/kg, i.p.) was delivered to wild type, 
Fyn-/- and PKCδ-/- mice. Mice were sacrificed 24 to 48 h later. Control groups for both MPTP 
and LPS received equivolume injections of saline. We injected 2 µL of 6-OHDA, diluted at a 
concentration of 5 µg/µL in 0.02% ascorbic acid, into the left striatum (0.2 µL/min) using the 
Angle 2 stereotaxic apparatus (Leica Biosystems, St. Louis, MO). The coordinates, relative 
to bregma were: 0.7 mm anteroposterior, 2 mm lateral, and 2.4 mm ventral. The contralateral 
side was either not injected or injected with 2 µL of 0.02% ascorbic acid diluted in sterile 
PBS as a negative control. All animal procedures were approved by the Iowa State 
University Institutional Animal Care and Use Committee (IACUC).  
 
Primary microglial cultures and treatments 
Primary microglial cultures were prepared from wild type, Fyn-/- and PKCδ-/- postnatal 
day 1 (P1) mouse pups as described previously (Gordon et al., 2011). Briefly, mouse brains 
were harvested, meninges removed, and then placed in DMEM-F12 supplemented with 10% 
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heat-inactivated FBS, 50 U/mL penicillin, 50 μg/mL streptomycin, 2 mM L-glutamine, 100 
μM non-essential amino acids, and 2 mM sodium pyruvate. Brain tissues were then 
incubated in 0.25% Trypsin-EDTA for 30 min with gentle agitation. The trypsin reaction was 
stopped by adding double the volume of DMEM/F12 complete medium and then washing 
brain tissues three times. Tissues were then triturated gently to prepare a single cell 
suspension, which was then passed through a 70-μm nylon mesh cell strainer to remove 
tissue debris and aggregates. The cell suspension was then made up in DMEM/F12 complete 
medium and seeded into T-75 flasks, which were incubated in humidified 5% CO2 at 37°C. 
The medium was changed after five to six days and the mixed glial cells were grown to 
confluence. Microglial cells were separated from confluent mixed glial cultures by 
differential adherence and magnetic separation to >97% purity, and then were allowed to 
recover for 48 h after plating. Primary microglia were treated in DMEM/F12 complete 
medium containing 2% FBS. For signaling experiments, the protocol employed by Stuart 
(2007) was utilized with a small modification. For this, the primary microglial cells were 
kept in 2% DMEM/F12 complete medium for 5 h at 37ºC prior to treatment. The microglial 
cells were treated with 100-200 ng/mL LPS and 10-30 ng/mL TNFα for durations sampled at 
pre-specified time points. We selected the LPS doses used in this study based on previous 
studies in which stimulation of cultured primary mouse microglia with 100 and 200 ng/ml 
LPS resulted in significant microglial activation (Haynes et al., 2006; Crotti et al., 2014; Lee 
et al., 2014).  
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siRNAs and transfections of microglia 
Transient transfections of primary microglia with Fyn promoter reporter were 
performed using Lipofectamine LTX & Plus Reagent according to the manufacturer’s 
protocol. Primary microglia were plated at 0.75 x 106 cells/well in 12-well plates one day 
before transfection. We transiently transfected 3 µg of Fyn promoter construct. Cells were 
treated 24 h after transfection with or without 200 ng/mL of LPS for 12 h and then lysed. 
Luciferase activity was measured using a Dual-luciferase assay kit (Promega) on a Synergy 2 
multi-mode microplate reader (BioTek). Firefly luciferase luminescence values were used to 
normalize Renilla luciferase luminescence values. The pre-designed, on-target plus SMART 
pool Fyn siRNA (a combination of four siRNAs, Cat. No. LQ-040112-00-0002) and 
scrambled siRNA (Cat. No. D-001210-03-05) were purchased from Dharmacon (Lafayette, 
CO). We carried out siRNA transfections in primary mouse microglial cells with 
Lipofectamine 3000 reagent according to the manufacturer's protocol. Briefly, primary 
microglia were plated at 2 x 106 cells/well in 6-well plates one day before transfection. For 
each well, 300 pmol of Fyn siRNA pool (75 pmol each) or an equal amount of scrambled 
siRNA mixed with 5 μl of Lipofectamine 3000 were added to the cells. Seventy-two hours 
after the initial transfection, cells were analyzed by Western blotting to confirm the extent of 
Fyn knockdown or treated with LPS (200 ng/mL) for 24 further hours, after which cytokine 
content was analyzed by Luminex bioassay. 
Transfection of BV2 microglia with WT Fyn-FLAG, Y417A Fyn-FLAG and Empty 
Vector pcDNA3.1 constructs was performed by using the AMAXA Nucleofector Kit. 
Briefly, BV2 cells were resuspended in transfection buffer (Solution 1: 400 μM ATP-
disodium (Sigma A7699), 600 μM MgCl2-6H2O in water; Solution 2: 100 μM KH2PO4, 20 
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μM NaHCO3, 5 μM glucose in water) to a final concentration of 3 x 106 cells per 100 μL and 
mixed with the respective vector; 5 μg of vector DNA was used per transfection. 
 
Immunohistochemistry and immunofluorescence studies 
Immunohistochemistry was performed on sections from the substantia nigra and other 
brain regions of interest as described previously (Jin et al., 2011b; Ghosh et al., 2013). 
Briefly, mice were anesthetized with a mixture of 100 mg/kg ketamine and 10 mg/kg 
xylazine and then perfused transcardially with freshly prepared 4% paraformaldehyde (PFA). 
Extracted brains were post-fixed in 4% PFA for 48 h and 30-µm sections were cut using a 
freezing microtome (Leica Microsystems). Antigen retrieval was performed in citrate buffer 
(10 mM sodium citrate, pH 8.5) for 30 min at 90°C. Sections were then washed several times 
in PBS and blocked with PBS containing 2% BSA, 0.2% Triton X-100 and 0.05% Tween 20 
for 1 h at room temperature. Sections were then incubated with primary antibodies overnight 
at 4°C and washed 7 times in PBS on a Belly Dancer Shaker (SPI supplies). The sections 
were incubated with Alexa dye-conjugated secondary antibodies for 75 min at room 
temperature and their cell nuclei were stained with Hoechst dye. Sections were mounted on 
slides using Prolong antifade gold mounting medium (Invitrogen) according to the 
manufacturer’s instructions. Samples were visualized using an inverted fluorescence 
microscope (Nikon TE-2000U) and images were captured using a Spot digital camera 
(Diagnostic Instruments Inc). 
Immunofluorescence studies in primary microglia were performed according to 
previously published protocols with some modifications (Gordon et al., 2011). Briefly, 
microglial cells were grown on poly-D-lysine-coated coverslips and treated 48 h later. At the 
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end of treatments, cells were fixed with 4% PFA, washed in PBS and incubated in blocking 
buffer (PBS containing 2% BSA, 0.5% Triton X-100 and 0.05% Tween 20) for 1 h at room 
temperature. The coverslips were then incubated overnight at 4°C with respective primary 
antibodies diluted in PBS containing 2% BSA. Samples were then washed several times in 
PBS and incubated with Alexa 488 and 555 dye-conjugated secondary antibodies. The nuclei 
were labeled with Hoechst stain (10 μg/mL) and coverslips were mounted with Fluoromount 
medium (Sigma Aldrich) on glass slides for visualization. Quantification of the number of 
microglial/astroglial cells obtained post-separation was accomplished using JACoP, a 
downloadable ImageJ plugin from Fabrice P. Cordelières. Original Hoechst or antibody TIFF 
files were converted into 8-bit black-and-white images, and a colocalization image was 
generated. Counting of Hoechst-positive and Iba-1+Hoechst-positive cells was done using 
the Cell counter function of the default ‘Analyze’ plugin in ImageJ. 
 
Confocal imaging and Z stack image acquisition and analysis 
Confocal imaging was performed at the Iowa State University Microscopy Facility, 
using a Leica DMIRE2 confocal microscope with the 63X and 43X oil objectives and Leica 
Confocal Software. One optical series covered 11-13 optical slices of 0.5-µm thickness each. 
Microglial neuronal contact identification and quantification were performed by counting the 
number of colocalizations of the two markers, with TH marked red by anti 555 and Iba-1 
marked green by anti 488 using the methodology described by Barcia and colleagues (Barcia 
et al., 2012). The Imaris software was used to analyze the Z stack images for contact 
identification. The surface reconstruction wizard in the Imaris software was used to make 3-
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D reconstructions of stacks for easier viewing of microglial-dopaminergic contacts and 
surface topology. 
 
qRT-PCR 
RNA isolation from primary microglial cells and brain tissue samples was performed 
using the Absolutely RNA Miniprep Kit, and then 1 μg total of isolated RNA was used for 
reverse transcription with the AffinityScript qPCR cDNA synthesis system (Agilent 
Technologies) according to the manufacturer’s instructions. Quantitative SYBR Green PCR 
assays for gene expression were performed using the RT² SYBR Green Master Mix with pre-
validated primers (SABiosciences qPCR assay system). Catalog numbers of the primers were 
Fyn - PPM04015A, pro-IL1β - PPM03109E, TNFα-PPM03113G. The mouse 18S rRNA 
gene (catalog number - PPM57735E) was used as the housekeeping gene for normalization. 
For each primer, the amount of template providing maximum efficiency without inhibiting 
the PCR reaction was determined during initial optimization experiments. For all 
experiments, dissociation curves were generated to ensure a single peak was obtained at the 
right melting temperature without non-specific amplicons. The fold change in gene 
expression was determined by the ΔΔCt method using the threshold cycle (Ct) value for the 
housekeeping gene and the respective target gene of interest in each sample. 
 
Western blotting 
Brain tissue and microglial cell lysates were prepared using modified RIPA buffer 
and were normalized for equal amounts of protein using the Bradford protein assay kit. Equal 
amounts of protein (12 to 25 µg for cell lysates and 30-40 µg for tissue lysates) were loaded 
51 
 
for each sample and separated on either 12% or 15% SDS-PAGE gels depending on the 
molecular weight of the target protein. After separation, proteins were transferred to a 
nitrocellulose membrane and the nonspecific binding sites were blocked for 1 h using a 
blocking buffer specifically formulated for fluorescent Western blotting (Rockland 
Immunochemicals). Membranes were then probed with the respective primary antibodies for 
3 h at room temperature or overnight at 4°C. After incubation, the membranes were washed 7 
times with PBS containing 0.05% Tween 20, and then Secondary IR-680-conjugated anti-
mouse (1:10,000, goat anti-mouse, Molecular Probes) and IR-800 conjugated anti rabbit 
(1:10,000, goat anti-rabbit, Rockland) were used for antibody detection with the Odyssey IR 
imaging system (LiCor). Membranes were visualized on the Odyssey infrared imaging 
system. Antibodies for β-actin and Tubulin were used as loading controls. 
 
Co-immunoprecipitation studies 
We adopted an immunoprecipitation (IP) protocol with slight modifications from Gao 
and colleagues (Gao et al., 2011). Cell lysates were prepared in TNE buffer (10 mM Tris-
HCl at pH 7.5, 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA, and 1:100 protease inhibitor 
cocktail) and centrifuged at 17,400g for 40 min at 4°C. The supernatant protein concentration 
was measured and normalized between samples. Approximately 50 μL of the sample 
containing 20 μg protein was used as input. For immunoprecipitation analysis, 1 mg of 
protein in 400 μL TNE buffer was used. Next, 10 μL (2 μg) of Fyn rabbit polyclonal 
antibody was added to the lysates, and the samples were set on an orbital shaker overnight at 
4°C. The next day, protein G Sepharose beads were spun down at 17,400g for 5 min and the 
ethanol supernatant was replaced with an equal volume of the lysis buffer. The Protein G 
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Sepharose slurry was washed once and 50 μL was added to each sample. The samples were 
set on an orbital shaker overnight at 4°C. Protein G beads were collected by centrifugation at 
2000g for 5 min and were washed four times with TNE buffer. The bound proteins were 
eluted by boiling in 2X protein-loading dye for 5 min. Immunoblots were performed on 12 % 
SDS-PAGE gels as described for Western blotting. 
 
Nuclear and cytoplasmic fractionation 
Nuclear and cytoplasmic fractions were performed using the NE-PER Kit (Thermo 
Scientific) as previously described (Jin et al., 2011a; Jin et al., 2014). Briefly, 5 X 106 cells 
were treated with LPS or TNFα for 15 min. CER1 reagent (200 μL) was used for each 
sample to extract the cytoplasmic fraction, and 50 μL of NER reagent was used to extract the 
nuclear fraction. Tubulin or β-actin was used as a cytosolic fraction marker. Lamin B was 
used as a nuclear fraction marker.  
 
Fyn kinase assays 
Cell pellets were washed with ice-cold PBS and resuspended in lysis buffer (25 mM 
HEPES at pH 7.5, 20 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1% Triton 
X-100, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 10 mM NaF, and 
4 µg/mL each of aprotinin and leupeptin) (Kaul et al., 2005). Next, 50 µg of crude protein 
was incubated with 150 mM Fyn kinase substrate (Biomol), 100 mCi of [γ-32P] ATP, Src-
Mn-ATP cocktail and Src reaction buffer (Millipore) for 10 min at 30°C with agitation. To 
bring about precipitation the Fyn kinase substrate peptide, 20 mL of 40% trichloroacetic acid 
was added. 25 μL of the mixture was then spotted onto a P81 phosphocellulose square, and 5 
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min after spotting, the squares were washed five times in 0.75% phosphoric acid in PBS with 
a final wash step in acetone. The squares were transferred into a scintillation vial and the 
CPMA counts were read in a liquid scintillation system after adding 5 mL of scintillation 
cocktail to each vial. 
 
PKCδ  kinase assays 
PKCδ IP kinase activity assays were performed as described previously (Anantharam 
et al., 2002; Latchoumycandane et al., 2011; Harischandra et al., 2014) with some 
modifications for microglial cells. Briefly, primary microglial cells were collected after 
treatments, washed in ice-cold PBS and resuspended in a mild RIPA lysis buffer containing 
protease and phosphatase inhibitor cocktail (Pierce Biotechnology). The cells were placed on 
ice for 20 min to allow for complete lysis and then centrifuged at 16,200g for 45 min. The 
supernatant protein concentration was determined using the Bradford protein assay kit. 
Samples were normalized to a uniform total protein concentration of 2 µg/mL, and then 200 
µg of total protein in a 250 μL reaction volume was immunoprecipitated overnight at 4°C 
using 5 μg of PKCδ antibody. The next day, protein-A agarose beads (Sigma-Aldrich) were 
incubated for 1 h at room temperature. The protein A-bound antibody complexes were 
collected and washed 3 times in 2X kinase assay buffer (40 mM Tris, pH 7.4, 20 mM MgCl2, 
20 μM ATP, and 2.5 mM CaCl2), and then resuspended in the same buffer. The kinase 
reaction was started by adding 40 μL of the reaction buffer containing 0.4 mg of histone H1, 
50 μg/mL phosphatidylserine, 4 μM dioleoylglycerol, and 10 μCi of [γ-32P] ATP at 3000 
Ci/mM to the immunoprecipitated samples. The samples were then incubated for 10 min at 
30°C and the kinase reaction was stopped by adding 2X SDS loading buffer and boiling for 5 
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min. Proteins were separated on a 15% SDS-PAGE gel and the phosphorylated histone bands 
were imaged using a Fujifilm FLA 5000 imager. Image analysis and band quantification 
were performed using ImageJ.  
 
Nitric oxide detection 
Nitric oxide production by primary microglia was measured indirectly by 
quantification of nitrite in the supernatant using the Griess reagent (Sigma Aldrich). 
Microglia were plated in poly-D-lysine-coated 96-well plates at 1 x 105 cells/well. Cells were 
treated with 100 ng/mL of LPS for 24 h and after 100 μL of supernatant was collected from 
each well, an equal volume of the Griess reagent was added. The samples were incubated on 
a plate shaker at room temperature for 15 min until a stable color was obtained. The 
absorbance at 540 nm was measured using a Synergy 2 multi-mode microplate reader 
(BioTek Instruments) and the nitrite concentration was determined from a sodium nitrite 
standard curve. 
 
Multiplex cytokine Luminex immunoassays 
Primary microglia obtained from wild type, PKCδ-/- and Fyn-/- mice were seeded in 
poly-D-lysine-coated 96-well plates at 1 x 105 cells/well. The cells were treated for 24 h with 
100-200 ng/mL LPS or 10 ng/mL TNFα. After treatment, 50 µL of supernatant from each 
well was collected and frozen at -80°C. The levels of cytokines and chemokines in the 
supernatants were determined using the Luminex bead-based immunoassay platform (Vignali 
2000) and pre-validated multiplex kits (Milliplex mouse cytokine panel – Millipore) 
according to the manufacturer’s instructions. 
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DAB immunostaining and grading of microglial morphology 
Iba-1 diaminobenzidine (DAB) immunostaining was performed on striatal and 
substantia nigral sections as described previously (Ghosh et al., 2010). Briefly, mice were 
perfused with 4% PFA and brains were post-fixed with PFA for 48 h before storage in 30% 
sucrose. Fixed brains were embedded in O.C.T compound (Tissue-Tek) and stored frozen 
at -80°C until the frozen blocks were sliced into 30-µm coronal sections using a cryostat. 
Sections were probed with the primary antibodies overnight at 4°C and then incubated with 
biotinylated anti-rabbit secondary antibody. The sections were then treated with Avidin 
peroxidase (Vectastain ABC Elite kit). The DAB reagent was used for producing the brown 
colored stain. Grading of microglial morphology was performed as described elsewhere 
(Lastres-Becker et al., 2012). For microglial grading, images were sharpened in ImageJ so 
the morphology could be more clearly visualized. The cell counter function in the ‘Analyze’ 
plugin was used to count the number of Type A, B, C and D microglia in the ventral 
midbrain sections. 
 
Data analysis 
Data analysis was performed using Prism 4.0 (GraphPad Software, San Diego, CA). 
The data was initially analyzed using one-way ANOVA and Bonferroni's post-test to 
compare the means of treatment groups. Differences of p<0.05 were considered statistically 
significant. Student's t-test was used when comparing two groups. 
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Results 
Fyn and PKCδ  are differentially expressed in primary astrocytes and microglia 
Primary mouse microglia were prepared as described in our recent publication using a 
magnetic separation method, which enables us to obtain a high-yield pure fraction of 
microglia from mixed glial cultures (Gordon et al., 2011). Iba-1 and GFAP 
immunocytochemistry confirmed that the microglial fraction obtained after magnetic 
separation was devoid of astrocytes (Fig. 1A). Quantification of Hoechst co-localized Iba-1-
positive microglia and GFAP-positive astrocytes using the ImageJ plugin JACoP revealed a 
microglial population that was ~97% pure post-separation (Figs. 1B-C). Immunoblotting 
analysis revealed that microglia-enriched fractions expressed significantly more Fyn (60 
kDa) and PKCδ (76 kDa) than did astrocyte-enriched (microglia-depleted) fractions (Figs. 
1D-E). The differential expression of both Fyn and PKCδ in microglia compared to 
astrocytes prompted us to study the roles these proteins may play in microglial pro-
inflammatory signaling. 
 
Fyn kinase is rapidly activated in microglial cells and in the ventral midbrain following 
inflammogen stimulation 
Our initial experiment to determine whether the non-receptor tyrosine kinase Fyn 
plays a role in regulating neuroinflammatory responses in PD was carried out in BV2 
microglial cells, which are widely used in-vitro models of neuroinflammation (Henn et al., 
2009; Gao et al., 2011; Kim et al., 2013b). We treated BV2 cells with 1 μg/mL LPS for 10-
60 min and measured Fyn activity using an in-vitro kinase assay (Saminathan et al., 2011). A 
kinase reaction mixture containing 32P-ATP and a Fyn-specific peptide substrate were added 
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to whole cell lysates. LPS stimulation of BV2 microglia rapidly induced Fyn activity as early 
as 10 min post-LPS stimulation (Fig. 2A), and maximal activity was attained 30 min post-
LPS stimulation.  In addition to the Fyn kinase activity assay, we also determined the 
phosphorylation status of the Y416 residue in its activation loop domain, by utilizing the 
phospho Y416 Src family kinase (p-Y416 SFK) antibody, which recognizes activated Src 
family kinases. This antibody has been used extensively to demonstrate Fyn kinase activation 
(Larson et al.; Um et al.; Wake et al., 2011; Kouadir et al., 2012). Our immunoblotting 
analysis of LPS-treated BV2 lysates using the p-Y416 SFK antibody revealed LPS-induced 
SFK activation (Fig. 2B). To further confirm inflammogen-induced Fyn activation in BV2 
microglia, we transiently transfected BV2 cells with FLAG-tagged WT-Fyn and Y417A-Fyn 
(activation loop mutant) constructs. We then performed immunoprecipitation studies in LPS-
treated transfected BV2 cells. We pulled down Fyn from FLAG-tagged WT-Fyn and Y417A-
Fyn transfected, LPS-treated BV2 cells and immunoblotted for p-Y416 SFK levels. A strong 
p-Y416 SFK signal was detected in the LPS-treated WT-Fyn-FLAG-transfected cells, but not 
in the LPS-treated Y417A-Fyn-transfected cells (Figs. 2C-D).  
Next, we extended our studies to primary microglia derived from both wild-type and 
Fyn-deficient (Fyn-/-) mice. These were treated with 200 ng/mL LPS for 0-30 min. In line 
with the analyses of BV2 cells, stimulation of the primary microglia from Fyn+/+ mice rapidly 
increased the levels of p-Y416 SFK (Fig. 2E). Interestingly, p-Y416 SFK was not detected in 
LPS-treated Fyn-/- microglia, suggesting that LPS preferentially induces Fyn phosphorylation 
in microglia over other Src family kinases. Treatment of wild-type and Fyn-deficient 
microglia with TNFα also yielded similar results. Both 10 ng/mL and 30 ng/mL TNFα 
treatments induced similar levels of p-Y416 SFK in wild-type, but not in Fyn-deficient 
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microglia (Fig. 2F). Pretreatment of wild-type microglia with either the TLR (Toll-like 
Receptor) antagonist IAXO-101 or the TNFα signaling antagonist Etanercept significantly 
attenuated both LPS- and TNFα-mediated Fyn activation, respectively (Fig. 2G). We also 
examined subcellular localization of activated Fyn following LPS stimulation. The Iba-1/p-
Y416 SFK double-immunocytochemical analysis showed that LPS treatment dramatically 
increased p-Y416 Fyn levels in WT primary microglia (Fig. 2H). Active Fyn seems to be 
preferentially expressed at the periphery of the microglia, possibly allowing it to become 
activated quickly in response to a pro-inflammatory stimulus. Additionally, activated Fyn 
was also found in the nucleus of LPS-treated primary microglia. Next, we wanted to confirm 
that LPS-treatment would activate Fyn in the substantia nigra of mice. Knowing that a single 
intraperitoneal LPS injection elicits microglial cell activation in the substantia nigra (Qin et 
al., 2007), we challenged Fyn+/+ and Fyn-/- mice with 5 mg/kg LPS or sterile PBS vehicle 
intraperitoneally for 3 h. Immunoblot analysis of ventral midbrain lysates revealed that LPS 
significantly increased p-Y416 SFK levels in wild-type compared to saline control, whereas 
LPS failed to increase p-Y416 SFK levels in the Fyn-/- ventral midbrain lysates.(Fig. 2I). 
These studies indicate that stimulating microglia with inflammatory stimuli rapidly activates 
Fyn kinase in both cell culture and animal models of neuroinflammation. 
 
Fyn contributes to LPS- and TNFα-induced tyrosine phosphorylation and activation of 
PKCδ in primary microglia 
It has been shown that Src family kinases, including Fyn, phosphorylate PKCδ at 
residue Y311 in platelets and in immortalized dopaminergic neuronal cells (Steinberg, 2004; 
Saminathan et al., 2011). Therefore, we investigated if Fyn-PKCd signaling regulates 
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microglial pro-inflammatory responses using primary microglia cultures from wild-type, Fyn-
/- and PKCδ-/- mice. Stimulation with LPS induced a rapid and time-dependent increase in p-
Y311 PKCδ in wild-type microglia. In contrast, LPS failed to increase Y311 phosphorylation 
of PKCδ in the Fyn-/- microglia (Figs. 3A-B). Similarly, TNFα stimulation of microglia also 
increased PKCδ Y311 phosphorylation in wild-type, but not in Fyn-deficient primary 
microglia (Figs. 3C-D). As expected, immunoblot analysis did not detect any LPS-induced 
phosphorylation of Y311 PKCδ in PKCδ-/- microglia. To confirm further that Fyn mediates 
the activation of PKCδ in activated microglia, we measured PKCδ kinase activity in wild-
type and Fyn-/- microglia. An in-vitro PKCδ kinase assay showed that LPS rapidly increased 
PKCδ kinase activity in wild-type microglia; however, LPS-induced PKCδ kinase activity 
was significantly less in Fyn-/- microglia (Fig. 3E). To further confirm the Fyn-PKCδ 
interaction, we performed co-immunoprecipitation studies in BV2 cells transfected with the 
WT-Fyn-FLAG construct. As shown in Figs. 3F-G from the co-immunoprecipitation results, 
co-IP analysis of WT-Fyn-FLAG transfected lysates revealed that Fyn and PKCδ interact 
during LPS stimulation.  Taken together with the PKCδ kinase activity results, these data 
reveal that Fyn kinase mediates LPS- and TNFα-induced activation of PKCδ in primary 
microglia.  
 
The Fyn-PKCδ signaling axis mediates MAP kinase activation in microglial cells 
We next examined whether the Fyn-PKCδ signaling axis plays a role in mediating 
activation of the MAP kinase pathway, a key hallmark of neuroinflammatory signaling in 
microglia. MAP kinases are important regulators of pro-inflammatory cytokine synthesis in 
microglial cells (Koistinaho and Koistinaho, 2002; Tansey and Goldberg, 2010). For this 
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purpose, we treated wild-type, Fyn-/-, and PKCδ-/- microglia with LPS for 15, 30 and 45 min 
each and determined MAPK activation. The LPS treatment significantly increased the 
phosphorylation of p38 and p44/42 (p-ERK) kinases in wild-type microglia (Figs. 4A-B), 
with LPS-induced phosphorylation peaking at 15 min and decreasing thereafter. In contrast, 
LPS-induced phosphorylation of p38 and p44/42 (p-ERK) was significantly reduced in Fyn-/- 
and PKCd-/- primary microglia. Similar results were obtained with TNFα treatment of wild-
type, Fyn-/- and PKCδ-/- microglia (Figs. 4C-D).  These results suggest that Fyn-PKCδ 
signaling is an important upstream regulator of MAP kinases in microglia during both LPS 
and TNFα stimulation.  
 
Fyn contributes to inflammogen-mediated NFκB pathway activation in microglial cells  
Pro-inflammatory signaling mediated by both LPS and TNFα converges at the NFκB 
pathway. Activation of NFκB signaling during the pro-inflammatory process is characterized 
by the phosphorylation and subsequent degradation of the inhibitory protein IκBα, after 
which the NFκB p65-p50 heterodimer enters the nucleus, leading to the transcription of 
various pro-inflammatory genes (Hayden and Ghosh, 2004). To elucidate whether the Fyn 
mediates the nuclear translocation and activation of NFκB signaling in activated microglia, 
primary microglia obtained from wild-type and Fyn-/- microglia were treated with LPS for 
15-45 min. Whole cell lysates were prepared and probed for IκBα. LPS treatment induced a 
greater degradation of IκBα in wild-type microglia than in Fyn-/- microglia at the 15 minute 
time point, followed by the resynthesis of IκBα 30 and 45 minutes post stimulation in the 
WT cells. Resynthesis of IκBα in Fyn-/- microglia was almost completely abrogated, 
indicating diminished NFκB activation (Figs. 5A-B). Next, we investigated the role of Fyn in 
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the nuclear translocation of the p65 component of the NFκB complex in response to LPS and 
TNFα treatments. Nuclear and cytoplasmic fractions were prepared from WT and Fyn-/- 
microglia treated with LPS or TNFα for 15 min before being assessed for p65 content. 
Immunoblotting revealed lesser nuclear translocation of p65 in LPS- and TNFα-treated Fyn-/- 
microglia than in wild-type microglia (Figs. 5C-D). These results were further supported by 
Iba-1/p65 double-immunocytochemistry showing strong LPS-induced nuclear translocation 
of p65 in wild-type, but not in the Fyn-/- microglia (Fig. 5E). Together, these results clearly 
suggest that Fyn kinase regulates NFκB activation in microglial cells.  
 
LPS- or TNFα-induced pro-inflammatory cytokine production is suppressed in Fyn/ 
PKCδ deficient microglia 
Next, we determined whether Fyn-PKCδ signaling axis regulates microglia-mediated 
pro-inflammatory mediator production. After treating wild-type, PKCδ-/- and Fyn-/- microglial 
cultures with LPS or TNFα, we utilized multiplexed immunoassays to quantify 
inflammogen-induced cytokine secretion. We observed significant production of the 
cytokines IL-6, IL-12p70, and TNFα from wild-type microglia treated with LPS (Fig. 6A). 
However, the production of these cytokines was significantly dampened in Fyn- and PKCδ-
deficient microglia, providing evidence for the hypothesis that attenuated pro-inflammatory 
signaling in Fyn-/- and PKCδ-/- microglia suppresses pro-inflammatory mediator production. 
When we knocked down Fyn expression in wild-type primary microglia by Fyn-specific 
siRNA (Fig. 6B), diminished amounts of the pro-inflammatory cytokines IL-6 and TNFα 
were produced in response to LPS treatment (Fig. 6C). Next, treatment of wild-type and Fyn-
/- microglia with TNFα yielded similar results, with the Fyn-/- microglia showing reduced IL-
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6 and TNFα production (Fig. 6D). Western blot analysis also demonstrated that Fyn-deficient 
microglia produced less TNFα relative to wild-type microglia (Fig. 6E). To further confirm 
the role of Fyn in pro-inflammatory cytokine production, we expressed Fyn wild-type (WT-
Fyn-FLAG) or activation loop mutant (kinase deficient Fyn kinase, Y417A Fyn-FLAG) in 
BV2 microglial cells (Fig. 6F). Following the transfection, BV2 cells transfected WT-Fyn-
FLAG, Y417A Fyn-FLAG or empty vector constructs were treated with 1 µg/mL LPS for 24 
h. Luminex immunoassay of cell supernatants revealed that overexpressing wild-type Fyn 
augmented pro-inflammatory cytokine release, whereas overexpressing the inactive Y417A 
Fyn mutant suppressed the production of IL-6 and IL-12 (Figs. 6F-G).  
 
Fyn/PKCδ regulates the induction of neuroinflammatory markers iNOS and gp91phox in 
microglia during LPS stimulation 
We further assessed whether Fyn alters the induction of iNOS and gp91phox, which are 
key pro-inflammatory responses of microglial activation following LPS treatment. Treatment 
with LPS induced a stronger nitrite response from wild-type microglia than from Fyn-/- 
microglia (Fig. 7A). This was further confirmed by immunostaining and immunoblotting for 
iNOS, the enzyme that mediates nitrite production. There was a greater induction of iNOS in 
Fyn wild-type microglia relative to Fyn-/- microglia (Figs. 7B-D). We also determined the 
expression of other key neuroinflammatory markers, including gp91phox and Iba-1, in 
response to LPS stimulation. We, as well as other groups, have previously shown increased 
expression of the NADPH oxidase component gp91phox and Iba-1 following LPS stimulation 
of primary microglia (Gao et al., 2011; Gordon et al., 2011). Western blot analysis revealed 
that LPS increased expression of both gp91phox and Iba-1 in wild-type, but not in Fyn-/- or 
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PKCδ-/- microglia (Figs. 7E-F). Collectively, these data indicate that Fyn-PKCδ signaling 
plays a major pro-inflammatory role in microglial cells.   
 
Fyn-/- and PKCδ-/- mice are resistant to LPS- and MPTP-induced neuroinflammatory 
responses 
To extend our findings from isolated primary microglia to in vivo animal models of 
neuroinflammation, we first used the LPS model, which has previously been used to evoke 
neuroinflammatory responses in vivo (Choi et al., 2007; Qin et al., 2007). Wild-type 
(PKCδ+/+ and Fyn+/+), PKCδ-/- and Fyn-/- mice were injected with 5 mg/kg LPS or PBS and 
were sacrificed 3 h later. Striatal mRNA contents of the pro-inflammatory cytokines pro-IL-
1β and TNFα were determined by qRT-PCR.  The levels of cytokine induction were almost 
identical in both wild-type groups, and we thus pooled the results. Systemic LPS 
administration strongly increased the levels of pro-IL-1β and TNFα transcripts in wild-type 
striata, but not in Fyn-/- and PKCδ-/- striata (Fig. 8A). To further establish the role of Fyn 
relevant to PD-associated neuroinflammation, we used the well-known Parkinsonian toxicant 
MPTP. We subjected wild-type and Fyn-/- mice to an acute MPTP regimen (4 × 18 mg/kg, 2 
h apart) and collected their brains for immunohistochemical analysis 24 h after the final 
MPTP injection. This acute MPTP model has been widely adopted for studying the 
neuroinflammatory response in the nigrostriatal pathway because maximal microglial 
activation occurs 24-48 h after the MPTP challenge (Wu et al., 2002; Wu et al., 2003; Sriram 
et al., 2006; Hirsch and Hunot, 2009).  Following the MPTP challenge, successive 30-µm 
ventral midbrain sections from Fyn+/+ and Fyn-/- mice were stained for the microglial marker 
Iba-1, and then microglial morphology was quantified using a recently well-established 
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morphometric rating scale as discussed by others (Lastres-Becker et al., 2012). 
Representations of Type A-D microglial phenotype are provided in Fig. 8B. Treating Fyn+/+ 
mice with the acute MPTP regimen increased Iba-1 expression and discernibly shifted 
microglial morphology from its typical ramified state to its more amoeboid, activated 
morphology. After MPTP administration, significantly fewer Type A and more Type B and 
C microglia were observed in the Fyn+/+ SN, but this shift in microglial morphology was not 
apparent in the Fyn-/- mice (Figs. 8C-D). We also determined the induction of the NADPH 
oxidase component gp91phox in MPTP animal model of neuroinflammation. Immunoblotting 
analysis revealed that MPTP increased expression of gp91phox in WT but not in Fyn-/- ventral 
midbrain tissues (Figs. 8E-F). Overall, these results confirm that our in-vitro data translate 
well to animal models of neuroinflammation.  
 
Fyn-/- and PKCδ-/- mice are protected against 6-OHDA-induced nigrostriatal 
dopaminergic neuronal deficits and microgliosis 
The 6-OHDA mouse model has recently been shown to elicit a neuroinflammatory 
response and neurodegeneration in the nigrostriatal dopaminergic system (Stott and Barker, 
2014). While studying the role of Fyn in dopamine D1 receptor agonist-induced 
redistribution of NMDA receptor subunits, it was serendipitously discovered that Fyn-/- mice 
were remarkably intransigent to 6-OHDA-induced behavioral deficits and striatal TH loss 
(Dunah et al., 2004). Fyn+/+ and Fyn-/- mice, injected unilaterally with 6-OHDA (Fig. 9B) 
were sacrificed 9 days post-treatment, since mice at this treatment stage concurrently exhibit 
fewer striatal dopaminergic terminals, significantly fewer TH-positive cells in the SN, and 
microgliosis within the SN (Stott and Barker, 2014). Fyn-/- mice were more resistant to 6-
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OHDA-induced striatal nerve terminal degeneration relative to Fyn+/+ mice (Figs. 9A and C). 
We also show in our studies that 6-OHDA induced massive gliosis coupled with 
dopaminergic neuronal loss (Fig. 9D). However, Fyn-/- mice show both greater survival of 
nigral dopaminergic neurons and a diminished neuroinflammatory microglial response.  
In the next set of in vivo experiments, we checked whether PKCδ-/- mice were also 
resistant to 6-OHDA-induced nigral microgliosis and dopaminergic neuronal loss. PKCδ+/+ 
and PKCδ-/- mice were injected unilaterally with 6-OHDA for 9 days, and DAB-TH 
immunostaining was performed on striatal sections as described above (Fig. 10B). Similar to 
Fyn-/- mice, PKCδ-/- mice showed reduced striatal TH loss following 6-OHDA treatment 
(Figs. 10A and C). We also assessed nigral microgliosis by double-staining ventral midbrain 
sections for TH and Iba-1. As shown in Fig. 10D-E, PKCδ+/+ mice showed less TH-positive 
neuronal staining in the SN along with significantly more microgliosis on the ipsilateral side 
than on the contralateral side; however, the PKCδ-/- mice showed a marked resistance to 6-
OHDA-induced nigral TH loss as well as microgliosis. Thus, results from both Fyn and 
PKCδ knockout models of 6-OHDA neurotoxicity confirm the role of the Fyn-PKCδ 
signaling axis in a neuroinflammatory response in the nigrostriatal dopaminergic system.  
 
Diminished 6-OHDA-induced glial neuronal contact formation in the Fyn-/- substantia 
nigra 
Recently, it was demonstrated that treating mice with MPTP rapidly increased the 
number of microglial-neuronal appositions, termed gliapses (Barcia et al., 2012). These 
contacts preceded neuronal phagocytosis by the microglia. Similar appositions between 
microglia and dopaminergic neurons were demonstrated in the 6-OHDA model, with 
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evidence suggesting that microglial cells actually phagocytized neurons (Virgone-Carlotta et 
al., 2013), which has been postulated to occur if the neurons are dysfunctional. Our confocal 
high magnification Z stack image analysis (Imaris software) revealed a sharply increased 
number of microglial-neuronal contacts formed in the Fyn+/+ SN post-6-OHDA treatment as 
indicated by arrowheads (Figs. 11A, B and F). The 3-D reconstructions of the respective 
stacks demonstrating contacts between dopaminergic neurons and microglia are shown 
adjacent to the original images (Fig. 11B). The number of gliapses per SN dopaminergic 
neuron was dramatically reduced in the 6-OHDA-injected Fyn-/- mice (Figs. 11C, D, and F). 
Typical contacts formed between microglial processes and dopaminergic neuronal cell bodies 
(termed Process-Body, or Pr-B contacts), and those formed between the microglial cell body 
and the dopaminergic neuronal cell body (Body-Body, or B-B contacts), are shown in Fig. 
11E. Image analysis involving optical slices through the Z plane allowed us to both easily 
count gliapses and visualize actual engulfment events. Representative (Figs. 11B and D) 
gliapses between a dopaminergic neuron and a microglial cell in the SN of 6-OHDA-injected 
Fyn+/+ and Fyn-/- mice reveal a conspicuous reduction in the number of gliapses per neuron. 
Collectively, our confocal imaging results demonstrate Fyn plays a key role in activation of 
microglial morphological changes in vivo during inflammatory insults in nigrostriatal system.    
 
Prolonged inflammogen stimulation effects Fyn induction upon microglial activation  
Thus far, our results demonstrated that short-term treatment of microglial cells with 
LPS and TNFα brings about an increase in Fyn activity, but not its expression. Strikingly, we 
discovered that prolonged treatment (12-24 h) of microglia with LPS or TNFα actually 
resulted in increased Fyn expression, evidenced by Western blot and immunocytochemistry 
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(Fig. 12A-C). To confirm whether this is really due to induction of Fyn protein or increased 
protein stability, we performed qRT-PCR for Fyn mRNA expression in control and LPS-
treated microglial cells. The result showed that treatment of microglia with LPS for 12 h 
brought about an increase in Fyn transcript levels (Fig. 12D). We also evaluated the effects 
of prolonged LPS treatment on Fyn promoter activity. For this, we transiently transfected 
primary microglia with a dual-luciferase Fyn reporter construct containing the 3.1 kb Fyn 
promoter fragment. LPS treatment significantly increased Fyn promoter activity (Fig. 12E), 
indicating strongly that Fyn is transcriptionally induced in microglial cells post-prolonged 
inflammogen administration. To further examine whether LPS upregulates Fyn mRNA 
expression, we injected wild-type mice with a single dose of LPS (5 mg/kg, i.p.) and 
evaluated the Fyn mRNA expression by qRT-PCR analysis. As shown in Fig. 12F, 
administration of LPS also induced Fyn transcript levels in the striatum. Together, these data 
suggest that prolonged LPS exposure induces Fyn gene upregulation in microglia, indicating 
that Fyn may have a sustained role in chronic neuroinflammatory processes.  
 
Discussion 
Evidence from experimental models and human PD post-mortem studies strongly 
implicates the microglial-mediated inflammatory response as a major driver in the 
progression of PD; however, the key upstream cell signaling mechanisms that govern the 
neuroinflammatory processes have yet to be elucidated. Our results obtained from both cell 
culture and animal models provide novel insight into the role of the Fyn-PKCδ signaling 
cascade in regulating microglia-mediated neuroinflammation as related to PD pathogenesis. 
We have demonstrated dual regulation of pro-neuroinflammatory responses in microglia 
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involving post-translational tyrosine phosphorylation of Fyn at its activation loop during the 
early stages of an inflammatory insult as well as transcriptional upregulation of Fyn upon 
prolonged exposure to pro-inflammatory stimuli. We have also showed that Fyn serves as a 
major upstream signaling molecule that works in concert with PKCδ to influence MAP 
kinase downstream and the NFκB pro-inflammatory cascade. Collectively, our study 
provides novel and significant insight into the pro-inflammatory function of Fyn-PKCδ 
signaling in PD models, and to the best of our knowledge, we are the first to discern this key 
signaling cascade that is relevant to microglia-mediated neuroinflammation in the 
nigrostriatal dopaminergic system. 
We demonstrate that both the tyrosine kinase Fyn and the serine/threonine kinase 
PKCδ are differentially expressed in microglia and astrocytes (Fig. 1). No prior comparative 
data are available on Fyn and PKCδ expression in primary microglia. Although the roles of 
Src family kinases in TLR signaling are being identified, most studies have used peripheral 
immune and non-immune cells to determine Src kinase signaling. For example, multiple Src 
family kinases were activated by LPS in human lung microvascular endothelial cells (Gong 
et al., 2008). The activation of Src kinases mediated by TLR agonists depends on CD14, 
TLR2 and TLR4 (Reed-Geaghan et al., 2009), and Fyn has been shown to be associated with 
TLR2 in TLR2-overexpressing HEK293 cells (Finberg et al., 2012). Peritoneal macrophages 
have often been used as putative substitutes for brain microglia; Fyn contributes to CD36-
mediated signaling responses upon Aβ1-42 stimulation of macrophages (Moore et al., 2002). 
Of note, the authors reported unaltered LPS-induced MAP kinase activation in Fyn-/- 
peritoneal macrophages when compared to WT macrophages. These apparent discrepancies 
may be attributed to the inherent differences between the microglial and macrophage gene 
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expression profiles (Hickman et al., 2013). Many studies have used the p-Y416 src family 
kinase antibody as a direct indicator of Fyn activation, without using immunoprecipitation or 
Fyn-/- primary microglia as confirmatory tools to establish Fyn activation. In the present 
study, we demonstrate that Fyn is rapidly activated in primary microglia within 15-30 min of 
exposure to inflammogens (Figs. 2A-F). Immunoprecipitation studies and experiments with 
Fyn-/- microglia clearly confirmed that Fyn kinase is specifically activated during LPS and 
TNFα stimulation.  LPS and TNFα activate microglia/macrophages via TLR4 and TNFα 
Receptor 1 (TNFR1) signaling, respectively (Olson and Miller, 2004; Parameswaran and 
Patial, 2010). Importantly, our study reveals that Fyn is a common signaling conduit in both 
TLR- and TNFR1-mediated signaling, since the TLR antagonist IAXO-101 and the TNFα 
signaling antagonist Etanercept attenuated Fyn activation (Fig. 2G). Immunocytochemistry 
analysis revealed that activated Fyn primarily localized to the microglial cell membrane. 
Although the functional relevance of this localization is not presently known, it is possible 
that movement of activated Fyn to the microglial membrane may regulate cell migration and 
cytokine release. Our results with the LPS mouse model provide in vivo evidence for rapid 
Fyn activation in the ventral midbrain region during inflammatory insults (Fig. 2I).    
Our group has previously shown that PKCδ kinase proteolytic activation promotes 
oxidative stress-induced pro-apoptotic signaling pathways in dopaminergic neuronal cells 
(Kaul et al., 2003; Zhang et al., 2007; Jin et al., 2011a; Jin et al., 2011b). Recently, it was 
demonstrated that PKCδ is proteolytically cleaved by caspase-3 in LPS-treated BV2 cells 
(Burguillos et al., 2011).   In the present study, we demonstrate that activated Fyn associates 
with PKCδ to phosphorylate the Y311 site, resulting in increased PKCδ kinase activity (Fig. 
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3). To the best of our knowledge, we are the first group to show the assembly of the Fyn-
PKCδ signaling complex in microglial cells during pro-inflammatory conditions.   
MAP kinase activation is necessary for cytokine production in various immune cell 
types, including microglia (El Benna et al., 1996; Koistinaho and Koistinaho, 2002). We 
demonstrate that Fyn-PKCδ signaling contributes to MAP kinase phosphorylation during 
microglial activation. Both LPS and TNFα stimulations rapidly activated the p38 and p-ERK 
MAP kinases in WT, but to a significantly lesser extent in the Fyn-/- and PKCδ-/- microglia 
(Fig. 4), indicating that Fyn-PKCδ signaling lies upstream of MAP kinase in microglia. 
Given that p38 is a prominent MAP kinase associated with the inflammatory cascade, our 
results suggest that Fyn and PKCδ are key upstream regulators of the pro-inflammatory 
function of this kinase. The downstream events of MAP kinase activation include NFκB 
signaling, which plays a cardinal role in eliciting pro-inflammatory responses in microglia. 
Selective inhibition of NFκB signaling has also proved beneficial in-vitro as well as in an 
experimental mouse model of PD (Ghosh et al., 2007). We show here that IκBα degradation 
and p65-NFκB nuclear translocation were diminished in Fyn-/- microglia stimulated with LPS 
or TNFα (Fig. 5), lending credence to the hypothesis that upstream Fyn signaling contributes 
to NFκB pathway activation in microglia. To our knowledge, the role of Fyn signaling in 
NFκB-mediated pro-inflammatory signaling in microglia has never been explored. Fyn has 
been shown to contribute to anaphylaxis inducer DNP36-HSA mediated NFκB activation in 
Mast cells (Gomez et al., 2005b). More recently, Fyn was shown to mediate the nuclear 
translocation of p65-NFκB downstream of NKG2D and CD137 activation in natural killer 
cells, utilizing a signaling mechanism dependent on ADAP (Rajasekaran et al., 2013). This 
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signaling pathway is almost certainly distinct from the Fyn-dependent microglial activation 
pathway, evidenced by the fact that ADAP-/- microglia display unaltered pro-inflammatory 
responses (Engelmann et al., 2013).  
Classical activation of microglia by TLR and TNFR1 agonists produces pro-
inflammatory cytokines and chemokines, which mediate the downstream effects of 
microglial activation. Recently, we showed that TNFα directly induces dopaminergic 
neuronal apoptosis (Gordon et al., 2012). In our present study, the induction of the cytokines 
IL-6, IL-12 and TNFα was all diminished in Fyn-/- and PKCδ-/- microglia in comparison to 
wild-type microglia (Fig. 6A). Consistently, genetic knockdown of Fyn via siRNA also 
resulted in diminished LPS-induced pro-inflammatory cytokine secretion (Figs. 6B-C). 
TNFα-mediated production of IL-6 and TNFα was also diminished in Fyn deficient 
microglia (Figs. 6D-E). Overexpressing the Fyn Y417A activation loop kinase deficient 
mutant construct in BV2 microglial cells also diminished LPS-stimulated cytokine 
production, implicating that the phosphorylation of tyrosine 417 is critical to pro-
inflammatory function of Fyn (Figs. 6F-G). Furthermore, we showed that the LPS-induced 
expression of iNOS and secretion of nitrite were significantly attenuated in the Fyn-/- 
microglia (Figs. 7A-D). We and several other groups have reported increased expression of 
the NADPH oxidase component gp91phox, as well as the microglial marker Iba-1 following 
pro-inflammatory stimulation of microglia (Gao et al., 2011; Gordon et al., 2011). We 
demonstrate herein that prolonged LPS stimulation brought about the induction of these 
neuroinflammatory markers in wild-type, but not in Fyn-/- and PKCδ-/- microglia (Figs. 7E-F).  
We extended our in-vitro studies to well-characterized animal models of 
neuroinflammation, wherein a single intraperitoneal injection of LPS in mice increases 
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TNFα in the brain to levels that remain elevated long after serum TNFα levels have returned 
to normal (Qin et al., 2007). We utilized this model system to check for LPS-induced striatal 
pro-inflammatory cytokine induction in wild type, Fyn-/- and PKCδ-/- mice. Strikingly, a 
single injection of LPS strongly increased WT striatal TNFα and pro-IL-1β mRNA levels; 
however, the induction of these cytokines was greatly diminished in Fyn-/- and PKCδ-/- striata 
(Fig. 8A). In addition to the LPS model, we also determined the pro-inflammatory role of 
Fyn in the well-studied acute MPTP model of neuroinflammation. MPTP induced reactive 
microgliosis and increased gp91phox expression in the nigra of WT mice, but not in Fyn-/- mice 
(Figs. 8E-F). Interestingly, a quiescent ramified state of microglial morphology was observed 
in MPTP treated Fyn-/- mice, while more amoeboid activated microglia were noted in Fyn 
wild-type mice (Figs. 8C-D). In addition to the MPTP model, we further utilized the 6-
OHDA-induced selective dopaminergic lesion model to validate that ablating Fyn or PKCδ 
confers resistance to nigrostriatal dopaminergic degeneration and microgliosis (Figs. 9-10).  
Taken together, our results indicate that the Fyn-PKCδ signaling axis plays an important role 
in mediating pro-inflammatory response in both cell culture and animal models of 
neuroinflammation.  
Recent imaging studies have demonstrated the formation of glial-neuronal contacts, 
called gliapses, formed between dopaminergic neurons and microglia that precede neuron 
loss in the MPTP model (Barcia et al., 2012; Barcia et al., 2013). To determine whether Fyn 
plays a role in microglial-dopaminergic neuron contact formation, we adopted the 6-OHDA 
mouse model. The formation of gliapses was described recently in the 6-OHDA model 
(Virgone-Carlotta et al., 2013). Our results from high magnification confocal analysis 
revealed the formation of gliapses was almost completely blocked in 6-OHDA injected Fyn-/- 
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mice (Fig. 11). The reduced number of gliapses correlated well with reduced dopaminergic 
neuronal loss following 6-OHDA administration to the Fyn-/- mice. Lastly, prolonged 
stimulation of microglial cells with inflammogens strongly elicited an induction in Fyn 
kinase expression levels (Fig. 12). The aggregated form of α-synuclein, the primary 
component of PD-associated Lewy bodies, can activate microglia by utilizing CD36- and 
TLR2-dependent pathways (Su et al., 2008; Kim et al., 2013a). Studies are underway in our 
lab to demonstrate the role that Fyn plays in aggregated α-synuclein-induced 
neuroinflammatory events. 
            We demonstrate that Fyn activation plays an upstream regulatory role in eliciting pro-
inflammatory signaling following both acute and chronic states of microglia stimulation. We 
arrived at this conclusion based on various lines of experimental evidence from cell culture, 
primary culture and in vivo models utilizing both Fyn and PKCδ knockout mice. Our 
mechanistic studies revealed that Fyn serves as a major upstream regulator of pro-
inflammatory signaling involving PKCδ, MAP kinase and the NFκB pathways. Thus, Fyn 
could be exploited as a potential signaling node in the development of novel anti-
neuroinflammatory drug candidates for treating PD and other related neurodegenerative 
diseases with associated microglia-mediated pro-inflammatory processes. 
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Figures 
 
Figure 1: Fyn and PKCδ are differentially expressed in primary astrocytes and 
microglia. A, Representative image from immunocytochemical analysis for the microglial 
marker Iba-1 and the astrocytic marker GFAP on both, the magnetically purified and pour-off 
fractions of cells obtained post-separation revealed almost no astrocytic contamination in the 
samples. Scale bar, 200 microns. B, The colocalization image of Hoechst (nuclear stain) and 
Iba-1 images in 6 random image fields were obtained using the ImageJ plugin JACoP. C, The 
number of Hoechst-positive and colocalization-positive cells were counted using ImageJ. 
The magnetically purified samples were >97% positive for microglial cells. D, E, Western 
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Blot analyses of the magnetically separated cells revealed that the microglial fraction 
expressed higher amounts of the non-receptor Src kinase Fyn and the serine threonine kinase 
PKCδ than did the astrocyte-rich pour-off fraction (*p < 0.05, **p < 0.01). 
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Figure 2. Fyn kinase is rapidly activated in microglial cells and in the ventral midbrain 
following inflammogen stimulation. A, Fyn kinase assay shows that Fyn activity was 
highly induced in BV2 microglia treated with 1 µg/mL LPS for 10, 15 and 30 min. (*p < 
0.05, **p < 0.01). B, Immunoblots showing a concomitant rise in p-Y416 SFK levels in BV2 
cell lysates post-LPS treatment. C, D, Immunoprecipitation studies revealed that Fyn+/+ (WT 
Fyn), but not active loop tyrosine-mutant Fyn (Y417A Fyn), when overexpressed in BV2 
microglia, was activated following LPS stimulation. E, Treatment of primary microglia with 
LPS and F, TNFα for 15 and 30 min increased p-Y416 SFK levels in primary microglia 
obtained from wild-type Fyn+/+, but not Fyn-/- mice, identifying Fyn as the primary Src family 
kinase that was activated by inflammogen stimulation. G, Pretreatment of primary microglia 
with the TLR-signaling antagonist IAXO-101 or the TNFα receptor decoy Etanercept 
abolished Fyn activation by LPS or TNFα stimulation (p-44/42 phosphorylation used as 
marker for early microglial activation) H, Immunocytochemistry of LPS-treated WT primary 
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microglia showing that activated Fyn expression greatly increased and was localized 
preferentially to the membrane periphery of the microglial cell. Scale bar, 20 microns. I, 
Immunoblots of ventral midbrain lysates showed that peripheral administration of the 
inflammogen LPS (5 mg/kg) increased p-Y416 SFK levels in Fyn+/+, but not in Fyn-/- ventral 
midbrain tissues. 
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Figure 3. Fyn contributes to LPS- and TNFα-induced tyrosine phosphorylation and 
activation of PKCδ in primary microglia. Western blot analysis revealed that stimulation 
of microglia with LPS (A, B) and TNFα (C, D) induced a time-dependent increase in p-Y311 
PKCδ levels in wild type but not Fyn-/- microglia (*p < 0.05, **p < 0.01). E, LPS-induced 
PKCδ kinase activity was reduced in Fyn-/- microglial lysates in contrast to wild type lysates, 
as measured by PKCδ kinase assay. F, G, Co-immunoprecipitation studies showed that LPS 
stimulation elicited a physical interaction between Fyn and PKCδ in WT Fyn-transfected 
BV2 microglial cells. 
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Figure 4. The Fyn–PKCδ signaling axis mediates MAP kinase activation in microglial 
cells. A, B, Immunoblot analysis demonstrated diminished LPS-induced p38 and p44/42 (p-
ERK) phosphorylation in Fyn-/- and PKCδ-/- microglia (*p < 0.05, ***p < 0.001). C, D, 
Diminished TNFα-induced p38 and p44/42 (p-ERK) phosphorylation in Fyn-/- and PKCδ-/- 
microglia (*p < 0.05).  
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Figure 5. Fyn contributes to inflammogen-mediated NFκB pathway activation in 
microglial cells. A, B, Immunoblot analyses of whole cell lysates of wild-type and Fyn-/- 
microglia treated with LPS for 15-45 min revealed reduced IκBα degradation in Fyn-/- 
microglia at 15 min, and attenuated IκBα resynthesis at 30 and 45 min (*p < 0.05, **p < 
0.01). C, D, Cytosolic and nuclear fractionation of LPS- and TNFα-treated wild type and 
Fyn-/- microglia revealed diminished nuclear translocation of the p65 subunit of the NFκB 
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complex in the Fyn-/- microglia (**p < 0.01, ***p < 0.001). E, Immunocytochemistry also 
showed reduced nuclear p65 in LPS-treated Fyn-/- microglia. Scale bar, 50 microns. 
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Figure 6. LPS- or TNFα-induced proinflammatory cytokine production is suppressed in 
Fyn/PKCδ deficient microglia. A, Luminex analyses of supernatants from LPS-treated 
wild-type, PKCδ-/- and Fyn-/- microglia revealed reduced secretion of the pro-inflammatory 
cytokines IL-6, IL-12 and TNFα (**p < 0.01,  ***p < 0.001). B, Wild-type primary 
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microglia were transfected with non-targeting and Fyn-specific siRNA for 72 hours. 
Knockdown of Fyn was evaluated by Western blot. C, Fyn depleted microglia demonstrated 
diminished IL-6 and TNFα secretion in response to LPS stimulation (**p < 0.01, ***p < 
0.001). D, TNFα stimulation of Fyn-/- microglia reduced IL-6 and TNFα production in 
contrast to wild-type microglia. (**p < 0.01, ***p < 0.001). E, Immunoblots showing 
reduced TNFα levels in Fyn-deficient microglia after TNFα stimulation in contrast to wild-
type microglia. F, G, Overexpressing the FLAG-tagged activation loop tyrosine mutant of 
Fyn in BV2 microglia attenuated IL-6 and IL-12 production when the cells were treated with 
LPS, as shown by Luminex cytokine analysis (*p < 0.05, **p < 0.01 and ***p < 0.001). 
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Figure 7. Fyn plays a role in LPS-induced iNOS expression, nitrite production and 
neuroinflammatory marker expression. A, Griess nitrite measurement assay demonstrated 
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that LPS-induced nitrite production was reduced in Fyn-/- microglia (*p < 0.05, ***p < 
0.001). B, C, D, Diminished iNOS expression in LPS-treated Fyn-/- microglia (**p < 0.01). 
Scale bar, 100 microns. E, F, Reduced gp91phox and Iba-1 expression in LPS-treated Fyn-/- 
and PKCδ-/- microglia, as shown by immunoblotting analysis (*p < 0.05, **p < 0.01). 
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Figure 8. Fyn-/- and PKCδ-/- mice are resistant to LPS- and MPTP-induced 
neuroinflammatory responses. A, Wild-type, PKCδ-/- and Fyn-/- mice were injected 
intraperitoneally with 5 mg/kg LPS for 3 h. Striatal cytokine mRNA levels, assessed by q-RT 
PCR, showed significantly reduced induction of pro-IL-1β and TNFα mRNA levels in 
PKCδ-/- and Fyn-/- mice in contrast to wild-type mice (*p < 0.05, **p < 0.01 and ***p < 
0.001). B, The transitional stages of microglial activation, from ramified (inactivated, type A) 
to amoeboid (activated, types B, C and D), are shown by representative images. C, D, Iba-1-
DAB immunohistochemistry in MPTP-injected Fyn-/- and wild-type ventral midbrain sections 
demonstrated nigral microgliosis, assessed by quantification of microglial morphology, in the 
WT, but not the Fyn-/- sections. Scale bar, 75 microns (*p < 0.05, **p < 0.01). E, F, Fyn-/- 
mice showed diminished induction of the proinflammatory marker gp91phox in ventral 
midbrain lysates following the acute MPTP regimen (*p < 0.05). 
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Figure 9. Fyn-/- mice are protected against 6-OHDA-induced nigrostriatal dopaminergic 
neuronal deficits and microgliosis. A, TH-DAB immunohistochemistry in 6-OHDA-
injected Fyn-/- and wild-type mouse striatal sections. Scale bar, 1000 microns. B, Schematic 
diagram of a coronal section through the mouse striatum at the level of the injection. C, 
Significant preservation of 6-OHDA-induced degeneration of dopaminergic terminals is seen 
in the Fyn-/- mice in contrast to wild-type mice (**p < 0.01, ***p < 0.001). D, 
Immunofluorescence staining of 6-OHDA-injected Fyn-/- and wild-type ventral midbrain 
sections reveals diminished microgliosis and concomitant nigral neuroprotection in Fyn-/- 
mice after 6-OHDA administration, in contrast to the massive microgliosis and nigral 
dopaminergic neuronal death observed in the wild-type mice. Scale bar, 200 microns. 
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Figure 10. PKCδ-/- mice are resistant to 6-OHDA-induced nigrostriatal dopaminergic 
neuronal deficits and microgliosis. A, TH-DAB immunohistochemistry in 6-OHDA-
injected PKCδ-/- and wild-type mouse striatal sections. Scale bar, 1000 microns. B, Schematic 
diagram of a coronal section through the mouse striatum at the level of the injection. C, 
Significant preservation of dopaminergic terminals is seen in the 6-OHDA-treated PKCδ-/- 
mice in contrast to wild-type mice (*p < 0.05, **p < 0.01 and ***p < 0.001). D, 
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Immunofluorescence staining of 6-OHDA-injected PKCδ-/- and wild-type ventral midbrain 
sections reveals reduced nigral TH degeneration and microgliosis in PKCδ-/- mice after 6-
OHDA administration, in contrast to the wild-type  mice. Scale bar, 200 microns. E, High 
magnification image of 6-OHDA-injected PKCδ-/- and wild-type ventral midbrain sections. 
Scale bar, 50 microns. 
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Figure 11. Diminished 6-OHDA-induced glial-neuronal contact (gliapse) formation in 
the Fyn-/- substantia nigra. A, C, Confocal Z stack maximum projection image analysis of 
ventral midbrain sections reveals a strongly increased number of microglial-neuronal 
contacts and appositions upon 6-OHDA treatment of Fyn+/+ but not Fyn-/- mice. Scale bar, 12 
microns B, D, Confocal Z stack images were rotated and optically sectioned along the Z 
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plane using Imaris software, allowing easy visualization of gliapse formation. Scale bar, 10 
microns E, Diagrams of Process-Body (Pr-B) and Body-Body (B-B) gliapses formed 
between dopaminergic neurons and microglia. F, Fyn ventral midbrain sections revealed 
significantly fewer gliapses formed per dopaminergic neuron in the SN (***p < 0.001). 
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Figure 12. Prolonged inflammogen stimulation induces Fyn upon microglial activation. 
A, B, Stimulation of primary microglia with LPS for 12 h and TNFα for 24 h increased Fyn 
expression, as evidenced by Western blotting (*p < 0.05). C, ICC analysis of Fyn expression. 
Scale bar, 20 microns. D, q-RT PCR analysis of Fyn mRNA levels in LPS-stimulated 
primary microglia and BV2 microglia revealed induction of Fyn at the message level (*p < 
0.05, **p < 0.01). E, Induction of Fyn promoter activity in primary microglia following LPS 
activation of wild-type primary microglia (*p < 0.05). F, Increased striatal Fyn mRNA levels 
were seen in the Fyn+/+ mice injected intraperitoneally with LPS (5 mg/kg) for 12 h, as 
assessed by q-RT PCR (**p < 0.01). 
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CHAPTER 3. FYN KINASE CONTRIBUTES TO HUMAN ALPHA-SYNUCLEIN-
INDUCED PRIMING AND ACTIVATION OF THE NLRP3 INFLAMMASOME IN 
MICROGLIA, LEADING TO EXACERBATED STERILE INFLAMMATION 
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Abstract 
Persistent neuroinflammation is recognized as a major pathophysiological contributor 
to the progression of Parkinson’s disease (PD). Microglia, the resident macrophagic cells of 
the brain, mediate chronic neuroinflammation through the production of pro-inflammatory 
factors. Identifying novel molecular signaling events that perpetuate sustained microglial 
activation, which in turn contributes to progressive neurodegeneration in PD could 
potentially identify drug targets that halt its progression. Hyperactivation of the NLRP3 
inflammasome, traditionally shown to be involved in the innate immune response to 
microbial pathogens and cellular stress, has recently been demonstrated to contribute to the 
pathology of Alzheimer’s disease. However, its role in PD pathogenesis is yet to be 
established. The signaling mechanisms that govern microglial NLRP3 inflammasome 
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signaling are poorly characterized. Herein, we show that aggregated human α-synuclein, the 
major component of Lewy bodies, can activate the inflammasome pathway in microglia 
through the activation of the non-receptor Src family kinase - Fyn. Aggregated α-synuclein 
treatment amplified LPS-induced priming of the NLRP3 inflammasome in murine primary 
microglia, synergistically promoting NLRP3 and pro-IL-1β induction, as well as subsequent 
IL-1β processing and Caspase-1 activation, culminating in the secretion of cleaved IL-1β 
into the supernatant. LPS primed Fyn-/- microglia showed diminished α-synuclein-induced 
NLRP3 inflammasome activation when compared to wild-type (WT) microglia. We then 
demonstrate that aggregated α-synuclein can mediate both priming and activation of the 
NLRP3 inflammasome independent of LPS stimulation. Fyn was found to be rapidly 
activated in microglial cells upon aggregated α-synuclein stimulation, and contributed to 
PKCδ activation and subsequent NF-κB activation, which induced pro-IL-1β and NLRP3 
mRNA and protein levels. Strikingly, Fyn was also found to play a role in the import of α-
synuclein into microglial cells, contributing to the generation of mitochondrial reactive 
oxygen species (MitoROS). We observed diminished production of IL-1β and other pro-
inflammatory cytokines from Fyn-deficient microglia in response to aggregated α-synuclein 
stimulation. Taken together, our studies show for the first time that aggregated α-synuclein 
can prime and activate the NLRP3 inflammasome, and that Fyn contributes to both these 
processes. 
 
Introduction 
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by 
progressive motor deficits and the death of dopaminergic neurons within the nigrostriatal 
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tract, which project from the Substantia Nigra (SN) to the striatum. Several causative factors 
contribute to PD-associated neurodegeneration, including mitochondrial dysfunction, 
oxidative stress and proteasomal impairment (Jenner and Olanow, 2006; Levy et al., 2009; 
Olanow, 2007; Przedborski, 2005).  Currently, there is no cure for PD and existing treatments 
focus on controlling the symptoms, rather than preventing the progression of the disease 
(Jankovic and Aguilar, 2008). 
Recently, sterile inflammation, mediated primarily by resident brain microglia and 
infiltrating monocytes, has been identified and gained traction as both an important abettor of 
neuron loss that contributes to the progressive nature of most neurodegenerative diseases, 
including PD, as well as an attractive drug target for neurodegenerative disease therapy. 
Various lines of evidence, including cell culture, animal models and post-mortem tissue 
analysis have implicated sustained neuroinflammation in being critical to PD progression 
(Block et al., 2007; Glass et al., 2010; Imamura et al., 2003; Tansey and Goldberg, 2010).  
Inflammasomes are large, multimeric protein complexes that comprise of a pattern-
recognition receptor such as the nucleotide-binding oligomerization domain (NOD) like 
receptors (NLRs), the adaptor protein ASC and Caspase-1. Inflammasome assembly is 
triggered by a variety of stimuli and culminates in the activation of Caspase-1, which then 
cleaves the inflammogen-inducible pro-Interleukin-1β (pro-IL-1β) to mature IL-1β (Latz et 
al., 2013; Walsh et al., 2014). The NLRP1b and NLRC4 inflammasomes can be activated 
independent of ASC (Lamkanfi and Dixit, 2014). 
The NLRP3 inflammasome is the most widely studied mediator of Caspase-1 
activation. Activation of this inflammasome is a two-step process; the first step, priming, 
involves the inflammogen-mediated induction of the proteins NLRP3 and pro-IL-1β by 
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activating the NF-κB pathway. The second step, known as activation, requires a second 
stimulus called a danger signal, which, through the disruption of cytosolic homeostasis, 
brings about the assembly of the inflammasome components into a functional complex, 
leading to the activation of Caspase-1 and subsequent Caspase-1-mediated cleavage of pro-
IL-1β to mature IL-1β, which is secreted. This two-step mechanism is hypothesized to serve 
as a checkpoint to prevent unabated release of IL-1β. The NLRP3 inflammasome-associated 
hypersecretion of IL-1β is, in turn, linked to the pathology of various inflammatory diseases, 
including Alzheimer’s disease (Heneka et al., 2013), diabetes (Lee et al., 2013) and 
atherosclerosis (Duewell et al., 2010; Sheedy et al., 2013). IL-1β has been shown to directly 
kill neurons and also increase pathological neuronal Tau phosphorylation (Li et al., 2003; 
Wang et al., 2005) and contribute to pro-inflammatory signaling in glial cells (Moynagh, 
2005). Increased IL-1β and cleaved Caspase-1 levels have already been demonstrated in PD 
patient tissues, but these studies were published before it was demonstrated that IL-1β 
processing is mediated by inflammasome complexes (Mogi et al., 1996; Mogi et al., 2000). 
The NLRP3 inflammasome, classically implicated in the response to cellular stress or 
microbial pathogens in peripheral immune cells, was first shown to be activated in microglia 
when fibrilar β-amyloid was used as a danger signal to activate them. This was also the first 
time that the NLRP3 inflammasome activation was shown to be mediated by a misfolded 
protein (Halle et al., 2008).  
Fyn is a non-receptor Src family tyrosine kinase. Within the peripheral immune 
system, it was demonstrated to mediate T cell and mast cell activation (Gomez et al., 2005; 
Palacios and Weiss, 2004). Recent studies also demonstrate that it contributes to Natural 
Killer cell activation (Rajasekaran et al., 2013). It is expressed by most cells within the 
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Central Nervous System (CNS), and has been shown to mediate β-amyloid-induced 
apoptosis in cortical neurons (Lambert et al., 1998), as well as contribute to astrocytic 
migration (Dey et al., 2008) and the differentiation of oligodendrocytes (Sperber et al., 2001). 
It was also shown to contribute to the activation of murine macrophages and microglia in 
response to fibrilar β-amyloid (Moore et al., 2002; Stuart et al., 2007). Our group has 
demonstrated how activated Fyn contributes to oxidative stress-induced pro-apoptotic 
signaling in N27 dopaminergic neuronal cells, as well as in inflammogen-activated 
microglial cells in in-vitro and in-vivo models of PD via PKCδ tyrosine phosphorylation 
(Kaul et al., 2005; Panicker et al., 2015; Saminathan et al., 2011).  To the best of our 
knowledge, no study exists on the role that Fyn plays in the activation of the NLRP3 
inflammasome in any cell type. Although it was demonstrated that PKCδ plays a crucial role 
in the activation of the NLRC4 inflammasome via S533 phosphorylation activation (Qu et 
al., 2012), this is also the first study that characterizes the role that this protein plays in 
NLRP3 inflammasome activation. 
The α-synuclein gene (SNCA), was the first gene that was linked to autosomal 
recessive PD (AR-PD). Missense point mutations or triplication of the α-synuclein gene can 
both cause autosomal dominant familial PD or PD-like conditions (Allen Reish and 
Standaert, 2015; Appel-Cresswell et al., 2013; Kruger et al., 1998; Lesage et al., 2013; 
Pasanen et al., 2014; Polymeropoulos et al., 1997; Zarranz et al., 2004). α-synuclein is a pre-
synaptic protein, which is predominantly expressed by neurons throughout the brain. It has 
the predilection to form fibrils, which under pathogenic conditions may form aggregates of 
varying degrees of organization. It constitutes the major component of Lewy bodies, the 
neuropathological hallmark of PD. A fascinating theory that has gained support and credence 
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in recent times postulates that α-synuclein, in its pathogenic forms, can propagate from cell 
to cell in a prionic manner, seeding the aggregation of non-pathogenic α-synuclein to form 
pathogenic aggregates, which can propagate inflammation and cell death in a progressive 
manner (Luk et al., 2012a; Luk et al., 2012b; Volpicelli-Daley et al., 2011). 
The signaling pathways through which α-synuclein mediates microglial activation 
have recently begun to be elucidated. It was demonstrated that recombinant endotoxin-free 
and aggregated α-synuclein was able to elicit the production of pro-inflammatory cytokines, 
including IL-1β in unprimed microglia, but the NLRP3 inflammasome was not selectively 
identified as the causative factor for this event (Boza-Serrano et al., 2014; Lee et al., 2010; 
Su et al., 2008). α-synuclein was also demonstrated to effect IL-1β production in monocytes 
(Codolo et al., 2013; Gustot et al., 2015). Though infiltrating monocytes contribute to the 
sterile inflammation in neurodegenerative diseases, they have constitutively activated 
Caspase-1, which enables them to produce Il-1β in response to a Toll-like receptor (TLR) 
ligand such as Lipopolysaccharide (LPS), without requiring an intervening danger signal step 
(Netea et al., 2009).  Because of this, pathways identified using these systems may not have 
significance to resident microglial cells. AAV-mediated overexpression of synuclein in the 
SN was also demonstrated to result in elevated striatal cytokine production, including IL-1β 
and TNFα, but again, inflammasomes were not directly implicated (Chung et al., 2009). We 
demonstrate conclusively that aggregated α-synuclein is able to both prime and activate the 
NLRP3 inflammasome in microglia.  
To the best of our knowledge, we are the first group to conclusively, through 
immunoprecipitation, demonstrate interaction between α-synuclein and its receptors TLR2 
and CD36. We also demonstrate here that α-synuclein stimulation of microglia results in the 
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association of CD36 with the non-receptor Src family tyrosine kinase Fyn, which 
phosphorylates PKCδ and subsequently contributes to PKCδ-dependent priming of the 
NLRP3 inflammasome as well as PKCδ-independent α-synuclein import into microglia, 
leading to mitoROS generation and subsequent mitochondrial dysfunction.  
 
Materials And Methods 
Chemicals and reagents  
Dulbecco’s modified Eagle’s medium/F-12 (DMEM/F-12), ascorbic acid, RPMI, 
fetal bovine serum (FBS), L-glutamine, Hoechst nuclear stain, penicillin, streptomycin and 
other cell culture reagents were purchased from Invitrogen (Gaithersburg, MD). L929 
conditioned medium was a kind gift from Douglas Jones at Iowa State University. 
Recombinant TNFα was purchased from Peprotech (Rocky Hill, NJ), and LPS (E. coli 
0111:B4, Endotoxin content 6.6000000 EU/mg) and 6-OHDA were purchased from Sigma 
(St. Louis, MO). SN50 and the rabbit antibody to human α-synuclein were obtained from 
EMD Millipore (Billerica, Massachusetts). The Mitotracker Red and MitoSOX dyes were 
obtained from Life Technologies (Grand Island, NY). Goat IL-1β, rat NLRP3, and goat CD-
36 and TLR-2 antibodies were obtained from R & D systems. Mouse NLRP3, Mouse 
Caspase-1 and rabbit ASC antibodies were obtained from Adipogen. The mouse Fyn and 
GAPDH antibodies was purchased from Thermo Scientific (Waltham, MA). Antibodies for 
rabbit Fyn, PKCδ, p-Y311 PKCδ, IκBα, Lamin-B, NOS2 (iNOS) and mouse Tubulin and 
human α-synuclein were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibodies against rabbit p-Src family kinase Y416 (p-Y416 SFK), native p65, were 
purchased from Cell Signaling (Beverly, MA). The TH antibody was purchased from 
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Chemicon (Temecula, CA). Mouse M2 FLAG and β-actin antibodies, as well as the rabbit β-
actin antibody were purchased from Sigma. Rabbit and goat Iba-1 antibodies were purchased 
from Wako Chemicals (Richmond, VA) and Abcam (Cambridge, MA), respectively. 32P-
ATP was purchased from Perkin Elmer (Boston, MA) and the histone substrate from Sigma. 
The Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). 
FLAG-tagged human Wild Type (WT) Fyn and Y417A mutant Fyn constructs were obtained 
as described previously (Kaspar and Jaiswal, 2011). The rat Caspase-11 antibody was 
purchased from Novus Biologicals. The WT and Caspase-1-/- microglial cell lines, as well as 
the ASC-CFP cell line were a gift from Dr. Douglas Golenbock at the University of 
Massachusetts. Femurs from WT, NLRP3-/-, ASC-/-, Caspase-1-/- and Caspase-11-/- mice were 
obtained from Dr. Jenny PY Ting at the University of North Carolina. 
 
Human α-synuclein purification, aggregation and removal of endotoxin content 
BL21 (DE3) cells transformed with a pT7-7 plasmid encoding WT human α-
synuclein were freshly grown on an ampicillin agar plate; then a single colony was 
transferred to 10 mL of LB medium with 100 μg/mL ampicillin incubated overnight at 37°C 
with shaking (pre-culture). The next day, the pre-culture was used to inoculate 1L of 
LB/ampicillin medium. When the OD600 of the cultures reached 0.5, protein expression was 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (Invitrogen), and the cells were 
further incubated at 37°C for 8 h before harvesting by centrifugation. Lysis was performed 
on ice, by resuspending the cell pellet in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and 1 
mM phenylmethylsulfonyl fluoride (PMSF) and ultrasonicated with 30 sec pulses followed 
by a 30 sec pause, for a total ultrasonication time of 2 min. Lysates were finally filtered 
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through 0.22 μm membranes and loaded onto a Bio-Rad UNO Q6 ion exchange column on 
BioLogic DuoFlow (Bio-Rad) system chromatography system. Fractions collected during 
elution with a salt gradient were assayed for the presence of α-synuclein protein by SDS-
PAGE followed by Coomassie staining. Fractions containing α-synuclein were pooled, 
dialyzed against 10 mM HEPES, 50 mM NaCl, pH 7.4 and protein concentration determined 
by Bradford assay. 
 
Primary microglial cultures and treatments 
Primary microglial cultures were prepared from WT, Fyn-/- and PKCδ-/- postnatal day 
1 (P1) mouse pups as described previously with slight modifications (Gordon et al., 2011). 
Briefly, mouse brains were harvested, meninges removed and then placed in DMEM-F12 
supplemented with 10% heat-inactivated FBS, 50 U/mL penicillin, 50 µg/mL streptomycin, 
2mM L-glutamine, 100 µM nonessential amino acids and 2 mM sodium pyruvate. Brain 
tissues were then incubated in 0.25% trypsin-EDTA for 15 min with gentle agitation. The 
trypsin reaction was stopped by adding double the volume of DMEM/ F12 complete medium 
and then washing brain tissues three times. Tissues were then triturated gently to prepare a 
single-cell suspension, which was then passed through a 70 µm nylon mesh cell strainer to 
remove tissue debris and aggregates. The cell suspension was then made up in DMEM/F12 
complete medium and seeded into T-75 flasks, which were incubated in humidified 5% CO2 
at 37°C. The medium was changed after 5–6 d, and the mixed glial cells were grown to 
confluence. Microglial cells were separated from confluent mixed glial cultures by 
differential adherence and magnetic separation to more than 97% purity and then were 
allowed to recover for 48 h after plating. Primary microglia were treated in DMEM/F12 
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complete medium containing 2% FBS. Microglia were primed with 1 µg/mL LPS for 3 h, is 
a dose and time point which has been used in several published studies (Halle et al., 2008). 
For signaling experiments, the protocol used by Stuart et. al. (Stuart et al., 2007) was used 
with a small modification. For this, the primary microglial cells were kept in 2% DMEM/F12 
complete medium for 5 h at 37°C before treatment. The microglial cells were treated with 
3.5-7 µg/mL aggregated α-synuclein, which is a similar dose used by several published 
articles (Boza-Serrano et al., 2014; Kim et al., 2013). For immunycytochemistry studies, 
microglia were obtained by the shake-off method as previously described (Gordon et al., 
2011). 
 
Primary BMDM macrophage and culture 
A sterile blade was used to cut the bone epiphyses off from the femurs exposing the 
marrow cavity. A 10 mL syringe with a 30 ga ½ inch needle was filled with 10% Fetal 
Bovine Serum (FBS) containing DMEM. This medium was flushed through the bone and the 
marrow was collected a sterile 14 mL falcon tube. The marrow was centrifuged at 250g for 
15 min at 4°C. Pellets were resuspended in bone marrow macrophage medium (DMEM 
medium containing 20% FBS, 30% L929 cell conditioned medium, Penicillin/Streptomycin, 
Sodium pyruvate). 15 X 106 cells were plated out in (15 mm x 150 mm) Petri dishes. 
Additional bone marrow macrophage medium was supplemented on day 3. The cells were 
kept at 37°C and 5% CO2 for 6 d. Adherent differentiated macrophages were trypsinized on 
day 6 and used for experiments.  
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Immunoblotting 
Lysates were prepared using modified RIPA buffer and were normalized for equal 
amounts of protein using the Bradford protein assay kit. Equal amounts of protein (6-10 µg 
for nuclear lysates and 10-25 µg for cell lysates) were loaded for each sample and separated 
on either 12% or 15% SDS-PAGE gels depending on the molecular weight of the target 
protein. After separation, proteins were transferred to a nitrocellulose membrane and the 
nonspecific binding sites were blocked for 1 h using a blocking buffer specifically 
formulated for fluorescent Western blotting (Rockland Immunochemicals). Membranes were 
then probed with the respective primary antibodies for 3 h at room temperature or overnight 
at 4°C. After incubation, the membranes were washed 7 times with PBS containing 0.05% 
Tween 20 and then Secondary IR-680-conjugated anti-mouse (1:10,000, goat anti-mouse, 
Molecular Probes) and IR-800 conjugated anti rabbit (1:10,000, goat anti-rabbit, Rockland) 
were used for antibody detection with the Odyssey IR imaging system (LiCor). Membranes 
were visualized on the Odyssey infrared imaging system. Antibodies for GAPDH, β-actin 
and Tubulin were used as loading controls.  Antibodies against Lamin B were used as the 
loading control for nuclear lysates. Immunoblots with cell supernatants, 400 μL methanol 
and 100 μL chloroform were added to 400 μL of cell supernatants obtained post-treatment 
from microglial cells treated in 12 well plates. The samples were vortexed vigorously for 30 
sec. They were then centrifuged at 13,000g for 5 min. The aqueous phase was removed using 
vacuum.  400 μL of methanol was added to each sample. The samples were vortexed 
vigorously. The samples were centrifuged at 13,000g for 5 min. Supernatant methanol was 
removed by vacuum. The pellets were dried for 5-10 min at 55°C and were subsequently 
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reconstituted in 32 μL of 1× SDS sample buffer + 8 μL β mercapthoethanol. The samples 
were then vortexed, boiled for 5 min and used for immunoblotting for IL-1β. 
 
qPCR 
The RNA extraction protocol was adapted and modified from published protocols 
(Seo et al., 2014). 2.5 X 106 microglia per treatment group obtained post separation were 
plated in a 6 well plate and after treatment RNA was extracted using the trizol chloroform 
extraction method. 1 µg of RNA was converted to cDNA using High Capacity cDNA 
Reverse Transcription Kit from Applied Biosystems (#4368814) following the 
manufacturer’s protocol. Quantitative RT-PCR was performed on the following genes using 
SYBRGreen Mastermix from Qiagen (#208056)- NLRP3 forward-
‘TGCTCTTCACTGCTATCAAGCCCT’, NLRP3 reverse-
‘ACAAGCCTTTGCTCCAGACCCTAT’ (synthesized in Iowa State University DNA 
facility) & IL-1β-Qiagen QuantiTect Primer Assay (QT01048355). 18SrRNA (Qiagen 
catalog #PPM57735E) was used as the house keeping gene for all the qPCR experiments. No 
template controls (NTCs) and dissociation curves were obtained for every experiments to 
make sure there was no cross contamination.  
 
Co-immunoprecipitation studies 
5 X 106 primary microglia per treatment group were treated with α-synuclein or 
vehicle for 30 min. Lysates were prepared using the TNE buffer. Cell lysates were prepared 
in TNE buffer (10 mM Tris-HCl at pH 7.5, 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA 
and 1:100 protease inhibitor mixture). Pellets were resuspended in TNE buffer and were kept 
on ice for 30 min. The lysates were then centrifuged at 17,400g for 35 min at 4°C. The 
119 
 
supernatant protein concentration was measured and normalized between samples. 
Approximately 50 µg protein was used as the input fraction. For immunoprecipitation 
analysis, 400-500 µg of protein per sample in 500 µL TNE buffer was used. 5 µg of goat 
polyclonal TLR2 or CD36 antibody were added to the lysates and the samples were set on an 
orbital shaker overnight at 4°C. The next day, protein G Sepharose beads were added to each 
sample. The samples were set on an orbital shaker overnight at 4°C. Protein G beads were 
collected by centrifugation at 2000g for 5 min and were washed four times with TNE buffer. 
The bound proteins were eluted by boiling in 2 protein loading dye for 5 min. Immunoblots 
were performed on 12% SDS-PAGE gels as described in the Immunoblots section. 
 
Caspase-1 assay 
WT and Fyn-/- microglial cells were plated out onto PDL-coated 96 well plates at 
150,000 cells per well. Cells were treated with α-synuclein at the pre-specified doses for 2 h 
post LPS priming. The FLICA dye was added in PBS for 30 min at 37°C. The cells were 
washed in PBS 3 times post treatment and the fluorescence read as per the manufacturer’s 
instructions. 
 
Nuclear and cytoplasmic fractionation  
Nuclear and cytoplasmic fractions were performed using the NE-PER Kit (Thermo 
Scientific) as previously described (Jin et al., 2011). Briefly, 5 X 106 cells were treated with 
α-synuclein for 30 min. CER1 reagent (150-200 μL) was used per sample to extract the 
cytoplasmic fraction and 45 μL of NER reagent was used to extract the nuclear fraction.  
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Nitric oxide detection  
Nitric oxide production by primary microglia was measured indirectly by 
quantification of nitrite in the supernatant using the Griess reagent (Sigma Aldrich). 
Microglia were plated in poly-D-lysine-coated 96-well plates at 1 X 105 cells/well. Cells 
were treated with α-synuclein for 24 h post priming with LPS for 3 h and after 100 μL of 
supernatant was collected from each well, an equal volume of the Griess reagent was added. 
The samples were incubated on a plate shaker at room temperature for 15 min until a stable 
color was obtained. The absorbance at 540 nm was measured using a Synergy 2 multi-mode 
microplate reader (BioTek Instruments) and the nitrite concentration was determined from a 
sodium nitrite standard curve. 
 
Multiplex cytokine Luminex immunoassays 
Primary microglia obtained from WT, PKCδ-/- and Fyn-/- mice were seeded in poly-D-
lysine-coated 96 well plates at 1 X 105 cells/well. The cells were treated with α-synuclein for 
24 h. After treatment, 50 µL of supernatant from each well was collected and frozen 
at -80°C. The levels of cytokines and chemokines in the supernatants were determined using 
the Luminex bead-based immunoassay platform (Vignali 2000) and pre-validated multiplex 
kits (Milliplex mouse cytokine panel – Millipore) according to the manufacturer’s 
instructions. 
 
Transfections of primary microglia 
The pre-designed, on-target plus SMART pool Fyn siRNA (a combination of four 
siRNAs, Cat. No. LQ-040112-00-0002) and scrambled siRNA (Cat. No. D-001210-03-05) 
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were purchased from Dharmacon (Lafayette, CO). We carried out siRNA transfections in 
primary mouse microglial cells with Lipofectamine 3000 reagent according to the 
manufacturer's protocol. Briefly, primary microglia were plated at 2 X 106 cells/well in 6-
well plates one day before transfection. For each well, 300 pmol of Fyn siRNA pool (75 
pmol each) or an equal amount of scrambled siRNA mixed with 5 μL of Lipofectamine 3000 
were added to the cells. 72 h after the initial transfection, cells were treated with aggregated 
α-synuclein for 4 h. Lysates were prepared in modified RIPA buffer as mentioned in the 
Immunoblotting section. Lysates checked for the expression of pro-IL-1β and Fyn. 
Transfection of primary microglia with WT Fyn-FLAG, Y417A Fyn-FLAG plasmid 
constructs was also performed using 5 μL of Lipofectamine 3000, but this was left on for 48 
h. FLAG immunoblots were performed to check for successful transfections. 
 
Immunofluorescence  
Immunofluorescence studies in primary microglia were performed according to 
previously published protocols with some modifications (Gordon et al., 2011). Briefly, cells 
were plated out onto poly-D-lysine-coated coverslips. At the end of treatments, cells were 
fixed with 4% PFA, washed in PBS and incubated in blocking buffer (PBS containing 1.5% 
BSA, 0.5% Triton X-100 and 0.05% Tween 20) for 1 h at room temperature. The coverslips 
were then incubated overnight at 4°C with respective primary antibodies diluted in PBS 
containing 1% BSA. Samples were then washed several times in PBS and incubated with 
Alexa 488 and 555 dye-conjugated secondary antibodies. The nuclei were labeled with 
Hoechst stain (10 μg/mL) and coverslips were mounted with Fluoromount medium (Sigma 
Aldrich) on glass slides for visualization. ASC-CFP fluorescence was imaged by assessing 
122 
 
the natural fluorescence using the CFP filter using the Leica DMIRE2 confocal microscope 
objectives.  
 
Mitochondrial ROS measurement 
Mitochondrial ROS generation was quantified using the MitoSOX red fluorescent 
indicator. WT and Fyn-/- microglia were plated out into coverslips at 150,000 cells per well. 
α-synuclein was added to the cells., The MitoSOX probe was added at the same time, to a 
final concentration of 1 μM. Fluorescence expressed by the generated mitochondrial 
superoxides were measured every hour for 0-12 hours using Cytation 3 Cell Imaging Multi-
Mode Reader as per the manufacturer’s instructions (BioTek- Winooski, VT).  
 
Mitochondrial visualization 
Microglia obtained via shale-off method were plated out onto PDL coated cover slips. 
After treatment under various paradigms, 300 μL of 166 nM CMXROS MitoTracker red dye 
diluted in serum-free DMEM/F12 media was added and incubated at 37°C for 13 min. After 
incubation, wells were gently washed with PBS 3-5 times and then fixed in 4% PFA for 30 
min. The wells were washed with PBS 3 times. After this, immunocytochemistry for Iba-1 
was performed as described in the immunofluorescence section. 
 
Data analysis  
Data analysis was performed using Prism 4.0 (GraphPad Software, San Diego, CA). 
The data was initially analyzed using one-way ANOVA and Bonferroni's post-test to 
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compare the means of treatment groups. Differences of p<0.05 were considered statistically 
significant. Student's t-test was used when comparing two groups 
 
Results 
Aggregated human α-synuclein acts as an efficient danger signal of the NLRP3 
inflammasome, effecting IL-1β  maturation and release 
Previous studies have demonstrated that misfolded proteins can activate the NLRP3 
inflammasome in microglia (Hafner-Bratkovic et al., 2012; Halle et al., 2008). Human α-
synuclein was obtained and purified as described in the Methods section. Aggregation of α-
synuclein was performed as previously described (Zhang et al., 2005). LPS-primed primary 
murine microglia were treated with α-synuclein for 24 h, with or without the pre-treatment of 
the pan-Caspase inhibitor ZVAD-FMK or the Caspase-1 specific inhibitor ZYVAD-FMK. α-
synuclein treatment sharply induced IL-1β cleavage and secretion, which was reduced in the 
group pre-treated with the Caspase inhibitors (Figure 1A). There was no significant change in 
the secretion/production of TNFα in the α-synuclein treated cells and only a marginal 
reduction of TNFα in the Caspase-1 inhibitor pre-treated groups. Next, we treated LPS-
primed bone marrow-derived macrophages (BMDMs) from WT, NLRP3-/-, ASC-/-, Caspase-
1-/- and Caspase-11-/- mice with aggregated human α-synuclein for 24 h (Figure 1B). There 
was a dramatic reduction in the secretion of IL-1β from NLRP3, ASC and Caspase-1 
deficient, but not Caspase-11 deficient macrophages (Caspase-11-/- macrophages were used 
as a control, since the Caspase-1-/- mouse line inherently also lacks Caspase-11). There was 
no change in the levels of supernatant TNFα in any of the genotypes. We also confirmed that 
none of these proteins played a role in the priming of the NLRP3 inflammasome by assessing 
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the levels of pro-IL-1β produced upon LPS treatment by immunoblot (Figure 1C).  Next, we 
assessed the inflammasome activating ability of aggregated human α-synuclein by utilizing 
the ASC-CFP reporter cell line. These cells overexpress ASC tagged with cyan fluorescent 
protein (CFP). Upon the activation of the NLRP3 inflammasome, the ASC coalesces to form 
a single speck within each cell. The number of ASC positive specks can be counted and used 
as a readout of inflammasome activation. ASC-CFP cells were primed with LPS and treated 
with aggregated synuclein for 2 h. Endogenous CFP fluorescence was assessed. In the 
synuclein treated group, specks of ASC were observed, indicating inflammasome activation 
(Figure 1D). These results indicate that aggregated α-synuclein serves as an efficient danger 
signal to activate the NLRP3 inflammasome. 
 
Fyn kinase contributes to LPS and TNFα  mediated priming of the NLRP3 
inflammasome 
Recently, we described how inflammogen stimulation of microglia resulted in rapid 
Fyn activation, and Fyn-dependent NF-κB pathway activation, which contributed to LPS and 
TNFα-mediated cytokine production and pro-inflammatory signaling (Panicker et al., 2015). 
Accordingly, we assessed the role of Fyn in LPS and TNFα-mediated priming of the NLRP3 
inflammasome. WT and Fyn-/- microglia were primed with various doses of the 
aforementioned inflammogens, and inflammasome priming was assessed by blotting for pro-
IL-1β and NLRP3. As expected, LPS and TNFα elicited a dose dependent induction of pro-
IL-1β and NLRP3 levels in WT microglia, but to a significantly lower extent in the Fyn-/- 
microglia (Figure 2A). We next treated WT and Fyn-/- mice with 5 mg/kg LPS for 24 h, and 
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checked for serum IL-1β via Luminex. The LPS-mediated serum IL-1β production in the 
Fyn-/- mice was strongly attenuated (Figure 2B). 
 
α-synuclein amplifies LPS induced priming of the NLRP3 inflammasome in a Fyn 
dependent manner 
The first step in the activation process of the NLRP3 inflammasome is priming, 
which entails the NF-κB-p65-mediated induction of pro-IL-1β and NLRP3, which occurs 
subsequent to the engagement of appropriate pro-inflammatory ligands or inflammogens to 
their respective receptors (Hayden and Ghosh, 2004). Having established that α-synuclein 
could act as an efficient danger signal of the inflammasome, we sought to elucidate the 
mechanisms through which it might activate the NLRP3 inflammasome. Immunoblot 
analysis of LPS primed, α-synuclein treated WT and Fyn-/- microglia revealed that synuclein 
treatment actually amplified the LPS mediated induction of pro-IL-1β and NLRP3 levels, 
and did so to a statistically lower extent in the Fyn-/- microglia (Fig 3A), leading us to 
hypothesize that aggregated α-synuclein directly potentiated LPS mediated priming by 
further activating the NF-κB pathway). The synuclein-mediated induction of pro-IL-1β and 
NLRP3 in microglia was abolished in cells pre-treated (post LPS priming and before α-
synuclein treatment) with SN-50, an NF-κB inhibitor (Figure 3B, C). We next checked the 
induction of pro-IL-1β and NLRP3 mRNAs in LPS and LPS + α-synuclein treated WT and 
Fyn-/- microglia. α-synuclein treatment effected the induction of pro-IL-1β and NLRP3 
mRNAs in the WT microglia, but the levels of the respective mRNA in the Fyn-/- microglia 
were consistently lower (Figure 3D). The well-utilized FLICA assay was then employed to 
assess the α-synuclein-mediated induction of Caspase-1 activity in primed WT and Fyn-/- 
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microglia. We discovered that Caspase-1 activity was strongly induced in WT microglia, but 
not at all in Fyn deficient microglia, strengthening our posit that Fyn played a role in the 
inflammasome activation (Figure 3E). The α-synuclein-mediated secretion of IL-1β and 
various other pro-inflammatory cytokines was also diminished in Fyn-/- microglia (Figure 
3F). NOS2 is the rate-limiting enzyme that mediates nitrite production in various immune 
cells including microglia. It has previously been shown to be induced in the APP/PS1 mice 
(Heneka et al., 2013). We show that α-synuclein treatment of LPS primed microglia also 
significantly elicited the induction of NOS2 and increase in supernatant nitrite levels in WT 
but did so to a lower extent in the Fyn-/- microglia (Figure 3G). Taken together, our results 
indicate that aggregated human synuclein amplifies LPS-induced priming, while 
simultaneously acting as a danger signal of the NLRP3 inflammasome, culminating in the 
release of mature IL-1β and nitrite, in a signaling pathway that utilizes Fyn kinase. 
 
Aggregated human α-synuclein primes and activates the NLRP3 inflammasome, 
resulting in IL-1β processing and secretion 
The current model of the NLRP3 inflammasome postulates a two-step mechanism, 
with a TLR or TNFR1 ligand acting as an initial signal to induce the expression of pro-IL-1β 
and NLRP3 proteins and a subsequent second signal that effects lysosomal rupture, 
mitochondrial ROS generation and/or K+ efflux that acts as a danger signal, resulting in the 
assembly and activation of the inflammasome complex, and the processing and secretion of 
IL-1β into the cell supernatant. Since we observed that α-synuclein can act as an efficient 
danger signal of the inflammasome, and can also amplify LPS mediated induction of the 
NLRP3 and pro-IL-1β at the message and protein level, we wondered if it could activate the 
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NLRP3 inflammasome independent of an LPS-mediated priming step. Unprimed, 
immortalized WT and Caspase1-/- microglial cells were treated with aggregated α-synuclein 
for 4 h and the levels of pro-IL-1β and NLRP3 assessed via immunoblot. Aggregated α-
synuclein effected the induction of pro-IL-1β and NLRP3 to equivalent levels in both cell 
types (Figure 4A). It also brought about the secretion of IL-1β in the WT, but to a strikingly 
lower extent, in the Caspase-1 deficient microglial cells. The secretion of IL-1β could also be 
inhibited by pre-treatment with Saracatinib, a Fyn inhibitor in a dose-dependent manner 
(Figure 4B). We next utilized primary bone marrow-derived macrophages from WT, NLRP3-
/-, ASC-/-, Caspase-1-/- and Caspase-11-/- mice and checked for the ability of α-synuclein to 
induce NLRP3 inflammasome activation in them. As expected, we saw no difference in the 
ability of macrophages of all aforementioned genotypes to induce pro-IL-1β and import α-
synuclein. However, the α-synuclein-mediated processing of Caspase-1 was almost 
completely absent in ASC-/-, NLRP3-/- and Caspase-1-/- macrophages (Figure 4C). Supernatant 
analysis of unprimed macrophages treated with α-synuclein for 12 h showed that α-synuclein 
elicited robust IL-1β production from WT macrophages, and this production was severely 
diminished in the NLRP3-/-, ASC-/- and Caspase-1-/- macrophages and was largely restored in 
the Caspase-11-/- macrophages (Figure 4D). The α-synuclein-mediated TNFα production was 
not statistically different in any of the cell types. 
 
Aggregated α-synuclein treatment rapidly activates Fyn. 
We then sought to elucidate the signaling mechanism through which α-synuclein activated 
the NLRP3 inflammasome in microglia. Various studies have indirectly implicated disparate 
receptors in binding to and mediating α-synuclein signaling; TLR2 was described to be 
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essential for α-synuclein induced pro-inflammatory signaling and to contribute to α-synuclein 
import into microglia (Kim et al., 2013). TLR4, CD36 and FcγR deficient microglia 
demonstrated attenuated neuroinflammatory responses in response to α-synuclein treatment 
(Fellner et al., 2013, Su et al., 2008, Cao et al., 2012). Misfolded α-synuclein was shown to 
interact with microglial TLR1/2 and mediate Myd-88 dependent pro-inflammatory signaling 
(Daniele et al., 2015). Since we had previously demonstrated early inflammogen-mediated 
activation of Fyn and PKCδ, we sought to link α-synuclein recognition by a microglial 
receptor to Fyn activation. Fyn has classically shown to be activated downstream of CD36 
(Chen et al., 2008; Moore et al., 2002), and more recently, TLR2 in TLR2 overexpressing 
HEK293 cells (Finberg et al., 2012). We immunoprecipitated CD36 and TLR2 in control and 
α-synuclein-stimulated WT microglia and checked for interaction of these receptors with 
both α-synuclein as well as Fyn. Both CD36 and TLR2 interacted with α-synuclein but Fyn 
only interacted with CD36 in α-synuclein-stimulated microglia (Figure 5A). We also checked 
if Fyn activation was inducible upon early α-synuclein stimulation of primary microglia. α-
synuclein treatment rapidly induced the active loop phosphorylation of Fyn. The p-Y416 Src 
family kinase (p-Y416 SFK) antibody was utilized to recognize activated Fyn, since this 
antibody recognizes all active Src family kinases, we checked for the synuclein-induced p-
Y416 SFK levels in Fyn-/- microglia and did not see any discernable Src kinase activation 
(Figure 5B). We also overexpressed FLAG tagged WT and activation loop mutant Fyn 
(Y417A Fyn) in WT primary microglial cells and treated cells with aggregated α-synuclein 
for 15, 30 and 45 min. Whole cell lysates were probed for FLAG and p-SFKY416 antibodies. 
WT Fyn-FLAG transfected cells demonstrated a rapid induction of p-Y416 SFK levels, 
which was abolished in the Y417A Fyn-FLAG transfected groups. The FLAG and p-Y416 
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SFK levels were assessed using secondary antibodies in the red and green channels 
respectively. The FLAG and p-Y416 SFK bands perfectly co-localized in the WT-Fyn 
transfected cells, indicating that Fyn as the Src family kinase that was preferentially activated 
in the cells following aggregated α-synuclein stimulation (Figure 5C). Lastly, 
immunocytochemistry analysis showed that p-Y416 SFK levels rapidly increased in 
microglial cells stimulated with aggregated α-synuclein. Active Fyn is preferentially 
localized along the membrane periphery, which is to be expected since it is activated rapidly 
following association with membrane-bound CD36 (Figure 5D). 
 
Fyn contributes to aggregated α-synuclein mediated NF-κB activation, contributing to 
priming of the NLRP3 inflammasome 
Priming of the NLRP3 inflammasome involves activation of the NF-κB pathway 
downstream of TLR/TNFR1 engagement of their respective ligands. The NF-κB complex 
comprises of heterotrimeric complex - IκBα, p65 and p50. Upon inflammogen stimulation, 
IκBα is phosphorylated and rapidly degraded, allowing the nuclear entry of the p65-NF-κB 
subunit. p65 is a transcription factor that binds to the promoters of various pro-inflammatory 
cytokine genes as well as the NLRP3 gene, bringing about their transcription, leading to the 
production of pro-inflammatory cytokines/pre-cytokines. We have previously shown that Fyn 
contributes to LPS and TNFα-mediated NF-κB activation in microglia (Panicker et al., 
2015). To assess the role of Fyn in α-synuclein-mediated priming of the NLRP3 
inflammasome, we first treated WT and Fyn-/- microglia with aggregated α-synuclein for 30 
min. We then prepared nuclear and cytosolic extracts and probed the nuclear extracts for p65. 
There was lesser α-synuclein-induced nuclear translocation of p65 in the Fyn-/- microglial 
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nuclear lysates (Figure 6A, B). To directly assess the role of Fyn in priming of the 
inflammasome, we treated WT and Fyn-/- microglial cells with α-synuclein for 45 min and 
evaluated mRNA levels of pro-IL-1β, NLRP3, as well as NLRC4 and AIM2. The α-
synuclein-mediated induction of pro-IL-1β and NLRP3 mRNAs was significantly attenuated 
in the Fyn-/- microglia. Notably, α-synuclein treatment did not bring about an induction of 
NLRC4 and AIM2 inflammasome levels, demonstrating that the NLRP3 inflammasome was 
preferentially activated (Figure 6C). We next checked for the induction of NLRP3, pro-IL-1β 
and the levels of cleaved Caspase-1 in the Fyn-/- microglial lysates. WT and Fyn-/- microglia 
were treated with α-synuclein for 2, 4 and 6 h. Immunoblotting analysis revealed that pro-IL-
1β, NLRP3 and cleaved Caspase-1 levels were significantly diminished in the Fyn-/- 
microglia (Figure 6D, E). We also knocked Fyn down using Fyn specific siRNA and 
observed diminished induction of pro-IL-1β in aggregated α-synuclein treated microglia 
(Figure 6F, G). Lastly, immunoblot and luminex analyses of α-synuclein treated microglial 
supernatants revealed diminished secretion of mature IL-1β as well as IL-12 from Fyn-/- cells 
(Figure 6H, I).  
 
 
Fyn contributes to α-synuclein import into microglial cells, thereby contributing to 
NLRP3 inflammasome associated mitochondrial dysfunction 
Although most existing studies agree on the steps that underlie priming of the NLRP3 
inflammasome, the exact nature of the danger or activating signal is contested. The current 
consensus points to lysosomal dysfunction, mitochondrial reactive oxygen species generation 
and potassium efflux as possible molecular events that lead to the assembly of the NLRP3 
inflammasome. Since we observed the interaction of Fyn with CD36, a receptor protein that 
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has been show to play a role in the uptake and aggregation seeding ability of fibrilar amyloid-
β(Sheedy et al., 2013), we wondered whether Fyn might play a role in the uptake of 
synuclein into microglial cells as well. To check for this, human synuclein was added to WT 
and Fyn-/- microglia for various time points, the cells washed 3 times with PBS, then fixed 
and stained for human synuclein to observe intracellular human synuclein. The human α-
synuclein taken up by microglia shows up as intracellular puncta. The number of puncta per 
cell per field were counted and quantified. Taken together, Fyn-/- microglia display 
diminished uptake of human α-synuclein (Figure 7A, B). We also quantified the uptake of 
human α-synuclein using immunoblot.  WT and Fyn-/- microglia were treated with human α-
synuclein for 15, 30 and 45 min. The cell supernatant was aspirated and the cells washed 
several times in PBS. Immunoblots of whole cell lysates for human α-synuclein indicated 
significantly attenuated uptake in the Fyn deficient cells (Figure 7C,D). Uptake of an 
inflammasome activator disrupts cellular homeostasis through several possible mechanisms. 
ROS generation, specifically from the mitochondria, has gained acceptance as a prime 
contributor to inflammasome activation (Zhou et al., 2011). We utilized the mitoSOX dye to 
quantify synuclein induced mitochondrial ROS generation in WT and Fyn-/- microglia. 
Treatment of cells with synuclein rapidly induced progressively increasing mitoROS 
generation in the WT microglia, but did so to a statistically lesser extent in the Fyn-/- 
microglia (Figure 7E). Mitochondrial dysfunction is also characterized by a change in 
morphology of mitochondria, changing from thread like to round. We quantified the 
synuclein-induced change in mitochondrial morphology in the WT and Fyn-/- microglia. 24 h 
post treatment, the microglia in the WT synuclein treated group demonstrated rounded 
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mitochondria, whereas there was no discernable change in mitochondrial morphology in the 
Fyn-/- microglia post synuclein treatment (Figure 7F, G,). 
 
PKCδ  contributes to aggregated α-synuclein mediated NF-κB activation but not α-
synuclein import into microglia 
We have previously demonstrated that upon activation following LPS and TNFα 
stimulation, Fyn associates with and tyrosine phosphorylates the serine threonine kinase 
PKCδ in microglial cells at residue Y311. We observed that α-synuclein also mediated an 
increase in p-Y311 PKCδ levels, but did not do so in the Fyn deficient microglia, suggesting 
a conserved pro-inflammatory signaling pathway downstream of inflammogen activation 
(Figure 8A). Upon checking nuclear lysates from aggregated α-synuclein treated PKCδ+/+ 
and PKCδ-/- cells for p65, we observed diminished activation of the NF-κB pathway, 
evidenced by reduced nuclear p65 in the PKCδ-/- nuclear fractions, reminiscent of the Fyn-
PKCδ mediated signaling cascade downstream of LPS and TNFα activation (Figure 8B,C). 
The aggregated α-synuclein mediated upregulation of pro-IL-1β mRNA was also 
significantly attenuated in the PKCδ deficient microglia (Figure 8D), as was the synthesis of 
pro-IL-1β and NLRP3 proteins (Figure 8E) and the production of supernatant IL-1β (Figure 
8F). We also wanted to check whether PKCδ played a role in α-synuclein import. We used 
whole cell lysates from PKCδ+/+ and PKCδ-/- microglia treated with aggregated α-synuclein 
for 30 and 45 minutes. Upon probing for human α-synuclein, we saw no change between 
either genotype with respect to α-synuclein import (Figure 8G). These results suggest a 
bifurcation of Fyn dependent signaling, showing that Fyn activation feeds into the PKCδ 
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dependent NF-κB pathway activation and priming of the NLRP3 inflammasome, and the 
PKCδ independent import of α-synuclein. 
 
Discussion 
A wealth of evidence from cell culture, animal models and post-mortem analysis of 
brains from PD patients implicates hyperactivation of the innate immune system in the brain 
as being central and contributive to the progressive nature of PD as well as other 
neurodegenerative disorders. This immune reaction is primarily mediated by microglia, the 
macrophagic cells of the brain. Another recent and intriguing hypothesis suggests that 
misfolded α-synuclein can seed aggregation of WT α-synuclein in a prionic manner, 
propagating the spread of neuron death and concurrent inflammation (Luk et al., 2012a; Luk 
et al., 2012b; Volpicelli-Daley et al., 2011). Aggregated α-synuclein has previously been 
demonstrated to effect microglial pro-inflammatory signaling and inflammatory mediator 
production (Zhang et al., 2005). However, the signaling pathways that are utilized to activate 
microglial cells, and specifically the NLRP3 inflammasome in microglia, are poorly 
characterized. This article describes a novel signaling mechanism through which α-synuclein 
aggregates effect the activation of the non-receptor tyrosine kinase Fyn, which contributes to 
both NF-κB priming of the inflammasome as well as α-synuclein import in the microglial 
cells, thereby contributing to the secretion of IL-1β as well as other inflammatory mediators, 
such as nitrite. Inhibitors of the NLRP3 inflammasome and Fyn have been used with success 
to limit the progress of experimental autoimmune encephalitis and AD respectively (Coll et 
al., 2015; Kaufman et al., 2015). It is hence envisageable that similar inhibitors could be used 
to halt the progression of PD. Activation of the NLRP3 inflammasome is a two-step 
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mechanism - a ‘priming’ step that induces levels of pro-IL-1β and NLRP3, and a second 
activating step, that induces the assembly of the inflammasome. Misfolded proteins have 
been shown to activate LPS-primed inflammasomes in microglia (Hafner-Bratkovic et al., 
2012; Halle et al., 2008). We first demonstrate that aggregated α-synuclein can elicit IL-1β 
production in microglia by activating the NLRP3 inflammasome, evidenced by the 
production of IL-1β and the formation of ASC specks in the ASC-CFP reporter cell line 
(Figure 1A-D). A recent paper indicated that commercially obtained aggregated α-synuclein 
couldn’t elicit IL-1β production (Gustin et al., 2015), but this finding is refuted by multiple 
studies that have used recombinant endotoxin-free aggregated α-synuclein to elicit microglial 
IL-1β production (Boza-Serrano et al., 2014; Daniele et al., 2015; Lee et al., 2010), although 
direct involvement of the NLRP3 inflammasome in the aforementioned studies was not 
proven. We sought to identify the signaling pathways through which it might activate the 
inflammasome. We discovered that aggregated α-synuclein amplified the LPS-induced 
expression of the inflammasome components pro-IL-1β and NLRP3 at both the mRNA and 
protein levels and did so in an NF-κB dependent manner (Figure 3A-D). We have previously 
demonstrated the role of the non-receptor tyrosine kinase Fyn in contributing to NF-κB 
activation in response to diverse inflammogens (Panicker et al., 2015). In agreement with 
these findings, we show that LPS and TNFα treatments elicit a dose dependent induction in 
NLRP3 and pro-IL-1β proteins, but do so to a significantly lower extent in Fyn-/- microglia 
(Figure 2A). Fyn-/- mice also demonstrated diminished serum IL-1β responses in response to 
intraperitoneal LPS administration (Figure 2B). The LPS and LPS + α-synuclein induced 
pro-inflammatory signaling was significantly dampened in the Fyn-/- microglia (Figure 3A-
D). The synuclein-mediated induction of Capsase-1 activity, as well as the secretion of pro-
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inflammatory cytokines and nitrite was significantly diminished in the Fyn deficient 
microglia (Figure 3E-G). We then reasoned that α-synuclein could prime and activate the 
NLRP3 inflammasome by itself, without requiring an intervening LPS mediated priming 
step. The α-synuclein-mediated induction of pro-IL-1β and NLRP3 were not changed in 
immortalized microglial cells obtained from Caspase1-/- mice, when compared to WT 
microglial cells. However, the processing of IL-1β was greatly diminished in the Caspase-1 
deficient cells, as evidenced by Luminex cytokine analysis of cell supernatant content 
(Figure 4A, B). Pre-treating cells with the Fyn inhibitor Saracatinib also reduced the 
production of IL-1β from the WT cells in a concentration dependent manner (Figure 4B). To 
prove the involvement of the NLRP3 inflammasome in this process, we showed that 
BMDMs from NLRP3-/-, ASC-/- and Caspase-1-/- had negligible α-synuclein-induced 
Caspase-1 activation (Figure 4C). Furthermore, the α-synuclein-mediated secretion of IL-1β, 
but not TNFα, was greatly diminished in the cell supernatants obtained from these cells, but 
not from cells obtained from Caspase-11-/- mice (Figure 4D). We used Caspase-11-/- BMDMs 
in this study since Caspase-1-/- mice were developed using an S129 mouse background, and 
these mice inherently lack Caspase-11 expression. Caspase-11 has been demonstrated to 
participate in the activation of a non-canonical inflammasome. Microglia obtained from 
Fyn+/+ mice (developed on an S129 background) and PKCδ+/+ (developed on a C57BL6 
background) had nearly identical IL-1β responses to aggregated α-synuclein. Although it has 
been shown in various studies to activate microglia, a direct biochemical interaction of 
synuclein with its receptors has yet to be demonstrated, with the exception of one that shows 
the interaction of TLR1/2 with synuclein, shown by Duolink immunocytochemistry (Daniele 
et al., 2015). We showed that synuclein could interact with the microglial receptors TLR2 
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and CD36 in untransfected, WT microglia. CD36 also interacted with Fyn following 
stimulation with α-synuclein aggregates (Figure 5A). There was a dramatic induction in Fyn 
activation post stimulation with α-synuclein aggregates(Figure 5B-D). In support of our 
hypothesis that Fyn plays a role in NLRP3 inflammasome priming, the α-synuclein-mediated 
nuclear translocation of p65-NF-κB and subsequent mRNA induction of IL-1β and NLRP3 
were diminished in the Fyn-/- cells (Figure 6A-C). The aggregated α-synuclein-mediated 
induction of pro-IL-1β and NLRP3 proteins and the cleavage of Caspase-1 were also 
significantly lesser in the Fyn-/- microglial lysates (Figure 6D, E), as was the production of 
IL-1β and IL-12 (Figure 6H, I). Knockdown of Fyn expression via siRNA-reduced α-
synuclein mediated induction of pro-IL-1β in WT microglia (Figure 6F, G). We also 
wondered whether Fyn activation might contribute to activation of the danger signal with 
regards to inflammasome activation. We first checked for the uptake of α-synuclein into WT 
and Fyn-/- microglia and discovered to our surprise that lesser amounts of α-synuclein were 
taken up by the Fyn-/- cells, as evidenced by ICC for as well as immunoblots for human α-
synuclein (Figure 7A-D). Among the signaling events that contribute to the danger signal 
activation with context to NLRP3 inflammasome activation, excessive ROS generation has 
now been accepted as a cardinal contributor to the activation of the NLRP3 inflammasome in 
various models and it was demonstrated that dysfunctional mitochondria might be the source 
of these species (Tschopp and Schroder, 2010; Zhou et al., 2011). Aggregated α-synuclein 
treatment induced a rapid, progressive, induction of mitoROS generation in WT microglia, 
but did so in the Fyn-/- microglia to a lesser extent (Figure 7E). Excessive mitoROS 
generation leads to eventual change in mitochondrial morphology. This change was observed 
in the WT but not the Fyn-/- microglia (Figure 7F, G). We also observed Fyn dependent 
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PKCδ tyrosine phosphorylation in the cells following α-synuclein stimulation (Figure 8A), 
which is reminiscent of the microglial activation pathway downstream of LPS and TNFα 
(Panicker et al., 2015). PKCδ-/- microglia imported aggregated α-synuclein with equivalent 
efficiency as their wild-type PKCδ+/+ counterparts (Figure 8G), but showed diminished α-
synuclein mediated priming of the NLRP3 inflammasome, and diminished secretion of 
supernatant IL-1β (Figure 8B-F).  
Mitochondrial dysfunction is one of the major causative factors identified to 
contribute to the progression of both sporadic and familial PD. However, most existing 
studies focus on the role of this process in dopaminergic neurons. Several of the PARK genes 
encode proteins that have mitochondrial functions. It is possible that the loss of function of 
these proteins, either through inherited mutations or post-translational inactivation, may 
contribute to mitochondrial dysfunction and consequent NLRP3 inflammasome 
hyperactivation in the microglia. There is evidence to support the notion that the NLRP3 
inflammasome may have relevance in animal models of PD and clinical relevance as well. 
Ole Isaacson and colleagues reported an increase in IL-1β striatal levels using the A53T α-
synuclein-AAV model in rats (although activation of the NLRP3 inflammasome was not 
looked at or discussed) (Chung et al., 2009). Overexpression of IL-1β in the mouse SN can 
directly bring about the death of dopaminergic neurons (Ferrari et al., 2006), and most 
recently, dopamine was shown to inhibit the NLRP3 inflammasome. MPTP treatment was 
utilized to induce a depletion of dopamine levels, which activated the NLRP3 inflammasome 
and subsequent NLRP3 dependent dopaminergic neuron loss (Yan et al., 2015). Our 
subsequent studies will utilize human α-synuclein overexpressing systems in Fyn+/+ and Fyn-/- 
mice to show the role of Fyn in activating the microglial NLRP3 inflammasome in-vivo. It 
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would be intriguing to assess whether sterile inflammation mediated by α-synuclein 
aggregates could act cooperatively with dopamine depletion to mediate unabated 
inflammasome activation that might contribute to the progressive neurodegeneration that 
characterizes PD. Since ASC released from activated peripheral immune cells was 
demonstrated to seed ASC oligomerization in a prionid manner (Baroja-Mazo et al., 2014), it 
might also be intriguing to explore whether microglia-released ASC could contribute to the 
spread of sterile inflammatory responses in PD brains. Overall, as summarized in Figure 9, 
our mechanistic studies demonstrate how Fyn plays a role in both, α-synuclein priming as 
well as activation of the NLRP3 inflammasome in microglial cells, identifying Fyn as a 
potential therapeutic target for inhibiting the sterile inflammation and inflammation-
dependent cell death in PD.  
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Figures 
 
Figure 1. Aggregated α-synuclein acts as a danger signal to elicit NLRP3 inflammasome 
dependent IL-1β processing in LPS primed microglia. A, Aggregated α-synuclein was 
able to elicit significant IL-1β, but not TNFα production from LPS primed microglia.  
Pretreatment of the cells with pan-Caspase and Caspase-1 specific inhibitors post priming but 
before α-synuclein treatment strongly attenuated the production of IL-1β, but minimally 
affected TNFα production. B, The α-synuclein-mediated production of IL-1β was largely 
mediated by the NLRP3 inflammasome, Supernatant cytokine analysis from LPS primed, α-
synuclein treated WT, NLRP3-/-, ASC-/-, Caspase-1-/- and Caspase-11-/- BMDMs revealed 
strongly diminished IL-1β, but not TNFα production from the NLRP3-/-, ASC-/- and Caspase-
1-/-, but minimally affected IL-1β production from the Caspase-11-/- cells, indicating that the 
canonical activation of the NLRP3 inflammasome was primarily responsible for the IL-1β 
production in response to aggregated α-synuclein. C, No discernable changes in the LPS 
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induced pro- IL-1β levels in WT, NLRP3-/-, ASC-/-, Caspase-1-/- and Caspase-11-/- BMDMs. 
D, Aggregated α-synuclein treatment induced speck formation in the ASC-CFP reporter cell 
line.  
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Figure 2. Fyn kinase contributes to the priming of the NLRP3 inflammasome in 
response to diverse inflammogens. A, WT and Fyn-/- microglia were treated with various 
doses of LPS (10. 100 and 1000 ng/mL) and TNFα (10 and 30 ng/mL). Both inflammogens 
elicited a dose-dependent induction of pro-IL-1β and NLRP3 in WT microglia, but did so to 
a significantly lesser extent in the Fyn-/- microglia. B, Fyn-/- mice treated with LPS (5mg/kg) 
for 24 hours showed diminished serum secretion of IL-1β when compared to Fyn+/+ mice. 
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Figure 3. Aggregated α-synuclein amplifies LPS induced priming of the NLRP3 
inflammasome and induces Caspase-1 activation, and pro-inflammatory cytokine and 
nitrite release in a Fyn dependent manner. A, Aggregated α-synuclein potentiated the LPS 
mediated induction of pro-IL-1β and NLRP3, but did so to a lesser extent in the Fyn deficient 
microglia. B, C, Treatment of microglial cells post priming and pre α-synuclein treatment 
with the NF-κB inhibitor SN-50 prevented the induction of pro-IL-1β and NLRP3 proteins 
D, α-synuclein treatment also increased the induction of pro-IL-1β and NLRP3 mRNAs in 
LPS treated WT, but not Fyn-/- microglial cells. E, The FLICA assay revealed strongly 
increased Caspase-1 activation in α-synuclein treated WT but not Fyn-/- microglia. F, LPS 
primed α-synuclein treated WT microglia produced higher amounts of pro-inflammatory 
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cytokines than Fyn deficient microglia. G, α-synuclein treatment induced the production of 
supernatant nitrite and NOS2 expression, but did so to a significantly lesser extent in the Fyn 
deficient microglia. 
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Figure 4. Aggregated α-synuclein can prime and activate the NLRP3 inflammasome to 
mediate IL-1β production. A, Aggregated α-synuclein elicited Caspase-1 independent 
induction of pro-IL-1β and NLRP3 levels, as evidenced by immunoblot analysis from 
synuclein treated WT and Caspase-1-/- microglial cell lysates. B, α-synuclein treatment 
induced the Caspase-1-dependent production of IL-1β from microglial cells, which was also 
inhibited with pretreatment of the Fyn inhibitor Saracatinib in a dose dependent manner. C, 
NLRP3-/-, ASC-/- and Caspase-1-/- BMDMs demonstrated equable α-synuclein mediated 
induction of pro-IL-1β and uptake of α-synuclein, but almost completely attenuated Caspase-
1 cleavage. D, The aggregated α-synuclein mediated production of IL-1β, but not TNFα was 
strongly attenuated in NLRP3-/-, ASC-/-, and Caspase-1-/-, but minimally affected in Caspase-
11-/- BMDM supernatants, indicating that α-synuclein is able to both prime, as well as 
activate the NLRP3 inflammasome primarily through its canonical activation. 
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Figure 5. CD36 associated Fyn is rapidly activated following α-synuclein stimulation. A, 
Upon its treatment to microglial cells, human α-synuclein associates with TLR-2 and CD36, 
as evidenced by co-immunoprecipitation analysis. Upon α-synuclein treatment, Fyn 
associates with CD36, but not TLR2. B, Immunoblot analysis of aggregated α-synuclein 
treated WT and Fyn-/- microglial lysates reveals a rapid induction of Src family kinase 
activation the WT, but not Fyn-/- microglia. C, Whole cell lysate analysis from α-synuclein 
treated wild type (WT) and activation loop deficient (Y417A) Fyn-FLAG transfected cells 
revealed a perfect overlap between the pY416-SFK and FLAG bands in the 30 and 45 min α-
synuclein treated WT Fyn –FLAG transfected samples, and a complete absence of pY416-
SFK activation in the Fyn activation loop mutant transfected samples D, 
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Immunocytochemistry analysis reveals a rapid increase in pY416-SFK levels in α-synuclein 
treated Iba-1 positive WT microglial cells. 
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Figure 6. Fyn contributes to α-synuclein mediated priming of the NLRP3 
inflammasome, resulting in diminished IL-1β and other pro-inflammatory cytokine 
production. A, B, Diminished α-synuclein induced nuclear translocation of NF-κB-p65 in 
the Fyn-/- microglial cells. C, Diminished induction of pro-IL-1β and NLRP3 mRNA levels in 
the Fyn deficient microglial upon α-synuclein treatment D, E, Reduced induction of pro-IL-
1β and NLRP3 protein levels, as well as Caspase -1 and IL-1β cleavage in Fyn-/- microglia. 
F, G, Knocking down Fyn using si-RNA reduces the α-synuclein mediated induction of pro-
IL-1β in primary WT microglia. H, I, Reduced supernatant IL-1β and other pro-
inflammatory cytokine production from α-synuclein treated Fyn-/- microglia. 
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Figure 7. Fyn contributes to aggregated α-synuclein uptake into microglial cells, 
resulting in the mitochondrial ROS generation. A, B, Immunocytochemistry (for human 
α-synuclein) revealed diminished uptake of the protein in the Fyn deficient microglia. C, D, 
Immunoblot analysis also reveals that human α-synuclein is taken up at lesser levels into 
Fyn-/- microglia E, Diminished mitoROS generation from α-synuclein treated Fyn-/- 
microglia. F, G, Diminished mitochondrial morphology deficits observed in the aggregated 
α-synuclein treated Fyn-/- microglia. 
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Figure 8. α-synuclein  treatment brings about Fyn mediated PKCδ  activation, which 
contributes to aggregated α-synuclein mediated priming of the NLRP3 inflammasome, 
but not to α-synuclein import into microglia. A, Immunoblot analysis of aggregated α-
synuclein treated WT and Fyn-/- microglial lysates reveals a rapid induction of pY311-PKCδ 
levels in the WT, but not Fyn-/- microglia. B, C, Reduced aggregated α-synuclein mediated 
p65 nuclear translocation seen in PKCδ-/- microglia.  D, Attenuated α-synuclein induced pro-
IL-1β mRNA induction in PKCδ deficient microglia. E, Reduced induction of pro-IL-1β and 
NLRP3 proteins, and F, secretion of IL-1β from PKCδ-/- microglia. G, No change in the 
import of aggregated α-synuclein import observed between PKCδ+/+ and PKCδ-/- microglia. 
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Figure 9. Aggregated α-synuclein mediated NLRP3 inflammasome activation pathway 
Aggregated α-synuclein binds to the receptors TLR-2 and CD36 on microglial cells. CD36 
recruits Fyn kinase, which in turn is activated and tyrosine phosphorylates PKCδ at Y311, 
leading to increased PKCδ dependent activation of the NF-κB pathway. p65 translocates to 
the nucleus and brings about the induction of pro-IL-1β and NLRP3 mRNAs. Aggregated α-
synuclein is also taken up by the microglia, following which it brings about mitochondrial 
dysfunction mediated activation of the NLRP3 inflammasome. Fyn, but not PKCδ 
contributes to this process as well. 
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CHAPTER 4. HUMAN ALPHA-SYNUCLEIN ACTIVATES THE NLRP3 
INFLAMMASOME IN A FYN-DEPENDENT MANNER IN ANIMAL MODELS OF 
PARKINSON’S DISEASE 
 
A paper to be submitted to Cell Reports. 
 
Nikhil Panicker1, Matthew Neal1, Dilshan S. Harishchandra1, Souvarish Sarkar1, Huajun Jin1, 
Vellareddy Anantharam1, Anumantha G. Kanthasamy1 and Arthi Kanthasamy1,2 
 
Abstract 
Parkinson’s disease (PD) is an age related neurodegenerative disorder characterized 
by the progressive degeneration of dopaminergic neurons within the substantia nigra (SN) 
and the concurrent development of motor deficits. It has now been accepted that the loss of 
dopaminergic neurons is accompanied and exacerbated by excessive microgliosis. The 
NLRP3 inflammasome is a multimeric protein complex of the cytosolic pattern recognition 
receptor NLRP3, the adaptor protein ASC, and Caspase-1, which upon assembly, mediates 
the autoproteolytic activation of Caspase-1 and the subsequent Caspase-1 mediated 
processing of pro-IL-1β to mature IL-1β. Hyperactivation of this complex by fibrilar β-
amyloid was previously demonstrated to contribute to the pathogenesis of Alzheimer’s 
disease (AD). We have shown that the aggregated PD associated protein α-synuclein can 
prime and activate the NLRP3 inflammasome in microglia in-vitro in a signaling pathway 
dependent on the non-receptor Src family tyrosine kinase Fyn. We wanted to investigate 
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whether the inflammasome could be activated in in-vivo models of PD involving α-synuclein 
aggregation or overexpression. We first demonstrate the activation of the inflammasome in 
the A53T human α-synuclein overexpression model and in ventral midbrain tissue lysates 
from PD patients. We then utilized the AAV-SYN overexpression model in Fyn+/+ and Fyn-/- 
mice to check for the role that Fyn plays in mediating microgliosis and inflammasome 
activation in-vivo. Both, the α-synuclein induced microgliosis, and ASC speck formation in 
the microglial cells was diminished in the Fyn-/- mice. Lastly, we also demonstrate the 
induction of Fyn within the microglia upon intrastriatal aggregated α-synuclein 
administration and in PD tissues. Taken together, our results suggest that Fyn could mediate 
inflammasome microgliosis and inflammasome activation in Parkinson’s Disease, 
contributing to the progression of the disease. 
 
Introduction 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized 
by the selective death of dopaminergic neurons of the Substantia nigra (SN) and the 
subsequent development of severe motor deficits. α-synuclein is a protein whose dysfunction 
is intimately associated with both idiopathic as well as genetically inherited PD. Point 
mutations and triplications of the SNCA gene, which codes for the α-synuclein protein, have 
been demonstrated to cause autosomal dominant PD (Allen Reish and Standaert, 2015; 
Appel-Cresswell et al., 2013; Kruger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; 
Polymeropoulos et al., 1997; Zarranz et al., 2004). Aggregated α-synuclein is also the major 
component of Lewy bodies, the neuropathological hallmark of idiopathic PD. Rodent models 
of PD are essential tools to both, identify and elucidate, the mechanisms though which the 
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disease progresses and also to identify potential therapeutic drug targets whose activation or 
inhibition could prevent or halt its advance. There are several models to study the disease, 
most of which perfectly mimic its most cardinal pathological hallmark, i.e. the death of 
dopaminergic neurons within the SN, which project to the striatum of the brain and mediate 
motor control. However, idiopathic PD is a progressive, age related disease, which occurs 
over decades and involves complicated non-motor deficits, the development of Lewy bodies, 
as well as non-dopaminergic neuronal cell death. The first rodent model system used to study 
PD utilized the unilateral intrastriatal injection of 6-hydroxydopamine (Ungerstedt, 1968). 
This treatment induced the rapid degeneration of dopaminergic neurons within the SN pars 
compacta region (SNpc), as well as a turning asymmetry towards the ipsilateral side. Even 
though this model is nearly 50 years old, it is still commonly used to study PD. Another 
model that was subsequently popularized was the MPTP (1-methyl, 4-phenyl, 1,2,3,6-
tetrahydropyridine) model, which was developed after it was discovered that addicts who had 
injected themselves with MPTP, mistakenly believing it to be the analgesic 1-methyl-4-
phenyl-4-propionoxypiperidine (MPPP) were admitted to the hospital with PD-like 
symptoms that were responsive to treatment with the traditional PD drug - 
levadopa/carbidopa. The offending substance was rapidly identified to be MPTP. Two 
studies that detailed how MPTP causes Parkinsonism in humans and primates rapidly 
followed (Burns et al., 1983; Langston et al., 1983). The MPTP model also effects the death 
of SN dopaminergic neurons, exacerbated neuroinflammation and motor deficits. Both the 
aforementioned models suffered from similar drawbacks; neither model was progressive 
(both treatment regimens induced cell death over days in rodent models, whereas PD occurs 
over decades in their human counterparts) nor displayed the formation of Lewy bodies. The 
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recently developed MitoPark model attempts to alleviate some of these problems by 
selectively knocking out the mitochondrial transcription factor TFAM from dopaminergic 
neurons. The resultant mice develop an age related progressive loss of dopaminergic neurons 
and development of motor deficits (Ekstrand et al., 2007). However, this model utilizes the 
mutation of a protein that has not been linked to genetically inherited PD development, and 
has “lewy body” like inclusions that lack α-synuclein, prompting several researchers to 
question the significance of using such a system.  Newer models of PD utilize mice that 
globally overexpress pathogenic forms of α-synuclein and have been used by several groups, 
but often display the inverse phenotype to the ones seen with the MPTP and 6-OHDA 
models - the formation of synuclein-positive lewy body like structures, progressive 
development of motor deficits but the absence of dopaminergic neuronal loss (Giasson et al., 
2002; Lee et al., 2002). In light of these considerations, it was recently suggested that the 
Adeno-associated Viruse (AAV) mediated α-synuclein (SYN) overexpression model of PD, 
wherein AAVs coding for α-synuclein, or GFP (as a control) are injected into the SNpc in 
mice, might prove to be a superior model when compared to classical PD models (Lindgren 
et al., 2012). This model has been recently shown to elicit progressive dopaminergic neuronal 
loss, as well as the concurrent development of α-synuclein-containing inclusions within the 
dopaminergic neurons (Decressac et al., 2012a; Decressac et al., 2012b). Inflammasomes are 
large multimeric protein complexes comprising of the cytosolic pattern recognition receptors, 
the adaptor protein ASC and Caspase-1. These complexes, when activated, mediate the 
production of the pro-inflammatory cytokines IL-1β and IL-18. The NLRP3 inflammasome 
is the best studied and characterized of the inflammasomes and has recently been implicated 
in the development of Alzheimer’s disease (AD) (Heneka et al., 2013). There is limited 
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evidence to suggest that the NLRP3 inflammasome might be activated in PD neuropathology 
using in vivo model systems; the MPTP-induced dopaminergic neuronal degradation was 
diminished in NLRP3-/- mice (Yan et al., 2015).  Viral vector-mediated overexpression of IL-
1β brought about dopaminergic neurodegeneration (Ferrari et al., 2006). Since we have 
previously demonstrated that aggregated α-synuclein could activate the Fyn-dependent 
NLRP3 inflammasome activation in microglial cells (in-vitro), we wanted to check if this 
finding also held true in PD model systems. To this effect, we utilized various models of 
synuclein-mediated PD, such as the A53T mice as well as the well-characterized AAV-SYN 
model system in Fyn+/+ and Fyn-/- mice. We discovered that viral overexpression of human α-
synuclein, as well as global overexpression of A53T α-synuclein could elicit the activation of 
the NLRP3 inflammasome. In the AAV-SYN model, Fyn-/- mice showed reduced 
microgliosis and inflammasome activation. 
 
Materials And Methods 
Chemicals and Reagents 
Green Fluorescent Protein (GFP) and Human α-synuclein overexpressing adeno-
associated viruses (AAV-GFP, 0.95 X 1013 viral particles per mL and AAV-SYN, 1 X 1013 
viral particles per mL) were obtained from The University of North Carolina Viral Vector 
Core. Both viral vectors were of the AAV-5 serotype and coded for GFP and human α-
synuclein respectively under a chicken β-actin promoter. Antibodies to rabbit ASC and 
Caspase-1 were purchased from Adipogen. Antibodies to rabbit and goat Iba-1 were obtained 
from Wako and Abcam respectively. Antibodies to goat IL-1β were obtained from R & D 
systems. The mouse antibodies for tubulin and human α-synuclein were purchased from 
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Santa Cruz. The rabbit antibody to human α-synuclein and mouse antibody to tyrosine 
hydroxylase (TH) were purchased from EMD Millipore (Billerica, Massachusetts). PD 
patient and age matched ventral midbrain sections were obtained from Dr. Asgar Zaheer at 
the University of Iowa. 
 
A53T mice 
The human α-synuclein A53T overexpressing mice were obtained from Jackson 
laboratories (B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J). These mice and their littermate 
controls were housed under standard conditions of constant temperature (22 ± 1°C), humidity 
(relative, 30%), and a 12-h light cycle with food and water provided ad libitum. These mice 
were sacrificed at 4 months of age and their tissues used for various studies. 
 
Animal studies 
The Fyn+/+ and Fyn-/- mice used in these studies were bred in our animal facility. Fyn-/- 
mice were originally obtained from Dr. Dorit Ron’s laboratory at the University of 
California, San Francisco and are available from Jackson Laboratory (stock number 002271). 
The mice were housed under standard conditions of constant temperature (22 ± 1°C), 
humidity (relative, 30%) and a 12-h light cycle with food and water provided ad libitum. Six- 
to eight-week-old male mice were used for all studies.  
 
Stereotactic injection of the AAV-SYN and AAV-GFP viral particles 
Mice were anesthetized with xylazine ketamine. Paw pinch was used to establish 
profound anesthesia. An incision was made at the back of the head and the area was 
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disinfected using povidone-iodine. Mice were mounted on the Angle 2 stereotaxic apparatus 
(Leica Biosystems, St. Louis, MO). The bregma was found and the injection into the SN 
subsequently performed. The coordinates, relative to bregma were: anteroposterior (AP) -3.1 
mm and mediolateral (ML) -1.2 mm relative to bregma, and dorsoventral (DV) -4.0. 0.2 mL 
of AAV-GFP or AAV-SYN solution was injected per min. The needle was left in for 5 min 
to ensure no backflow. The needle was retracted at the rate of 1 mm per min. Intradermal 
injections of lactated ringer’s solution was administered post injection to assist the recovery 
of the mice. 
 
Stereotactic injection of recombinant human aggregated α-synuclein into mice 
Mice were anesthetized as previously described. The mice were injected with 4 mL of 
aggregated  α-synuclein or vehicle. The coordinates, relative to bregma were: 0.7 mm 
anteroposterior, 2 mm lateral and 2.4 mm ventral. 
 
Immunoblotting 
Brain tissue lysates were prepared using modified RIPA buffer and were normalized 
for equal amounts of protein using the Bradford protein assay kit. Equal amounts of protein 
(30-40 µg) were loaded for each sample and separated on either 12% or 15% SDS-PAGE 
gels depending on the molecular weight of the target protein. After separation, proteins were 
transferred to a nitrocellulose membrane and the nonspecific binding sites were blocked for 1 
h using a blocking buffer specifically formulated for fluorescent Western blotting (Rockland 
Immunochemicals). Membranes were then probed with the respective primary antibodies for 
3 h at room temperature or overnight at 4°C. After incubation, the membranes were washed 7 
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times with PBS containing 0.05% Tween 20, and then Secondary IR-680-conjugated anti-
mouse (1:10,000, goat anti-mouse, Molecular Probes) and IR-800 conjugated anti rabbit 
(1:10,000, goat anti-rabbit, Rockland) were used for antibody detection with the Odyssey IR 
imaging system (LiCor). Membranes were visualized on the Odyssey infrared imaging 
system. Antibodies for GAPDH, β-actin and Tubulin were used as loading controls. 
 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on sections from the SN and other brain 
regions of interest as described previously (Ghosh et al., 2013; Jin et al., 2011). Briefly, mice 
were anesthetized with a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine and then 
perfused transcardially with freshly prepared 4% paraformaldehyde (PFA). Extracted brains 
were post-fixed in 4% PFA for 48 h and 30-µm sections were cut using a freezing microtome 
(Leica Microsystems). Antigen retrieval was performed in citrate buffer (10 mM sodium 
citrate, pH 8.5) for 30 min at 90°C. Sections were then washed several times in PBS and 
blocked with PBS containing 2% BSA, 0.2% Triton X-100 and 0.05% Tween 20 for 1 h at 
room temperature. Sections were then incubated with primary antibodies overnight at 4°C 
and washed 7 times in PBS on a Belly Dancer Shaker (SPI supplies). The sections were 
incubated with Alexa 488, 555 and 633 dye-conjugated secondary antibodies for 75 min at 
room temperature and their cell nuclei were stained with Hoechst dye. Sections were 
mounted on slides using Prolong antifade gold mounting medium (Invitrogen) according to 
the manufacturer’s instructions. Samples were visualized using an inverted fluorescence 
microscope (Nikon TE-2000U) and images were captured using a Spot digital camera 
(Diagnostic Instruments Inc). Samples were then washed several times in PBS and incubated 
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with Alexa 488 and 555 dye-conjugated secondary antibodies. The nuclei were labeled with 
Hoechst stain (10 μg/mL) and coverslips were mounted with Fluoromount medium (Sigma 
Aldrich) on glass slides for visualization.  
 
Confocal imaging and Z stack image acquisition and analysis  
Confocal imaging was performed at the Iowa State University Microscopy Facility, 
also using the Leica DMIRE2 confocal microscope with the 63X and 40X oil objectives and 
Leica Confocal Software. One optical series covered 11-13 optical slices of 0.5 µm thickness 
each. The Imaris software was used to analyze the Z stack images. The surface reconstruction 
wizard in the Imaris software was used to make 3D reconstructions of stacks for easier 
viewing of microglial-dopaminergic contacts. IHC on human sections was performed as 
described above, but with modifications to the protocol. Antigen retrieval was carried 
overnight in citrate buffer (10 mM sodium citrate, pH 8.5) at 4°C prior to the 90°C step. The 
autofluorescence eliminator reagent (Chemicon) was used to eliminate autofluoroscence in 
the sections. 
 
Data analysis  
Data analysis was performed using Prism 4.0 (GraphPad Software, San Diego, CA). 
The data was initially analyzed using one-way ANOVA and Bonferroni's post-test to 
compare the means of treatment groups. Differences of p<0.05 were considered statistically 
significant. Student's t-test was used when comparing two groups. 
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Results 
Activation of the NLRP3 inflammasome in the A53T model and in post-mortem PD 
brain lysates 
NLRP3 inflammasome has previously been conclusively demonstrated in the 
APP/PS-1 AD model, as well as in post-mortem AD brains (Heneka et al., 2013). The major 
readout of inflammasome activation in the aforementioned study was increased levels of 
cleaved Caspase-1. Accordingly, 4 month-old A53T and littermate control striatal lysates 
were assessed for cleaved Caspase-1 levels. There was a striking increase in the levels of 
cleaved Caspase-1 in the A53T striatal lysates, indicating that α-synuclein 
aggregation/overexpression is able to elicit inflammasome activation in-vivo (Fig. 1A). We 
also checked PD patient and age-matched control patient nigral tissue lysates for Caspase-1 
and IL-1β. Both, Caspase-1 and IL-1β levels were significantly increased in the human PD 
lysates (Fig. 1B). Although both Caspase-1 and IL-1β levels were previously shown to be 
elevated in PD brain and CSF samples, these discoveries were made before the concept of the 
inflammasome was postulated (Mogi et al., 1996; Mogi et al., 2000). Data from the A53T 
model and from PD patient lysates provide evidence that there may be in-vivo activation of 
the inflammasome. 
 
AAV-mediated targeted expression of α-synuclein in the ventral midbrain can effect the 
death of dopaminergic neurons in the SN of mice in a Fyn dependent manner. 
We stereotaxically injected AAV-GFP and AAV-SYN into the Fyn+/+ and Fyn-/- 
SNpc. 45 d later, the mice were sacrificed and brains collected, fixed and sectioned. To 
ensure that our injections were precise and no non-specific areas were targeted, we stained 
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the 30 µM thick sections with antibodies for GFP/human synuclein and tyrosine hydroxylase 
(TH), a dopaminergic neuronal marker in separate channels. The SNpc was perfectly targeted 
by the injected by the AAV injections, with a large degree of green and red channel overlap 
seen on the left hand side of the sections (Fig. 2A). Higher magnification images of the 
injected side were taken to greatly appreciate the degree of SNpc dopaminergic neuronal 
targeting (Fig. 2B). The AAV-SYN injected side in the WT mice showed a modest decrease 
of TH positive neurons 45 d post-injection when compared with the AAV-GFP injected 
animals, but there was no such loss in the Fyn-/- mice (Fig. 2A, B). 
 
AAV-SYN overexpression in the SNpc elicits massive microgliosis and microglial-
dopaminergic neuronal gliapse formation in WT, but not the Fyn-/- mice 
Sections from the above study were also stained with antibodies against Iba-1 and TH 
to demonstrate microgliosis, specifically around the SN. This was done because in PD cases, 
the greatest degree of microgliosis is observed within the SNpc itself, contributing to a local 
loss of dopaminergic neurons (Bartels and Leenders, 2007; Mosley et al., 2006; Whitton, 
2010). IHC analysis revealed that overexpression of human-α synuclein, but not GFP, 
induced massive microgliosis within the SN, specifically in the area of maximal 
dopaminergic neuronal loss in the WT mice, supporting the hypothesis that the 
hyperactivation of the microglal inflammatory response might contribute to the loss of 
dopaminergic neuronal loss. No increased microgliosis was observed in the Fyn-/- mouse SN 
sections (Fig. 3A). Recently, it was shown that MPTP intoxication rapidly increased the 
number of microglial-neuronal appositions, called gliapses. The formation of these contacts 
was rapidly followed by microglial phagocytosis of neurons, and inhibiting the formation of 
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these contacts proved to be neuroprotective in the MPTP model (Barcia et al., 2012). Similar 
results were obtained using the 6-OHDA model (Virgone-Carlotta et al., 2013). The Fyn-
dependent formation of microglial-neuronal contacts was an area we explored using the 6-
OHDA model (Panicker et al., 2015). Confocal maximal projection Z stack images were used 
to make 3D reconstructions to visualize the microglial-dopaminergic neuronal contact 
formation with more clarity. As seen in Figure 3B, AAV-SYN overexpression induced a 
massive increase in the microglial cells within the SNpc, and the number of gliapses formed 
per neuron. The Fyn-/-, mice on the other hand, demonstrated diminished microgliosis and 
fewer gliapses (Fig. 3B). 
 
Fyn kinase contributes to microglial inflammasome activation in the AAV-SYN mouse 
model of Parkinson’s disease 
Activation of the NLRP3 inflammasome in PD models is still a dynamic area of 
investigation and has not been conclusively demonstrated yet. However, there is some 
evidence to suggest that it may be activated under certain conditions; the transgenic db/db 
diabetic cell line, when subjected to a regimen with the Parkinsonian toxicant MPTP results 
in activation of the NLRP3 inflammasome and exacerbates neuroinflammation and 
neurodegeneration (Wang et al., 2014). Moreover, synuclein AAV overexpression in the 
nigra results in a significant production of IL-1β and TNFα in a rat model of 
synucleinopathy, even though the role of the inflammasome in this process was not 
conclusively proven (Chung et al., 2009). A recent study showed that NLRP3-/- mice were 
resistant to MPTP-induced TH-positive cell loss (Yan et al., 2015).  One of the means to 
validate activation of the inflammasome in vivo is the formation of ASC specks in the 
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microglia. This was done in the APP/PS1 mice AD model (Heneka et al., 2013). 
Accordingly, to assess whether microglial inflammasome activation could be driven by 
human α-synuclein overexpression in vivo, we stained sections from this study with 
antibodies to ASC and Iba-1. The number of microglial cells that showed ASC specks per 
field were counted and quantified. AAV-SYN-injected WT, but not Fyn-/- mice demonstrated 
a significant increase in the number of ASC speck-positive microglia, showing that the AAV-
SYN model effected the Fyn-dependent activation of the inflammasome in microglia  (Fig. 
4A, B). 
 
Intrastriatal injection of α-synuclein aggregates effects microgliosis with concurrent 
upregulation of microglial Fyn 
We have previously demonstrated that prolonged exposure to the inflammogens - 
LPS and TNFα results in the upregulation of Fyn kinase in microglial cells (Panicker et al., 
2015).  We wanted to observe whether these results could be extended to in-vivo models of 
microgliosis. Stereotactic injections of aggregated α-synuclein have previously been 
demonstrated to elicit pro-inflammatory responses (Couch et al., 2011). We injected Fyn+/+ 
mice with 4 µg of α-synuclein protein in the striatum. Coronal brain sections from these mice 
were then stained for Iba-1 to mark microglia as well as Fyn. We saw that on the injected 
side, there was a dramatic shift of microglial morphology from ramified to amoeboid, 
indicating microglial activation, along with increased Fyn expression within the Iba-1-
positive microglia (Fig. 5). 
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Microglial upregulation of Fyn in post-mortem PD brain sections 
To provide a clinically relevant role for Fyn kinase in PD pathology, we stained 
human PD and age-matched control ventral midbrain sections with antibodies to Fyn and 
Iba-1. We observed that there was a strikingly increased expression of Fyn within the Iba-1-
positive microglia in the PD brain sections providing clinical significance to our in-vitro and 
in-vivo findings (Fig. 6). 
 
Discussion 
PD is a devastating neurodegenerative disorder characterized by the loss of 
dopamine-producing neurons within the SNpc. It has now been universally accepted that this 
loss of neurons is accompanied by an excessive neuroinflammatory response, which 
contributes to the progressive nature of the disease. In-vivo models of Parkinsonian 
dysfunction are able to recapitulate various facets of PD with varying degrees of success; 
both the well utilized and characterized MPTP and 6-OHDA models can bring about the 
selective death of dopaminergic neurons within the SNpc, along with a concomitant 
neuroinflammatory response, but have been criticized for not being able to recapitulate the 
finer neuropathological hallmarks of PD, vis-à-vis the formation of Lewy bodies, a 
progressive age-dependent loss of neurons, etc. Among the new generation of PD models 
developed, the A53T human α-synuclein overexpressing mice and the AAV-SYN model 
have several advantages over the aforementioned classical models, such as the development 
of proteinaceous inclusions and progressive dopaminergic neuron loss (Decressac et al., 
2012a; Decressac et al., 2012b). Using the AAV-SYN model is also of significance to us 
because it evokes a marked pro-inflammatory response. Previously we demonstrated how 
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aggregated human α-synuclein mediated the Fyn kinase-dependent priming and activation of 
the NLRP3 inflammasome in microglia. We wanted to assess whether inflammasome could 
be activated in the AAV-SYN model, and whether Fyn contributed to this response. We first 
provide evidence for the posit that inflammasomes might be activated in the A53T model and 
in PD post-mortem tissues, both of which showed greater levels of cleaved Caspase-1 than 
the control littermate/age-matched human control brain lysates respectively (Fig. 1A, B). We 
next stereotactically injected AAV-SYN or AAV-GFP constructs into Fyn+/+ and Fyn-/- mice. 
The SNpc was targeted perfectly, with the TH-positive dopaminergic neurons on the injected 
side in both genotypes expressing human α-synuclein or GFP respectively (Fig. 2A, B). Just 
45 d post-injection of the AAV-SYN, but not the GFP-SYN constructs, Fyn+/+ mice displayed 
some loss of dopaminergic neurons on the injected side. The Fyn-/- mice showed no such loss 
(Fig. 2A). PD is characterized by microgliosis within the SN. To check for nigral 
microgliosis, we stained sections for TH (as a dopaminergic neuron marker) and Iba-1 (as a 
marker of microglia). There was massive microgliosis observed in the AAV-SYN injected 
Fyn+/+ mice, and a complete absence of the same in the Fyn-/- mice. AAV-GFP 
overexpression did not seem to elicit a microglial inflammatory response in either the Fyn+/+ 
or Fyn-/- mice (Fig. 3A, B). ASC oligomerization and speck formation are classical hallmarks 
of inflammasome activation in microglial cells, which have previously been demonstrated in 
AD models (Heneka et al., 2013). There is evidence to support the notion that the NLRP3 
inflammasome may have relevance in animal models of PD and clinical relevance as well. 
Ole Isaacson and colleagues reported an increase in IL-1β striatal levels using the A53T α-
synuclein-AAV model in rats (although activation of the NLRP3 inflammasome was not 
looked at or discussed) (Chung et al., 2009). Overexpression of IL-1β in the mouse SN can 
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directly bring about the death of dopaminergic neurons (Ferrari et al., 2006), and most 
recently, dopamine was shown to inhibit the NLRP3 inflammasome. MPTP treatment was 
utilized to induce a depletion of dopamine levels, which activated the NLRP3 inflammasome 
and subsequent NLRP3-dependent dopaminergic neuron loss (Yan et al., 2015). We assessed 
the ASC speck formation within microglia in the AAV-SYN and AAV-GFP injected Fyn+/+ 
and Fyn-/- mice. There was an induction of ASC specks in the WT mice injected with AAV-
SYN, but no such change in the Fyn-/- mice microglia (Fig. 4A, B). This supports our 
hypothesis that α-synuclein overexpression might contribute to inflammasome activation in 
vivo, and that Fyn might mediate this process. We also recently demonstrated that prolonged 
exposure of microglial cells to various inflammogens upregulated the levels of Fyn kinase 
(rather than just increasing kinase activity). To test whether this might occur in in-vivo 
models, we injected WT and Fyn-/- mice with aggregated α-synuclein (4 µg) for 4 d in the 
striatum. α-synuclein injection elicited a distinct shift in the microglial morphology from 
ramified (unactivated) to amoeboid (activated), along with a concomitant increase in Fyn 
expression in the Iba-1-positive microglia (Figure 5). We also assessed the expression of Fyn 
in human PD and age-matched control ventral midbrain sections. We observed upregulated 
expression of Fyn in the Iba-1-positive microglia within the SN, providing clinical relevance 
for our findings (Figure 6). It would be intriguing to assess whether sterile inflammation 
mediated by α-synuclein aggregates could act cooperatively with dopamine depletion to 
mediate unabated inflammasome activation that might contribute to the progressive 
neurodegeneration that characterizes PD. Since ASC released from activated peripheral 
immune cells was demonstrated to seed ASC oligomerization in a prionid manner (Baroja-
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Mazo et al., 2014), it might also be intriguing to explore whether microglia released ASC 
could contribute to the spread of sterile inflammatory responses in PD brains.  
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Figures 
 
 Figure 1. Inflammasome activation is elicited in A53T human α-synuclein 
overexpressing mice and in PD ventral midbrain lysates. A, Immunoblot analysis of 4 
month old A53T striatal lysates revealed significant increase in the levels of cleaved 
Caspase-1 levels, when compared to littermate controls. B, Immunoblot analysis of PD nigral 
tissue lysates revealed significantly increased IL-1β and Caspase-1 p20 levels when 
compared to age –matched control nigral lysates. 
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Figure 2. Viral mediated targeted overexpression of human synuclein and GFP in the 
SNpc of Fyn+/+ and Fyn-/- mice. A, Fyn+/+ and Fyn-/- mice were intranigrally injected with 
AAVs encoding GFP and human α-synuclein. Coronal brain sections were stained for 
GFP/human α-synuclein and TH. B, Higher magnification images of the injection sites 
reveal that the dopaminergic neurons were well targeted, with a large degree of overlap 
between the red (for TH) and green (for GFP or human α-synuclein) channels. 
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Figure 3. Diminished microgliosis in Fyn deficient mice using the AAV-SYN PD model.  
A, Massive microgliosis was observed within the SN in the Fyn+/+ mice injected with the 
AAV-SYN construct, but not the Fyn-/- mice. AAV-GFP overexpression did not induce 
microgliosis. B, 3-D reconstruction of the Z-stack images in the ventral midbrain of AAV-
SYN injected WT and Fyn-/- reveals the disparity of the microglial response/ neuron between 
the genotypes.  
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Figure 4. Fyn contributes to microglial inflammasome activation in the AAV-SYN PD 
model.  A, Formation of ASC specks within the microglial cells in the Fyn+/+, but not Fyn-/- 
AAV-SYN injected ventral midbrain sections. B, Quantification of the microglial population 
positive for  ASC specks upon AAV-GFP or AAV-SYN injection in Fyn+/+ and Fyn-/- ventral 
midbrain sections. 
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Figure 5. Intrastriatal injection of aggregated α-synuclein elicits Fyn protein induction 
within the Iba-1 positive microglia. Aggregated α-synuclein intrastriatal injection results in 
the activation of microglia, as seen by the shift in microglial morphology from ramified to 
amoeboid, along with a concurrent induction of Fyn within the microglia.  
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Figure 6. Microglial Fyn is upregulated in PD patient brains over age-matched control 
brains.  PD patient and age-matched control ventral midbrain sections were stained for Iba-1 
and Fyn. PD patient brains display more Iba-1 expression, and increased Fyn expression 
within the Iba-1, indicating microgliosis and microglial Fyn upregulation. 
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CHAPTER 5. GENERAL CONCLUSION AND FUTURE DIRECTIONS 
This section presents a general overview of the results and findings described in the 
thesis, with special emphasis on future directions and overall implications of these findings 
for the pathogenesis and progression of Parkinson’s disease.  The major findings pertaining 
to each research manuscript and their specific implications are covered in the ‘results and 
discussion’ sections of the relevant chapters. 
 
Fyn and Fyn-dependent PKCδ activation contribute to pro-inflammatory responses in 
microglia 
The primary finding from Chapter 2 of the thesis is that the non-receptor Src family 
tyrosine kinase Fyn is rapidly activated following stimulation of microglia with both TLR 
and TNFR1 ligands. The activated Fyn then tyrosine-phosphorylates PKCδ, which in turn 
contributes to the activation of the MAP kinase and NF-κB pathways and the subsequent 
production of pro-inflammatory mediators in microglia. Although we have demonstrated 
conclusively that the NF-κB activation is diminished in Fyn-/- and PKCδ-/- microglia 
(Panicker et al., 2015) (Panicker et al., 2015, Gordon et al., submitted), future studies will 
identify what substrates PKCδ phosphorylates to mediate pro-inflammatory responses. Other 
studies involving peripheral immune cells offer clues as to what these substrates might be. It 
was shown that PKCδ not only phosphorylates the p47 subunit of the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase complex, which mediates production of ROS from 
immune cells (Cheng et al., 2007), but also the p65 subunit of the NF-κB complex in 
vascular smooth muscle cells (Ren et al., 2014). PKCδ also phosphorylates PKD1 at residue 
S744 (Asaithambi et al., 2011; Doppler and Storz, 2007). PKD1 is an indispensable 
193 
 
component of the Myd-88 dependent pro-inflammatory signaling pathway downstream of 
TLR ligands (Park et al., 2009). A wealth of data has emerged showing how PKCδ is cleaved 
by Caspase-3, contributing to the pro-apoptotic pathway in dopaminergic neurons 
(Anantharam et al., 2002; Kitazawa et al., 2003; Yang et al., 2004). PKCδ is cleaved into a 
regulatory fragment (RF) and a catalytic fragment (CF), the latter of which enters the nucleus 
and induces apoptosis. Interestingly, PKCδ can be cleaved in microglial cells where the CF 
contributes to NF-κB activation (Burguillos et al., 2011). In summary, PKCδ is activated by 
Fyn-mediated tyrosine phosphorylation at Y311, which contributes to an increase in its 
kinase activity. Activated PKCδ contributes to NF-κB activation in a variety of ways, which 
will be explored in future studies. 
 
Fyn- and PKCδ-deficient mice are resistant to neuroinflammation and 
neurodegeneration in PD models 
In Chapter 2, we showed that Fyn-/- and PKCδ-/- mice display attenuated pro-
inflammatory striatal cytokine responses upon LPS treatment. They also exhibit less 
microgliosis and neuron death in the 6-OHDA PD model. To build upon these studies, we 
next utilized known Fyn inhibitor compounds and their analogues to test whether they have 
anti-inflammatory effects in various PD mouse models. Recently, the Fyn inhibitor 
Saracatinib was shown to prevent microgliosis in an AD mouse model (Kaufman et al., 
2015). In addition, rosmarinic acid was demonstrated to be a Fyn inhibitor (Jelic et al., 2007). 
We intend to assess the ability of this compound and its analogues to inhibit Fyn in vitro and 
also to prevent microglia activation in PD mouse models. Next, to prove that microglial Fyn 
contributes to PD dopaminergic neuronal death, we will selectively knock out Fyn in the 
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microglial cells. To accomplish this, we will utilize the CX3CR1 Cre-ER mice, available 
from Jackson laboratories. Microglia express high amounts of the chemokine receptor 
CX3CR1, but the other resident cells of the CNS, the neurons and astrocytes do not. 
Investigators have made use of the CX3CR1 gene promoter, replacing the gene downstream 
of the promoter with the gene for Cre recombinase fused to a mutant estrogen ligand binding 
domain (ER) that requires the presence of tamoxifen to be activated. These mice will be 
crossed with Fynfl/fl mice, which have the Fyn gene flanked by two loxP sites. Upon 
administration of tamoxifen, the microglial cells express Cre recombinase, which then 
catalyzes the site-specific recombination between the loxP sites, effectively knocking out 
Fyn. Peripheral immune cells that express Fyn will also undergo Fyn knockout, but these 
cells have short half-lives and are replaced within 4 weeks, whereas microglial cells are long-
lived and are not replaced. Hence, 4 weeks post-tamoxifen injection, only the resident 
microglial cells have no Fyn expression. This strategy was utilized to selectively knock out 
the protein TAK1 from microglia (Goldmann et al., 2013). Conditional microglial-specific 
Fyn knockout mice will be subjected to PD-related inflammogens including LPS, 6-OHDA, 
and MPTP to further characterize downstream signaling-associated neuroinflammatory 
processes in PD.  Additional characterization of Fyn-dependent proinflammatory signaling 
will eventually yield novel disease-modifying strategies for slowing or halting the 
progression of neurodegenerative processes underlying Parkinson’s disease.   
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Fyn contributes to α-synuclein-mediated priming and activation of the NLRP3 
inflammasome 
Chapter 3 demonstrates that Fyn is rapidly activated by aggregated α-synuclein, the 
major component of PD-associated Lewy bodies, and mediates PKCδ Y311 phosphorylation, 
which in turn feeds into NF-κB pathway activation. Fyn also contributes to the uptake of α-
synuclein into microglial cells, which in turn acts as a danger signal, causing the release of 
MitoROS to activate the NLRP3 inflammasome. We predict that the ability of Fyn to 
regulate α-synuclein entry into microglial cells occurs in tandem with the membrane-bound 
receptor CD36.  We also think that CD36 regulates Fyn activity, and that the 
inhibition/knockdown of CD36 prevents Fyn-mediated priming and activation of the NLRP3 
inflammasome. To evaluate this hypothesis, we cultured primary microglia extracted from 
CD36-/- mice (Jackson Laboratories) and checked for the aggregated α-synuclein-mediated 
induction of NLRP3 and IL-1β proteins, as well as the uptake of aggregated α-synuclein. We 
also reduced CD36 expression/activity either by knocking down the expression of CD36 via 
siRNA or by using CD36 inhibitor peptides. Usage of CD36 inhibitors has been described 
previously (Angin et al., 2012; Kuda et al., 2013). 
 
Alpha-synuclein aggregates activate the NLRP3 inflammasome in a Fyn dependent 
manner in PD mouse models 
In Chapter 4, we utilized the A53T model, showing that these mice have hugely 
elevated levels of cleaved or activated Caspase-1. Lysates from control and PD brain tissues 
also showed elevated Caspase-1 levels under PD conditions. We then used the AAV-SYN 
model to show diminished microgliosis, ASC speck formation and TH neuronal loss in Fyn-
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deficient mice. As mentioned previously, the pre-formed fibril (PFF) model of α-synuclein 
spread has gained support, whereby aggregated forms of α-synuclein can seed aggregation 
and propagate in a prionic manner. Astrogliosis, but not microgliosis, has been demonstrated 
in this model (Luk et al., 2012a; Luk et al., 2012b; Volpicelli-Daley et al., 2011). As our next 
logical step, we injected WT and Fyn-/- mice with α-synuclein PFFs and sacrificed them at 
various time points to check for microgliosis, ASC speck formation and Caspase-1 activation 
(via in-vivo FLICA assay). Some mice were also used to make tissue lysates to check for 
increased cleaved Caspase-1 levels. Since we demonstrated that prolonged exposure to 
inflammogens results in the induction of Fyn expression in microglial cells in vivo and in 
vitro, we anticipated the microglial upregulation of Fyn in this model. We assessed this by 
performing IHC for Iba-1 and Fyn. We also stereotaxically injected WT and microglial 
specific conditional Fyn knockout animals with the AAV-GFP and AAV-SYN constructs 
and checked for microgliosis, inflammasome activation and neurodegeneration at various 
time points. 
To conclusively prove that the hyperactivation of the NLRP3 inflammasome 
contributes to α-synuclein-induced pathology in PD models, we will either have to breed the 
A53T mice to NLRP3-/-, ASC-/- and Caspase-1-/- mice, or stereotaxically inject shRNAs to 
these proteins within the ventral midbrain in WT and A53T mice. Even though neither 
method will cause a microglial-specific knockdown of the proteins, the results might prove 
useful in implicating the NLRP3 inflammasome as being instrumental in PD progression. 
Similar results were obtained with the APP/PS1 AD mouse model. When crossed to NLRP3-
deficient or Caspase-1 deficient mice, AD pathology was almost completely attenuated 
(Heneka et al., 2013). We anticipate similar results with the A53T model.  Finally, we intend 
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to cross the A53T line with our global Fyn knockout mouse line to generate A53T/Fyn-/- 
double transgenic mice.  Inflammasome activation, microgliosis, and neuronal pathology will 
be assessed at various time points in these mice. 
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